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ABSTRACT
The transforming growth factor beta (TGF) pathway has been conserved
throughout evolution and plays important roles in tissue homeostasis.
Dysregulation of the TGF pathway has been implicated in a number of
disorders, including cancer, fibrosis, and vascular conditions. The signalling
potential of the TGF pathway is regulated by the route of internalization of its
cell-surface receptors: Receptors internalized by clathrin-mediated endocytosis
propagate signal transduction while those internalized by membrane rafts are
targeted for degradation. Given the importance of trafficking of the TGF
receptors to signal propagation, this thesis focuses on evaluating proteins which
direct TGF receptor internalization and trafficking. Initial work in this thesis
shows that the extracellular domain of the type II TGF receptor (TRII) and the
glycosylation state of the cell are important factors in permitting membrane-raft
localization of TRII. Using this information I assessed the ability of TRIII, a
glycosylated cell surface protein, to direct TRII internalization. I found that
TRIII increases membrane-raft independent internalization of TRII, increases
TRII/TRI complex half-life, and basal TGF signalling. I next assessed the role
of arrestin2, a protein which interacts with TRIII, in regulating TRII trafficking
and signalling. I show that arrestin2 interacts with TRII and traffics with TRII
to the early endosome to increase Smad-dependent signalling. Also, I show that
depletion of arrestin2 increases Smad-independent signal transduction. In the
last data chapter of this thesis, I evaluate the role of TGF1 and TGF3 to direct
TGF trafficking and signalling. I found that TGF3 is less potent than TGF1 at
propagating TGF signalling. I also show that TGF3 induces a different binding
ratio of TRII/TRI cell-surface complexes, which could explain its decreased
potency. Overall my studies highlight the role of receptor-interacting proteins in
directing TGF receptor trafficking and signal transduction. Since this pathway is
dysregulated in a number of pathologies, my studies suggest that TGF receptor
trafficking is an important avenue to modifying TGF signal transduction.
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CHAPTER 1

INTRODUCTION

2

1

Introduction
1.1

TGFOverview

The transforming growth factor beta (TGF) signalling pathway is
essential for numerous cell functions and was thought to arise with the
development of metazoans. In development TGFplays numerous roles,
including induction of epithelial-to-mesenchymal transition (EMT) in endocardial
cells which is necessary for normal heart development (1). TGFalso has
several roles in normal tissue homeostasis, regulating such diverse functions as
cellular differentiation, apoptosis, cell-cycle arrest, extracellular matrix production,
and cellular migration. Partly owing to its pleiotropic effects in numerous celltypes, TGFhas also been implicated in several pathologies including cancer
and fibrosis. In cancer, TGFappears to have a dual role: On one hand, it is a
tumour-suppressor, promoting cell-cycle arrest and apoptosis; on the other hand,
TGFcan increase cancer cell migration, invasion, and immune evasion (2). In
wound healing, TGFpromotes wound closure and resolution through the
production of extracellular matrix (ECM) proteins and inhibition of matrix
metalloproteinases. However, in fibrotic diseases, excessive TGFproduction
and signalling promotes extensive tissue fibrosis which can compromise normal
tissue function (3). Given the numerous roles of TGFin both homeostasis and
pathology, understanding the regulation of this pathway is critical.

3

1.1.1

TGF Cytokines
The TGF superfamily consists of structurally and functionally related

cytokines that interact with serine/threonine kinase receptors to mediate
downstream transcriptional events. The TGF superfamily contains over 30
ligands, including the TGF/Activin/Nodal subfamily and the bone morphogenetic
protein (BMP)/growth and differentiation factor (GDF)/ Müellerian inhibiting
substance (MIS) subfamily (4).
In the canonical TGFsignalling cascade, there are three TGF cytokines
which have been conserved throughout evolution- TGF1, TGF2 and TGF3;
indeed, orthologs to human TGF can be found in D. melanogaster and X. laevis
(reviewed in (1)). The three TGFligands are produced by a number of different
cell types and the production of all three occurs during development, although
TGF1 is the predominant type in adults (5,6). Each TGF ligand has relatively
specific, non-overlapping functions in vivo. The TGF ligands share significant
sequence homology; together they have greater than 76% identity in their active
domains (7).
TGF ligands are secreted as inactive, homodimeric pro-proteins (8). The
activation of TGF1 is the best characterized of the three ligands, and latent
TGF1 is found in one of three forms: a small latent complex, a large latent
complex, or a form that is associated with 2-macroglobulin (9). In its small
complex form TGFis synthesized as a pro-protein dimer, which is cleaved
intracellularly by furin convertase and then associates with two precursor chains,
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the latency associated peptides (LAPs) (9,10) (Figure 1.1). The large complex
also consists of latency associated peptides, dimerized TGFand a third protein,
the latent TGFbinding protein (LTBP), which is essential for proper secretion of
TGF(11)In the extracellular matrix TGFis activated by molecules, such as
matrix metalloproteinase 2, thrombospondin-1, plasmin or in vitro in acidic
conditions (12-14). It has been shown that TGF2 and TGF3 also exist in latent
complexes (15,16), which suggests that the activation of TGFin the
extracellular matrix may represent an important regulatory mechanism. In their
active form, all three TGF ligands are homodimers stabilized by disulfide
bridges and hydrophobic interactions when in their active form (17).
Despite structural similarities, TGF ligands have distinct affinities for
TGF receptors. The type II TGF receptor (TRII) is able to bind both TGF1
and TGF3, with slightly higher affinity for TGF3 (18,19). TGF2 on the other
hand, requires betaglycan (TRIII) in order to bind to TRII (20). Furthermore,
mice containing deletions of the genes encoding the three TGF ligands illustrate
that these ligands have non-overlapping functions. Tgfb1-/- mice develop
significant problems in utero including vasculogenic and hematopoietic defects
(21). Mice that survive gestation develop a severe wasting inflammatory
syndrome (21). Tgfb2-/- mice have a myriad of developmental defects, including
skeletal, cardiovascular, pulmonary and visual problems (22). Interestingly,

Figure 1.1 Latent and active forms of TGFligand

TGFcan be found in active and inactive forms. In order for proper secretion of TGF1
to occur, it must associate with latent TGFbinding protein (LTBP) (A), and this, along
with two latency associated peptides (LAPs) forms the large latent complex. In its small
latent complex form (B) TGFexists as a homodimer following its cleavage by furin
convertase, and is associated with two latency associated peptide proteins (furin
convertase cleavage site indicated by *). TGFis converted to its active form following
secretion into the extracellular matrix by proteases or acidic conditions (C)
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Figure 1.1
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Tgfb3-/- null mice have the least defects and die after birth due to an inability to
suckle caused by cleft palate (23).
Similar to their non-redundant roles in development, the TGFligands
have different effects in various disease states. For example, in the wound
microenvironment, there are a large variety of growth factors that promote
production of extracellular matrix and wound-closure. In adults, TGF1 is found
at very high levels in the wound microenvironment and promotes myofibroblast
differentiation, extracellular matrix production, and fibroblast chemotaxis
(reviewed in (24)). Overall, TGF1 promotes the formation of a scar during adult
wound healing. Surprisingly, injuries obtained in utero heal scar-free.This may be
due to the relative ratios of TGF1 vs. TGF3. It has been shown that the
embryonic wound microenvironment contains high levels of TGF3 and low
levels of TGF1 (24). Furthermore, adding exogenous TGF3 to an adult wound
also promotes scar-free healing in rats, possibly through decreasing inflammation
(25). Currently, a topical cream, called Avotermin, containing TGF3 as its active
ingredient is being promoted as a therapy for the improvement of scar
appearance in humans (26).
In tumourigenesis, TGF1 is well-established as playing a dual role in
cancer progression: in pre-malignant states TGF1 is anti-tumourigenic and
induces cell-cycle arrest and apoptosis; in advanced tumours TGF1 correlates
with a more aggressive phenotype and induces EMT, migration, and invasion of
tumour cells (27). Similarly, it has been shown that TGF2 is highly over-
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expressed in malignant gliomas and correlates with advanced disease state (5).
Inhibitors of TGF2, such as the antisense oligonucleotide AP 12009, have been
shown to decrease glioma and pancreatic cancer cell migration (5,28). However,
there is a lack of information regarding the role of TGF3 in the tumour
microenvironment. Studies have illustrated that TGF3 is highly expressed in
breast cancer samples (29), and other studies have shown that high levels of
TGF3 are associated with good prognosis in breast cancer (30). Overall, many
of the roles of TGF3 in the tumour microenvironment are assumed to be the
same as TGF1. If one were to consider that the tumour microenvironment has
many of the same cellular players as the wound microenvironment, and TGF1
and TGF3 have vastly different outcomes in the wound microenvironment, it is
unlikely that these two ligands share the same function in tumour growth.
1.1.2 TGF Receptors
There are three principal receptor subtypes in the classical TGF
pathway: TGF receptor I (TRI), TGFreceptor II (TRII) and TGFreceptor III
(TRIII). TGF receptor I (TRI) and TGF receptor II (TRII) are structurally
related glycoproteins which contain serine-threonine kinase domains, whereas
TRIII is a large, membrane-bound proteoglycan lacking kinase activity (17)
(Figure 1.2). Together, these receptors function to activate cell-type specific
signalling programmes through the activation of a family of transcription factors
called the Smads. TGFsignalling can also activate non-Smad mediated
pathways such as the MAPK pathway. Each TGFreceptor type has specific,

Figure 1.2 TGFReceptors

In the canonical TGFpathway there are three receptor types: TRIII (which consists of
two different receptors- betaglycan and endoglin), TRII and TRI. TRII and TRI
possess Ser/Thr kinase activity and are the signalling receptors in the pathway. The role
of TRIII is primarily ligand presentation to the TRII and TRI complex. While all of the
receptors are primarily found as homodimers at the cell surface, they have been drawn
as single receptors for the sake of simplicity in this diagram. Structural differences are
indicated and described in the figure.
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non-overlapping functions that are crucial to signal transduction.
In the TGFsuperfamily there are five type II TGFreceptors which can
form homomeric complexes to bind ligand: Act-RIIA, Act-RIIB, BMPR-II, AMHRII and TRII (31). In the classical TGFpathway, TRII is the primary type II
receptor. TRII is a 62 kDa protein containing a short cysteine-rich, Nglycosylated extracellular domain, a single transmembrane domain and a serinethreonine kinase intracellular domain (reviewed in (18)).The cytoplasmic domain
of TRII is also serine-threonine rich, which is lacking in TRI (32).

At the cell

surface, TRII exists as a homodimer in the absence and presence of ligand
(33). TRII binds TGF1 and TGF3 with relatively high affinity (34,35), but is
unable to bind TGF2 without TRIII (18). In the absence of ligand, TRII is
capable of autophosphorylation on serine residues Ser549, Ser551, Ser223, Ser226
and Ser227 (34,36). Interestingly, TRII also has tyrosine kinase activity and its
cytoplasmic tyrosine residues are subject to both autophosphorylation or Src
phosphorylation leading to signalling cross-talk with the MAP kinase family (37).
In response to TGF binding the receptor forms a heterotetrameric complex with
and phosphorylates TRI. TRII function is tightly regulated by post-translational
modification through ubiquitination, sumoylation, and/or phosphorylation, all of
which result in specific signal transduction events (reviewed in (38)).
In the TGFsuperfamily there are 7 type I receptors called activin linked
kinases (or ALKS) 1 through 7. The type I receptor in the classic TGFsignalling
pathway is TRI, also known as ALK5. TRI and TRII are structurally similar,

10

though TRI contains a shorter extracellular domain than TRII and cannot bind
ligand in the absence of TRII (39). Akin to TRII, TRI also contains a
serine/threonine kinase intracellular domain and exists as a homodimer at the
cell surface (18). However, TRI contains a unique intracellular GS
(glycine/serine rich) region that is highly conserved between type I receptor
isoforms, and that is phosphorylated by TRII (17). Once phosphorylated, the GS
domain of TRI acts as a docking platform for receptor-regulated Smad proteins
(40). The receptor-regulated Smads are then phosphorylated by TRI, initiating a
Smad signal cascade that culminates in transcription. Mutations of the GS
domain have highlighted the importance of this region to TGFsignal
transduction: Mutations of two or more glycine or serine residues in the GS
domain impairs TGFsignalling activity (41). Mutation of threonine 204 to
aspartic acid increases TGFsignal transduction in the absence of ligand, as it
generates a constitutively active TRI (41). These mutational studies confirm that
TRI is the key player in Smad signal transduction. Furthermore, SB-431542, a
specific inhibitor of TRI, prevents TGF-induced Smad-mediated transcription,
but does not affect the cross-talk of TGFwith the MAP kinase family,
highlighting the role of TRI in Smad-dependent TGFsignalling (42).

There are two type III TGF receptors: endoglin and betaglycan. These
receptors are considered accessory receptors with roles in ligand presentation,
as no enzymatic activity has been identified for either receptor. Betaglycan and
endoglin are structurally related, with large, heavily glycosylated extracellular
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domains, and a short cytoplasmic region with high sequence similarity (43-45).
Both receptors can be phosphorylated on serine/threonine residues in their
cytoplasmic domain (46-48). At the cell surface, endoglin and betaglycan form
homodimers (49) (50), as well as complexes with TGF receptors I and II
(46,51). Though similar, these receptors differ in their ligand-binding ability and
expression. Betaglycan can bind all three TGF ligand isoforms with high affinity
(50); while it has been reported that endoglin requires complex formation with the
TRII/TRI complex to bind ligand, and even in complex can only bind TGF1
and TGF3 (46,47). Betaglycan is the most widely-expressed TGF receptor,
and is expressed in a number of adult and fetal tissues (18), whereas endoglin is
primarily expressed on proliferating endothelial cells (52). Future studies to
examine compensatory effects of the two type III TGF receptors would be
interesting, as both Tgfbr3

-/-

(betaglycan) and Eng

-/-

(endoglin) mice die mid-

gestation due to cardiovascular defects (52,53).

1.2

TGFSignal Transduction

To propagate TGF signalling, homodimeric TGF is presented by
betaglycan (TRIII) to TRII (54) (Figure 1.3). The binding of ligand to TRII
recruits TRI to the ligand-receptor complex, forming a receptor complex of two
TRII and two TRI. TRII then phosphorylates TRI at serine-threonine
residues in its GS domain (55). Phosphorylated TRI is essential in driving
TGFsignal transduction, and works to activate a group of transcription factors
known as Smads. There are three classes of Smads which are activated by the

Figure 1.3 Smad Signal Transduction Pathway
In the canonical TGFsignalling pathway, the ligand-bound, activated receptor complex
propagates Smad signal transduction. Following ligand binding by TRII, TRI becomes
active and phosphorylates Smad2/3 on its SSXS motif (where S=serine and X= any
amino acid). This phosphorylation promotes its disengagement from TRI and promotes
the association of Smad2/3 with the common Smad, Smad4. The Smad complex then
translocates to the nucleus to activate transcription.
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TGFsuperfamily of ligands: the receptor-regulated Smads (or R-Smads, Smads
1, 2, 3, 5 and 8), which are able to interact with the type I receptor; the comediator Smad (Smad4), which can associate with R-Smads; and the inhibitory
Smads (or I-Smads, Smads 6 and 7) which compete with R-Smads for receptor
binding and target TGF receptors for degradation (17). In the classical
TGFsignalling pathway, the R-Smads are Smads 2 and 3, whereas the
inhibitory Smad is Smad7. Smads typically consist of two domains separated by
a variable linker region. The amino MH1 (Mad homology 1) domain has DNA
binding capabilities in some Smad sub-types, while the carboxy MH2 (Mad
homology 2) domain has been shown to mediate interactions with a variety of
proteins (56). The activated GS domain of TRI serves as a docking site for
Smad2 via its MH1 domain (55). The specificity of R-Smad binding is determined
by the L45 loop, a nine amino acid sequence between the kinase subdomains IV
and V of TRI (57). TRI phosphorylates R-Smads on the conserved SSXS motif
located at the C-termini of Smads 2 and 3 (serine residues 465 and 467 in the
MH2 domain of Smad2, for e.g.) (58-60). The phosphorylated serine residues of
Smad2 serve as a docking site for Smad4, and promote the dissociation of
Smad2 from TRI and the formation of a heteromeric complex with Smad4
(31,59). Smad2 is generally located cytoplasmically in the absence of ligand, but
upon ligand stimulation translocates to the nucleus with Smad4, which in the
absence of ligand is found distributed equally between the nucleus and the
cytoplasm (4). Smad4 is able to translocate to the nucleus due to its interactions
with nucleoporins; the interaction of Smad4 with the nucleoporin importin-1is
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thought to mediate the translocation of the Smad heteromeric complex to the
nucleus (61). In the nucleus the heteromeric complex binds to promoters or
enhancers of TGFtarget genes, such as the Smad binding element, via its MH1
domain and interacts with transcriptional co-activators and co-repressors in order
to induce cell-specific transcriptional programmes (4,17) (Figure 1.3).

1.3

Membrane Trafficking of TGFReceptors

Endocytosis refers to the process whereby cell-surface associated
molecules enter the cell without passing through the plasma membrane.
Essentially, the plasma membrane invaginates, budding off and forming a vesicle
containing the internalized cargo. Internalization of cell-surface receptors is
important in the control of signal transduction, functioning either to down-regulate
signalling or trafficking receptors to specific endocytic compartments. There are
several methods of endocytosis of cell-surface receptors, including membraneraft dependent endocytosis, caveolin-dependent endocytosis, Arf6-dependent
endocytosis, and clathrin-mediated endocytosis (reviewed in (62)). As clathrinmediated endocytosis and membrane-raft/caveolin-mediated endocytosis are
implicated in the TGFpathway (63), these processes will be the focus of this
introduction.

1.3.1

Clathrin-mediated Endocytosis
Clathrin-mediated

endocytosis

is

a

highly

conserved

mechanism

implicated in the internalization of many receptor types. Clathrin-mediated
endocytosis occurs when clathrin from the cytosol is recruited to the plasma
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membrane and aggregates to form pits (62). Protein motifs of cargo play a role in
the development of clathrin-coated pits, as di-leucine and tyrosine motifs in the
cytoplasmic domains of receptors are detected by adaptor protein 2 (AP-2) and
promote clathrin polymerization (64,65). The AP-2 complex is critical in the
formation and function of clathrin-coated pits. AP-2 along with Eps15 (epidermal
growth factor pathway substrate 15), aid in the polymerization of clathrin into
lattices increasing plasma membrane curvature (62). Upon sufficient membrane
curvature, dynamin forms a helix around the neck of the clathrin-coated pit and
with GTP hydrolysis promotes scission of the clathrin-coated pit from the plasma
membrane (66). These excised pits then form clathrin-coated vesicles, lose their
clathrin-coat and become endosomes. Endosomes may be routed to the cell
membrane for recycling, or may mature and go on to form other compartments.
Ligand-binding is not a requirement for clathrin-mediated endocytosis: while
some receptors are internalized following ligand stimulation, such as the
epidermal growth factor receptor, other receptors such as the transferrin receptor
and the T-cell receptor CTLA-4 internalize independently of ligand stimulation
(67,68).

1.3.2

The role of Rab GTPases following endocytosis
Following receptor internalization, receptors are directed into distinct

endocytic components by a large family of small GTPases called the Rab
GTPases (Figure 1.4). There are over 60 members of the Rab GTPase family
which function as molecular “on and off” switches- in their “on” state, they are

Figure 1.4 Rab GTPases in vesicular trafficking following endocytosis
The Rab small GTPase family is important in mediating trafficking of intracellular
vesicles. Different endosomal compartment are enriched in distinct Rab GTPases. Rab4
and Rab5 are found enriched in the early-endosome. From the early endosome, cargo
may traffic to the recycling endosome, which is enriched in Rabs 4 and 11, or to the late
endosome, which are enriched in Rabs 7 and 9.
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bound to GTP, and in their “off” state, they are bound to GDP (69). Rab proteins
are activated by Rab GEFs (GDP-GTP exchange factors), which promote the
GTP bound form, and are inactivated by GAPs (GTPase activating proteins) (70).
Rab GTPases can associate with membranes, vesicular coat components, and
molecular motors to direct vesicular traffic by regulating the process of docking
and tethering between compartments (Figure 1.4) (69,70).
One of the best-studied Rab proteins, Rab5, has been shown to play a
crucial role in the formation of clathrin-coated pits and the internalization of
transferrin receptors via clathrin-mediated endocytosis (71). GTP-bound Rab5 is
also involved in early-endosome fusion (72) and has been used extensively as a
marker for the early endosome. Following trafficking into the early endosome, it
has been proposed that cargo can either be recycled to the plasma membrane,
or progress to the late endosome. A study by Rink et al. elegantly illustrated that
progression from the early to late endosome is mediated by the loss of Rab5
occurring simultaneously with the acquisition of Rab7 (73). Rab5 replacement
with Rab7 depends on the GTP hydrolysis activity of Rab5, as a Rab5 mutant
lacking hydrolytic activity recruited Rab7 but was not replaced by Rab7 (73).
Following trafficking to the late endosome, cargo can be trafficked to the
lysosome, which is mediated by Rab7, or to the trans-Golgi network, which is
mediated by Rab9 (69). As mentioned, instead of progressing to the late
endosome, cargo may traffic to a recycling endosome, which is enriched in Rab 4
and 11 in distinct domains that do not intermix (69,74). These proteins are
proposed to have different functions in the recycling pathway: Rab4 has been
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implicated in “fast” recycling of cargo from to the cell-surface, whereas cargo in
Rab11- positive vesicles has been proposed to take a “slow” recycling route, and
can transition through the trans-Golgi network and secretory pathways (74).
Overall, the regulation of cargo trafficking within the cell is essential for
cellular function. Rab dysregulation can occur in a number of cancers, such as
breast and ovarian cancer, which have been found to have over-expression of
Rab25 (69).

1.3.3

Membrane-raft mediated endocytosis
Clathrin-independent endocytosis through membrane rafts is also a

common mechanism for the uptake of signals and nutrients from the extracellular
environment. First introduced in 1997, the membrane raft model proposes that
cholesterol-sphingolipid-protein complexes form in the plasma membrane to
make a tightly packed, liquid-ordered phase mediating endocytosis and signal
transduction (75). Importantly, the lipid composition of membrane rafts is distinct
from the rest of the plasma membrane as they are enriched in cholesterol and
sphingolipids and are therefore more rigid and less fluid than the surrounding
plasma membrane (76). Membrane rafts have been shown to be especially
important in the endocytosis of proteins with glycophosphatidyl-inositol (GPI)
binding domains (77). It is thought that clustering of GPI-containing receptors
may increase the affinity of the receptor complex for membrane rafts and
increase membrane raft stability (78). Furthermore, it has been suggested that
cytoskeletal proteins, such as actin, play an important role in forming membrane
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rafts (79). Disrupting the actin cytoskeleton has major effects on the clustering of
raft proteins (80). In a feed-forward mechanism, the clustering of proteins
enriched in membrane rafts enhances the concentration of actin, which then
further stabilizes membrane raft formation (81).
The study of membrane rafts has been limited at times due to previous
methodology used to isolate rafts.

Membrane rafts have been isolated by their

detergent-insolubility. The tight packing of lipids in the liquid-ordered phase of
membrane rafts prevents detergent incorporation and therefore disruption by
detergents (82). Following detergent extraction of membrane rafts, cell lysates
are frequently subjected to sucrose-density ultracentrifugation, as the enrichment
of membrane rafts with cholesterol and sphingolipids increases their buoyancy
relative to the rest of the plasma membrane. Unfortunately, using detergentinsolubility as the sole defining characteristic is laced with inconsistency.
Different results can be obtained depending on the type of detergent and the
duration of extraction (83). As it is possible to isolate membrane rafts using a
detergent-free method with sodium carbonate (51,63,84,85), using this method
may decrease extraction-based artifacts of membrane raft isolation.

1.3.4

The role of Caveolae in endocytosis
Another important mediator of TGFendocytosis are caveolae. Caveolae

are a subset of membrane rafts which are composed of flask-shaped
invaginations approximately 60-80 nm in diameter (77). Caveolae are enriched in
a protein called caveolin-1. The caveolin family consists of three proteins:
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caveolin-1, caveolin-2, and caveolin-3. Caveolin-1 and caveolin-2 are found in
non-muscle cells, while caveolin-3 is primarily expressed in muscle (86,87).
Caveolin-1 and caveolin-3 can form caveolae, whereas loss of caveolin-2 does
not affect caveolae formation (88). As caveolin-3 is only expressed in muscle,
caveolin-1 is the primary contributor to caveolae formation in most cells (89).
Caveolin proteins have a unique hairpin structure. Their N and C termini are
cytoplasmic, whereas the hairpin structure is embedded in the plasma
membrane, associating with approximately 1-2 cholesterol molecules (90).
Caveolae are formed by the oligomerization of caveolin-1 molecules and
association with cholesterol-rich membrane rafts. This oligomerization results in a
liquid-ordered, stable domain in the plasma membrane enriched in cholesterol,
sphingolipids, and caveolin-1(89). Caveolin-1 has been shown to be important for
clathrin-independent,

membrane-raft

dependent

endocytosis

through

its

interactions with the actin cytoskeleton (91). Caveolae-dependent endocytosis
has been implicated in the uptake of viruses, nutrients, and cell-membrane
receptors (92).
Disruption of the caveolin-1 gene has provided insight into the many
potential roles of this membrane protein. In the initial characterization of Cav1-/mice it was shown that the loss of caveolin-1 disrupted caveolae formation in the
lung, adipose tissue, kidney, and heart (93). Overall, these mice are viable but
have significant vascular defects, and have increased deposition of extracellular
fibrillar matrix in the lungs, suggesting that loss of caveolin-1 may initiate fibrosis
in the lungs (93). However, loss of caveolin-1 expression also induced the hyper-
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proliferation of angioblastic cells (93). Further studies illustrated that loss of
caveolin-1 induced many changes consistent with promoting tumourigenesis
such as the spontaneous progression through the epithelial-to-mesenchymal
transition in epithelial cells (94), increasing the susceptibility of mouse embryonic
fibroblasts to transformation (95), and increasing beta-catenin transcriptional
activation (96). Overall, these studies illustrate that caveolin-1 may have greater
roles in signal transduction than simply in the internalization of cell-surface
receptors.

1.4
Intriguingly,

Endocytosis in TGFSignal Transduction
a

role

for

membrane-raft/caveolar

mediated

signal

transduction has been identified for TGF signalling by Di Guglielmo and
colleagues. At the cell surface, TGF receptor complexes can access both
clathrin-coated pits and membrane rafts (63) (Figure 1.5). Inhibition of clathrincoated pit internalization through the use of a dominant-negative Eps15 mutant
shifted receptors into membrane raft fractions; similarly, inhibition of membrane
raft formation through cholesterol depletion shifted receptors back into nonmembrane raft fractions (63). TGF receptors internalized via clathrin-mediated
endocytosis access the early endosome, a signalling endosome, which
propagates TGF signal transduction through the recruitment of R-Smads
(63,97). Membrane-raft mediated endocytosis, however, promotes ubiquitindependent receptor degradation (63,98,99). The landmark paper by Di Guglielmo
and colleagues illustrated an important principle regarding TGFsignal

Figure 1.5 Regulation of TGFSignalling by Clathrin-dependent and -independent
endocytosis
TGFreceptors can be internalized by clathrin-dependent mechanisms and clathrinindependent, membrane-raft dependent mechanisms. Receptors internalized via
clathrin-coated pit mediated endocytosis traffic to the early endosome and propagate
signal transduction. Receptors internalized by membrane-raft dependent endocytosis
traffic to the caveolin-1 positive vesicle where they are targeted for degradation and
prevented from signalling.
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transduction: endocytic route plays a powerful role in dictating TGFreceptor
intracellular trafficking and signal transduction (Figure 1.5).

1.4.1

The role of the early endosome in TGFSignal Transduction
While the classic paradigm of signal transduction suggests that following

receptor endocytosis signal transduction is terminated, it has been shown in
many different systems that signalling continues following receptor internalization
into endosomes. Following ligand-binding and internalization, receptors can
undergo modifications that attract intracellular signalling molecules and can
therefore continue to propagate signals (100). Early endosomes are considered
to be a sorting station for internalized receptors, and are classified by their
enrichment in Rab5 and EEA1 (early endosomal autoantigen 1) (100).
As previously described, clathrin-mediated endocytosis of TGFreceptors
targets their localization to the early endosome (63,97), which enhances
TGFsignalling. An elegant study performed by Runyan and colleagues
illustrated that internalization of the TGFreceptor complex is essential for
maximal signal transduction (101). The authors illustrated that inhibition of
clathrin-mediated endocytosis did not greatly prevent the ability of the receptor
complex to phosphorylate Smad2; but inhibition of endocytosis did prevent
nuclear translocation of Smad2 thus preventing TGF-dependent transcription 
(101). This paper suggested that there is a spatial component to TGFsignalling.

One key player in the spatial control of TGFsignalling is SARA (Smad
anchor for receptor activation). SARA was first identified by Tsukazaki and
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colleagues by screening a X. laevis expression library using Smad2 as a bait
(102). SARA contains a FYVE domain (Fab1, YOTB, Vac1, EEA1), a common
motif in early endosomal proteins that has been shown to bind to phosphatidylinositol-3-phosphate (PtdIns3P) (103). Since phosphatidyl-inositol-3 (PI3) kinase
activity has been implicated in vesicular trafficking, and FYVE domains can
directly bind PtdIns3P, proteins containing FYVE domains have been suggested
to mediate endosomal trafficking (103). SARA has also been shown to bind to
Smad2 and Smad3 via their MH2 domains, and preferentially binds the
unphosphorylated forms of the Smads (102). Furthermore, TGFreceptors traffic
into EEA1/SARA positive endosomes and disruption of SARA localization
through the deletion of the FYVE domain perturbs Smad2/3 nuclear translocation
(104). It has been proposed that SARA functions to link the TGFreceptors with
Smad2. Once Smad2 has been phosphorylated by the receptor complex, Smad2
dissociates from SARA and binds Smad4, translocating to the nucleus and
initiating TGF-driven transcription (102).

The length of time which TGFreceptors reside in the early endosome
may also affect their signalling capacity. As previously mentioned, the early
endosome is enriched in Rab5. Rab5 can control vesicular trafficking by
promoting trafficking to the late endosome which is enriched in Rab7 (73). A
Rab5 guanosine exchange factor (GEF), RIN1, has been shown to promote
Smad signal transduction by activating Rab5 (105). Interestingly, SNAI1 a
transcriptional target of TGF/Smad signalling, acts through a negative feedback
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mechanism

to

decrease

RIN1

expression

and

therefore

decrease

TGFsignalling (105).

There is little information regarding the trafficking of TGFreceptors
following their endocytosis to the early endosome. It has previously been shown
that TGFreceptors can co-localize with Rab11, a recycling Rab protein (63).
Furthermore, a dominant-negative version of Rab11 has been shown to impair
the recycling of TGFreceptors to the cell surface (97); however, the authors of
this paper used a hybrid GMCSF-TRII receptor composed of the extracellular
domain of GMCSF and the cytoplasmic domain of TRII, therefore studies using
wild-type TRII to assess TGFreceptor recycling would further improve our
understanding of TGFreceptor recycling.

1.4.2

The role of the caveolin-1 positive vesicle in TGFsignalling
Membrane raft endocytosis of TGF receptors results in receptors being

targeted to the caveolin-1 positive vesicle. Indeed, Razani et al., identified a
caveolin-binding motif in the cytoplasmic tail of TRI which mediates its
interaction with the scaffolding domain of caveolin-1 (106). Unlike the early
endosome, the caveolin-1 positive vesicle promotes association of Smad7, not
Smad2, with the receptor complex (63). Smad7 belongs to the inhibitory Smads,
or I-Smads, along with Smad6. Smad7 antagonizes the canonical TGFpathway
and its expression is induced by TGFfamily ligands (107). The antagonistic role
of Smad7 is mediated by two mechanisms. Firstly, Smad7 is able to interact with
activated TRI and therefore sterically inhibits the association of TRI with
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Smad2/3, preventing the subsequent activation of Smad2/3 and its association
with Smad4 (108,109). Importantly, a mutant of Smad7 that is unable to bind to
TRI (Smad7 408) loses its inhibitory activity of the TGFpathway, suggesting
that the ability of Smad7 to bind to TRI is critical in its antagonistic function
(109). Secondly, Smad7 acts as an adaptor between the TGFreceptor complex
and a ubiquitin regulatory factor, Smurf2 (99). Smurf2 is an E3 ubiquitin ligase
which is localized primarily in the nucleus (99). Upon TGFstimulation however,
Smurf2 translocates to the cytoplasm and forms a stable interaction with Smad7
and the receptor complex (99). Smurf2 then ubiquitinates the receptor complex,
targeting it for degradation via proteasomal and lysosomal pathways (99,110).
Further supporting the role of membrane rafts in receptor degradation, an
interesting study by Chen and colleagues found that increasing cholesterol
concentrations can inhibit cell TGFresponsiveness and promote receptor
degradation. This suggests that cholesterol may shift TGFreceptors into
membrane rafts and subsequently caveolin-1-positive vesicles (111).

1.5

TGFReceptor Motifs Influencing Internalization

At the cell surface, TRII and TRI are generally found in a heteromeric
complex consisting of two TRII and two TRI. It has been well established that
these receptors undergo internalization and degradation, but the mechanisms
directing this internalization are not clear. The internalization rate of the
TGFreceptors appears to vary depending on cell-type, with receptors being
maximally internalized after 40 minutes of ligand-stimulation in Mv1Lu cells (112),
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60 minutes after stimulation in HEK 293 cells (112), and less than 25% of
receptors were internalized after 30 minutes in CR-26 mink lung cells (113).
While other receptor systems, such as the EGFR and numerous GPCRs, display
agonist-induced internalization (114,115), this is not the case for the
TGFreceptors. Mitchell and colleagues have shown that hybrid receptors
consisting of the extracellular domain of GMCSFR and the intracellular domain of
TRII undergo similar rates of internalization and recycling both in the presence
and absence of ligand (97). Similarly, it has been shown that wild-type full-length
TRII shows similar EEA1-endosomal enrichment (63) and partitioning into
membrane rafts in the presence and absence of ligand (84).
While it does not appear that ligand binding plays a role in TGFreceptor
internalization, several studies have identified motifs in the cytoplasmic domains
of both TRII and TRI that permit their association with components of
endocytic machinery. Yao and colleagues illustrated that the cytoplasmic
domains of both TRII and TRI can bind directly to the 2 subunit of AP-2 and
clathrin (116). While TRI has a slightly lower affinity for binding to AP-2 than
TRII, the presence of ligand does not affect the ability of either receptor to bind
AP-2 or clathrin (116). The authors concluded that this interaction was essential
for clathrin-mediated endocytosis of the receptors. TRII has another consensus
sequence in its cytoplasmic tail that links it to the clathrin-mediated endocytic
machinery. Ehrlich et al. identified a di-leucine motif in the cytoplasmic tail of
TRII (I218I219L220) which is essential for its clathrin-mediated internalization (117).
Indeed, mutation of each of the residues in the di-leucine motif to alanines
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prevented internalization of the receptors (117). Importantly, the constitutive
internalization of TRII via its di-leucine motif was also independent of ligand
stimulation (117).
While studies have identified motifs that link TRI and TRII to
components of the clathrin-mediated endocytic machinery, others have shown
that the receptors can also associate with components of the membrane-raft
endocytic machinery. As previously mentioned, Razani et al. identified a
caveolin-binding motif in the cytoplasmic tail of TRI which mediates its
interaction with the scaffolding domain of caveolin-1 (106). Importantly, the
interaction of TRI with caveolin-1 has functional consequences as well.
Caveolin-1 is a marker for the caveolin-1 positive vesicle, where receptors are
targeted for degradation and sterically prevented from interacting with the RSmads. In the study by Razani et al. it was shown that even when a constitutively
active TRI construct was used, co-expression of caveolin-1 decreased TGFdependent transcription (106). Since the kinase activity of TRI is necessary for
propagating Smad signal transduction, the interaction of TRI with caveolin-1
may act as a powerful negative regulator of TGFsignalling.

1.5.1

The role of receptor-interacting proteins on TGFendocytosis
TRII and TRI can bind a number of proteins at the cell surface and

many of these proteins have been shown to direct receptor endocytosis.
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ADAM12 (a disintegrin and metalloprotease protein 12) is an example of a
cell-surface TGF receptor interacting protein that enhances TGF signal
transduction. ADAM12 is a proteoglycan with an extracellular metalloprotease
domain and intracellular signalling domain (118). Using TRII as bait, ADAM12
was identified as a novel binding partner for TRII, directing the receptor to
undergo clathrin-mediated endocytosis. ADAM12 traffics receptors into the early
endosome, and in agreement with other studies, accumulation of receptors into
the early endosome enhances TGF signal transduction (119). The authors
illustrated this increase in TGFsignal transduction by showing that ADAM12
increases Smad2 phosphorylation, Smad2-Smad4 association, as well as
increased modulation of gene transcription (119).
There are also several cell-surface interacting proteins that direct TGF
receptors into the degradative pathway. CD109 is a large glycophosphatidyl
inositol (GPI)-linked protein which has been shown to bind TGF1 ligand and
form a complex with TRI, TRII and TRIII (120). As previously mentioned, GPIlinked proteins tend to accumulate in membrane rafts (77). Furthermore CD109
can also interact with caveolin-1 (121). An interesting paper by Bizet et al.,
demonstrated that the association of CD109 with the TGF receptor complex
increased the internalization of the receptors via caveolae and enhanced
receptor degradation (121). In a follow-up paper, Bizet et al., illustrated the
importance of the subcellular localization of the receptors in terms of
degradation, as CD109 enhanced the degradation of TRI by Smad7/Smurf2 by
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enhancing the co-localization of TRI with Smurf2 (122).
The atypical protein kinase C (PKC) family represents another class of
proteins that direct TGF internalization into the caveolin-1-positive vesicle.
PKC and PKCare members of the atypical protein kinase C family. These
proteins are serine-threonine kinases, which unlike members of the classic or
novel groups of PKC family do not require diacylglycerol for their activation
(reviewed in (123)). Previously, Ozdamar et al., observed that PKC interacts
with TRII through an association with Par6 to control EMT in breast cancer cells
(124). Our lab has shown that the atypical PKCs direct TRII into caveolin-1
positive vesicles, and treatment with either inhibitors to the atypical PKCs (such
as GF109203X), or siRNA directed against the atypical PKCs, extends Smad2
phosphorylation and TRII half-life (125). As the PKC family is primarily known
for its role in GPCR endocytosis and trafficking (126), the identification of this
family as controlling TGF receptor trafficking suggests that the PKCs may have
a more general role in endocytosis than previously appreciated.
Finally, cytoplasmic proteins have also been shown to control the
endocytosis of TGFreceptors. arrestin2 is a multi-functional scaffolding protein
best known for its role in GPCR signalling. Upon agonist stimulation, GPCRs are
phosphorylated by G protein receptor kinases (GRKs). Following GPCR
phosphorylation, arrestin2 binds to the phosphorylated receptor, promoting
uncoupling of the receptor from the G protein and targeting the receptor for
internalization (126). Interestingly, it has been shown that arrestin2 is also able
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to interact with TRIII and mediate the endocytosis of TRIII and TRII (48).
More specifically, the authors illustrated that TRII phosphorylates TRIII to
recruit arrestin2. They also showed that when arrestin2 expression is
decreased in HEK293 cells, TGF dependent apoptosis is increased (48),
suggesting that arrestin2 has a negative regulatory effect on TGF signalling.
Since arrestins have been shown to interact with components of the clathrinmediated endocytic machinery, such as clathrin and AP-2 (reviewed in (127)), it
would be expected that the interaction of arrestin2 with TRII and TRIII would
promote clathrin-mediated endocytosis, but the authors simply evaluated the
internalization of the receptors, not their route. Furthermore, as clathrin-mediated
endocytosis promotes TGF signalling (51,63), it would be of interest to assess
the mechanism by which arrestin2 mediates signal down-regulation, in
particular in regards to trafficking.

1.6
1.6.1

TGFBiology
TGFand Cell-cycle Arrest

While virtually every cell in the body is responsive to TGFits effects are
context- and cell-dependent (Figure 1.6). TGFstimulates the growth of
fibroblasts as well as their deposition of extracellular matrix proteins, such as
fibronectin and collagen (128). However, in tissues such as the epithelium,
mammary gland, endothelium and nervous system, TGF is growth inhibitory
(129). Initial studies evaluating the growth-suppressive effects of TGFillustrated

Figure 1.6 Cell-type Dependent TGFSignalling Outcomes

While nearly all cells are responsive to TGFsignalling, the outcome of TGFsignalling
is cell-type and context-dependent. In epithelial cells TGFis generally growthinhibitory, while in fibroblasts it stimulates ECM deposition and cell differentiation. In
tumour cells TGFtransitions from being growth-inhibitory to stimulating migration and
invasion.
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Figure 1.6
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that TGFprevented the phosphorylation of retinoblastoma protein (pRb) (130).
Retinoblastoma protein has been proposed to function as a “gate-keeper”
regulating the cell cycle. In its under-phosphorylated state, Rb protein arrests the
cell in the G1 phase of the cell cycle, while in its phosphorylated state it allowsthe
cell to undergo mitosis (131). The phosphorylation of pRb in the G1 phase is
mediated by the cyclin-dependent kinases CDK4 and 6 (131). Later work
illustrated that TGFinhibits cell-cycle progression by up-regulating the cyclindependent kinase inhibitors p15 and p21, therefore arresting cells by inhibiting
the actions of CDK4 and CDK6 (129,132). TGFhas also been shown to inhibit
the expression of the growth-stimulatory transcription factor c-Myc through
stimulating the formation of a complex consisting of Smad3, p107 and E2F4/5
(133). Therefore, TGFpotently inhibits growth through two mechanisms in
epithelial cells.

1.6.2

TGFand Apoptosis
Not only is TGFanti-tumourigenic through promoting cell-cycle arrest, but

TGFhas also been shown to induce apoptosis in a number of cells via several
mechanisms. There are two principal apoptotic pathways: the extrinsic/death
receptor pathway and the mitochondrial pathway (134). Activation of either
pathway results in the cleavage of caspase-3, inducing DNA fragmentation,
protein degradation, and the expression of ligands to stimulate phagocytic cells
to engulf the apoptotic cell (134). The extrinsic/death receptor pathway is initiated
by transmembrane receptors responding to extracellular stimuli, such as the Fas
ligand/Fas receptor complex (134). The binding of ligand to the Fas receptor
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induces the accumulation of intracellular adaptor proteins which eventually
results in the formation of the DISC, or death-inducing signalling complex, which
stimulates caspase cleavage (135). The intrinsic pathway is mediated by
mitochondria responding to either apoptotic signals or to the absence of certain
growth factors or signals (135). TGFhas been shown to activate both apoptotic
pathways.

For example, TRII is able to interact directly with Daxx, an

intracellular component of the Fas-mediated apoptotic programme to activate
JNK-mediated apoptosis (136). TGFcan also activate apoptosis via the intrinsic
pathway. Jang and colleagues illustrated that Smad signal transduction initiated
by TGFinduces the production of death-associated protein kinase, or DAPkinase

(137).

DAP-kinase

functions

upstream

of

mitochondrial-induced

apoptosis. It has been shown that a dominant-negative form of DAP-kinase
blocks the ability of TGF to induce cytochrome C release from mitochondria
(137).

1.6.3

TGFand EMT
Another important and well-studied outcome of TGFsignal transduction

is EMT, a process whereby epithelial cells lose their apical-basal polarity and
cell-cell junctions (such as tight junctions and adherens junctions) and gain a
mesenchymal phenotype, increasing their ability to produce extracellular matrix
proteins, migrate, and invade into other tissues (138) (Figure 1.7). The process of
EMT is studied in vitro through the progressive loss of epithelial markers, such as
E-cadherin, ZO-1, and cytokeratin; with the gain of mesenchymal markers such
as N-cadherin, fibronectin, and vimentin (138).

Figure 1.7 The Epithelial-to-Mesenchymal Transition (EMT)
EMT can occur in both physiological conditions as well as pathologies such as cancer.
During EMT epithelial cells lose their epithelial markers (such as E-cadherin and
cytokeratins) as well as their apico-basal polarity and gain mesenchymal markers (such
as N-cadherin and -SMA) and a mesenchymal phenotype.
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Figure 1.7
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TGFwas first shown to induce EMT in 1994 in a study by Miettinen and
colleagues. They found that TGFinduced mammary epithelial cells to gain a
mesenchymal

phenotype.

This

process

is

dependent

on

the

type

I

TGFreceptor, as the over-expression of a dominant-negative form of TRI
lacking the kinase domain prevented EMT (139). TGFmediates many of the
phenotypic changes associated with EMT. One important event during EMT is
the dissolution of tight junctions. A study by Ozdamar et al. showed that in
epithelial cells, TGFtreatment induces TRII to phosphorylate Par6, thereby
recruiting Smurf1, an ubiquitin ligase belonging to the same family as Smurf2,
and targeting RhoA for degradation (124). The degradation of RhoA by Smurf1
begins the dissolution of tight junctions in epithelial cells (124). Another important
step in EMT is the down-regulation of E-cadherin. E-cadherin is an epithelial cellcell adhesion receptor and is important in regulating the epithelial phenotype
(140). Loss of E-cadherin decreases epithelial cell junctions and also results in catenin being localized in the nucleus, activating the Wnt signalling pathway
(140). TGFpotently decreases E-cadherin levels through the induction of the
transcription factors SNAI1 and SNAI2 via Smad3 (141). SNAI1 and SNAI2
repress E-cadherin transcription, therefore decreasing steady-state levels of Ecadherin (142,143). Furthermore, not only do cells decrease E-cadherin during
EMT, but they also undergo a “cadherin switch” increasing the production of Ncadherin, or neuronal cadherin (144). N-cadherin up-regulation is also induced by
TGF(145)and increased levels of N-cadherin are associated with an increase
in cell motility, an important trait of mesenchymal cells (146). TGFalso induces
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the production of fibronectin, which contributes to cell-adhesion and motility
(128).
EMT is essential in development for the generation of the three-layered
body plan of the embryo consisting of endoderm, mesoderm, and ectoderm,
which arises through gastrulation (140). Indeed, blocking EMT prevents
development beyond the blastula stage (140). TGF is implicated in EMT during
heart valve formation in the developing embryo. TGF3 expression is upregulated by atrioventricular endothelial cells and works in concert with BMP-2 to
initiate EMT in these cells (147).
While EMT is essential for body patterning and organogenesis in
development, it has also been implicated in a number of pathologies including
cancer. In order for a tumour cell to disseminate to distant sites, it must first
detach from adjacent tumour cells, invade into the tissue, intravasate into the
blood or lymphatic system, extravasate and grow at a distant site (148). In
cancer, the ability of an epithelial-derived cancer cell to obtain mesenchymal
characteristics permits the migration and invasion of that cell to distant sites (2).
Indeed, a number of histological sections of cancers show cells undergoing EMT
at the leading edge of the invasive front of the tumour (2). Interestingly, EMT has
recently been shown to endow cancer cells with stem-cell like features, such as
the expression of stem-cell markers and self-renewal (149,150). Therefore, EMT
gives two advantages to a cancer cell. By giving cells the ability to migrate and
invade, EMT promotes metastasis, but by promoting stem-cell features, EMT
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also imparts on these cells the potential for self-renewal (149). Therefore,
identifying the mechanisms whereby TGFinduces and regulates EMT is an
important area of research.

1.7

Smad-independent Signalling

While the activation of the classical Smad-mediated TGFpathway has
been well established, TGFhas also been shown to undergo cross-talk with
several pathways including the PI3 kinase/Akt pathway, the Wnt pathway, the
Notch pathway and the MAP kinase pathway (reviewed in (151)). For the
purposes of this thesis I will focus on the cross-talk of TGFwith the Wnt and
MAPK pathways.
The WNT and TGFpathways are both implicated in important processes
such as development, fibrosis, and cancer. Research by Labbe and colleagues
illustrated that TGFhas been shown to have a synergistic effect with Wnt
signalling. For example, using a microarray approach, Labbe and colleagues
found 78 novel genes up-regulated only by treatment with both TGFand Wnt3a
and not each ligand independently, illustrating that the ligands are not simply
having an additive effect (152). Importantly, a number of these TGF/Wnt3a
target genes, such as CTGF, Inhba, and MMP14 are over-expressed in tumours
from patients with familial adenomatous polyposis (152). Numerous cancers also
have elevated Inhba, such as breast, lung, pancreatic and intestinal cancers
(152). While the mechanism through which Wnt and TGFco-operatively signal
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is not yet established, the co-operation of these two signalling pathways in
tumourigenesis may have important implications in cancer progression.
The ability of TGFto activate components of the MAP kinase pathway
has long been observed, however, the exact mechanisms whereby it accesses
this pathway independently of Smads have only been recently elucidated. The
MAP kinase pathway consists of a series of phosphorylation events, ultimately
resulting in the formation of a complex to activate transcription. There are three
principle MAP kinase pathways: the ERK1/ERK2 pathway, the Jun N-terminal
Kinase (JNK) pathway, and the p38 pathway. The MAP kinases are
phosphorylated by the MAP kinase kinases (MAP2Ks), which in turn are
activated by MAP kinase kinase kinases (MAP3Ks), which are activated in
response to extracellular stimulation. ERK1/2 has been shown to be protumourigenic, with high expression levels in many tumours, whereas JNK and
p38 kinases are stress-induced pathways with more complex roles in cancer
(153).
TGFcan activate all three MAP kinase pathways. It has been shown that
TGFactivates Erk1/2 via TRI. Briefly, TGFstimulation induces TRI to
directly phosphorylate ShcA on serine and tyrosine residues, though at a lower
level than its phosphorylation of Smads (154). The phosphorylation of ShcA
allows it to interact with Grb2, an adaptor protein which is constitutively
associated with Sos (Son of sevenless) (155). Sos is a guanine nucleotide

Figure 1.8 Smad-independent activation of p38 and JNK by TGF
TGFstimulation

can

activate

the

p38

and

JNK

MAP

kinase

pathways.

TGFstimulation facilitates Traf6 interaction with the receptor complex, where it is
ubiquitinated. The ubiquitinated Traf6 then recruits TAK1 to activate p38 and JNK
signalling. 
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Figure 1.8
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exchange factor which promotes the exchange of GDP for GTP on Ras, thereby
leading to the activation of Ras/ERK pathway (154,155).
TGFactivates both p38 and JNK MAP kinase pathways via TAK1 (TGF
activated kinase 1) (Figure 1.8).

TAK1 is a MAP3K and was shown to be

activated in response to TGFto induce MAPK-dependent transcription (156). A
study by Yamashita and colleagues identified Traf6 as a functional link between
the TGFreceptors and TAK1 (157). Traf6 can interact directly with the
TGFreceptor complex and in response to TGFstimulation, is ubiquitinated
which facilitates its interaction with TAK1 (157). The authors further illustrated
that Traf6 is essential for TGF-mediated activation of the MAPK pathway, as
siRNA mediated silencing of Traf6 abrogated the ability of TGFto increase p38
and JNK phosphorylation (157) (Fig. 1.8). The importance of the p38 pathway to
TGFsignalling has been highlighted by a study which illustrated that p38 is
required for TGF-induced EMT as well as apoptosis (158). The p38 inhibitor,
SB203580, blocked TGFinduction of cleaved caspase as well as the loss of Ecadherin, but did not affect the ability of TGFto induce Smad2 phosphorylation;
highlighting the fact that the p38 pathway is activated independently of Smad
signalling (158). Therefore, when studying TGFsignal transduction, it is
important to assess both Smad-dependent and Smad-independent signalling
pathways.
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1.8

Purpose of study, hypothesis, aims

The TGFsignalling pathway is crucial to both normal development and
tissue homeostasis. The regulation of this pathway must be tightly controlled- this
is evident in pathologies which show hyper-activation of the TGFpathway such
as cancer and fibrosis. Indeed, TGF signalling is commonly dysregulated in
cancer, and the ability of TGFto induce EMT is a crucial step in cancer
progression and the dissemination of tumour cells to distant sites. Interestingly,
the endocytic route of the TGFreceptors directly influences their signalling
outcome. Receptors internalized via clathrin-mediated endocytosis propagate
TGFsignalling, while internalization of TGFreceptors via membrane rafts
targets the receptors for degradation. Therefore, identifying proteins that direct
TGF trafficking will directly impact TGFsignal transduction. Therefore, I
hypothesize

that

protein

interactions

which

alter

TGFreceptor

endocytosis will have a direct effect on TGFsignal transduction.

The

specific aims of this study are:
Aim 1: Identify TRII motifs that direct membrane raft partitioning.
Aim 2: Evaluate the role of TRIII to TRII/TRI trafficking and signalling.
Aim 3: Assess the impact of -arrestin2 on TGFreceptor trafficking and signal
transduction.
Aim 4: Study the role of TGFligand sub-types on TRII/TRI trafficking and
signalling in non-small cell lung cancer cells.
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CHAPTER 2

THE EXTRACELLULAR DOMAIN OF THE TGF TYPE II RECEPTOR
REGULATES MEMBRANE RAFT PARTITIONING

A version of this chapter has been published in Biochem J. (2009) 421, 119131.

55

2

Chapter 2
2.1

Chapter summary

TGF-dependent Smad signal transduction has been shown to be mediated
by the endocytosis and trafficking of the TRII/TRI complex. Receptors
internalized by clathrin-mediated internalization traffic to the early endosome and
propagate Smad signaling, while those internalized by membrane-rafts traffic to
the caveolin-1 positive vesicle and are targeted for degradation. However, the
signal(s) which direct membrane raft partitioning of the signal complex are
unknown. In this chapter, I evaluate structural motifs of TRII which direct its
partitioning and endocytosis. This chapter illustrates that the extracellular domain
of TRII increases its entry into membrane-raft fractions and that the
glycosylation state of the cell as a whole, but not of TRII itself, decreased entry
of TRII into membrane rafts. Importantly, I showed that a chimeric construct
consisting of the extracellular domain of GMCSF and the intracellular domain of
TRII, does not greatly partition into membrane rafts, although the extracellular
GMCSF is glycosylated similar to TRII. My data from this chapter therefore
suggests that a glycosylated protein interacts with the extracellular domain of
TRII to influence its partitioning.
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2.2

Introduction

Endocytosis of cell surface proteins occurs via multiple pathways, two of
which are clathrin-dependent and membrane raft-dependent, with the latter
leading in part to entrance into caveolin-positive endosomes (1). Clathrin-coated
vesicles, which form from the fission of plasma membrane clathrin-coated pits,
carry receptors to the PtdIns3P-enriched early endosome, from which they can
recycle back to the plasma membrane or continue into the late endosomal
system for degradation (1). Membrane rafts are heterogeneous microdomains in
the plasma membrane that act to compartmentalize cellular processes (2). They
are enriched in cholesterol, sphingolipids, and glycolipids, and fractionate based
on light buoyant density on sucrose gradient (3).

Membrane raft/caveolar

internalization of receptors occurs through small flask-shaped invaginations
called caveolae (3). They are rich in caveolins, hairpin-like palmitoylated integral
membrane proteins that bind cholesterol (3).

Caveolae can act as signaling

platforms from which receptors such as GPCRs, receptor tyrosine kinases, and
steroid hormone receptors aggregate so as to facilitate downstream signaling
events (4). Raft dependent internalization and caveolin-positive endosomes have
also been described for the uptake of various viruses and toxins (4).
The transforming growth factor- (TGF) superfamily regulates many
cellular functions, including proliferation, differentiation, apoptosis, migration and
extracellular matrix production (5). The signal transduction pathway initiated by
cell surface TGFreceptor complexes is dependent on ligand binding as well as
receptor internalization and trafficking (1). Activation of the receptor is initiated
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through ligand-induced heteromeric complex formation of type I (TRI) and type
II (TRII) transmembrane Ser/Thr kinase receptors that target both Smaddependent and independent signaling pathways (6). Smad activation by TGF
involves the phosphorylation of the regulatory Smads, R-Smad2 and R-Smad3.
TGF employs two internalization pathways one of which is clathrin-dependent
and the other is clathrin-independent and membrane raft-dependent (rev. by (1)).
Entrance into the early endosome is thought to promote Smad activation through
Smad anchor for receptor activation (SARA) protein, which binds the receptors
and recruits Smads to the membrane.

The early endosome also contains

hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), which cooperates with SARA to facilitate TGF signaling (7), and cytoplasmic
promyelocytic leukemia protein (cPML), a scaffolding molecule that is necessary
for TGF signaling (8).

TGF signaling is antagonized by the inhibitory Smad7, which interacts
with TRI and recruits the E3 ubiquitin ligase Smurf2, which directs ubiquitindependent degradation of the TGF receptors (9,10).

Smad7 and Smurf2

complexes are localized to the caveolin-positive compartment and perturbation of
membrane rafts increases signaling and reduces the rate of receptor degradation
(11-13).
The partitioning of cellular transmembrane proteins into membrane rafts is
complex and can be dependent on the extracellular domain, as in the case for
the EGFR (14), the transmembrane domain as is the case for carboxypeptidase
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E (15) or the intracellular domain as is the case for adenylyl cyclases (16).
Recently, membrane rafts have been implicated in the endocytosis of other TGFβ
superfamily members, namely bone morphogenetic receptor 1 and 2 (BMPRI,
BRII) (17,18). While cell surface TGF receptors reside in both membrane raft
and non-raft membrane domains (11-13,19) the determinant that controls
partitioning is unknown.

A short peptide sequence (I218I219L220) on the

cytoplasmic region of TRII is the major signal for clathrin-mediated endocytosis
(20) and the TGF receptors associate with both clathrin and AP-2 (21).
However, the cytosolic TRII domain also contains consensus sequences that
were previously identified as caveolin scaffolding domains (22) and the major
binding partner of TRII, the type I TGF receptor, has also been shown to
associate with caveolin-1 (13,23). On the extracellular surface of the plasma
membrane Galectin 3, a -galactose binding protein that contains a
carbohydrate recognition domain (24), associates with receptors and is
postulated to influence receptor internalization into EEA1 and caveolin-1 positive
vesicles (25). Due to the numerous interacting partners on both facets of the
plasma membrane, the primary determinants that partition receptors into
membrane rafts remain unclear.
Using subcellular fractionation and mutants of TRII I demonstrate that the
extracellular domain of TRII mediates receptor partitioning into membrane rafts.
Consistent with these results, I illustrated that a GMCSF-TRII hybrid receptor
that replaces the native TRII extracellular domain with that of the GMCSF
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receptor, results in a chimeric receptor that is largely excluded from membrane
rafts and caveolin-1-positive structures.

Also, studies using tunicamycin

perturbed receptor membrane raft partitioning. Importantly, I showed that this
was not due to a disturbance of membrane raft formation, as treatment of cells
with tunicamycin did not disrupt membrane rafts. Furthermore, the glycosylation
of TRII itself did not account for its differential membrane partitioning,
suggesting that partitioning involves interactions with other cell surface
glycoproteins. Taken together, my results indicate that the extracellular region of
TRII is necessary for receptor membrane raft partitioning.

2.3
2.3.1

Materials and Methods
Reagents

Polyclonal anti-HA, anti-Flag and anti-TRII (Santa Cruz), monoclonal
anti-HA

(12CA5,

Laboratories),
(Bioscience)

Boehringer),

monoclonal
and

polyclonal

monoclonal

anti-Flag

anti-EEA1

(Sigma),

anti-caveolin-1

monoclonal

(Transduction

(Transduction
anti-CD131
Laboratories)

antibodies were used as per the manufacturers’ instructions. Tunicamycin was
purchased from Sigma-Aldrich. TGF1 ligand was purchased from Peprotech.

2.3.2

Constructs
Constructs encoding for the amino or carboxyl terminally hemagglutinin

(HA) epitope-tagged wild-type TGF type II receptor (HA-TRII or TRII-HA;
(26)), the intracellularly truncated receptor (HA-TRII-Cyt; (27)) and the
GMCSF-TRII hybrid receptor (28), and the GMCSF2RB receptor (a.k.a. bC;
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(29)) were previously described. The full length carboxyl HA-tagged TRII in
pCMV5 was used as the template to construct a receptor that has the signal
sequence and 13 amino acids of the extracellular domain (TRII-EX-HA) and
the glycosylation mutant substituting asparagines 70, 94 and 154 of the TRII to
aspartic acid residues (TRII-3ND-HA). All constructs were generated using a
PCR-based mutagenesis approach and were validated by sequencing analysis.

2.3.3

Cell Culture
HEK 293T human kidney epithelial cells (American Type Culture

Collection) were cultured in DME medium (Gibco) supplemented with 10% fetal
bovine serum.

Cells were maintained at 37C in a humidified atmosphere

containing 5% CO2 .

2.3.4

Transfection
HEK 293T cells were transiently transfected using the calcium phosphate

precipitation method as previously described (12). Briefly, HEK293T cells were
plated at approximately 50% confluency in 6 well dishes. The following day cells
were transfected with 1.0 g of TRII-HA, 1.5 g of HA-TRII-Cyt, 0.5 g of
TRII-EX-HA and/or 1.0 g TRI-flag as indicated in Figure 2.1.

2.3.5

Preparation of Membrane Rafts/caveolin-enriched fractions
The caveolin/raft-rich membrane fractions were isolated as previously

described (12). Briefly, transfected cells grown to confluence in 100-mm dishes
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were used to prepare the membrane fractions. All steps were carried out at 4C.
After two washes with cold 1 phosphate-buffer saline (PBS) cells were lysed
with 0.5 M Na2CO3, pH 11.0, containing protease inhibitors. After scraping, the
cell lysate was collected and homogenized three times for 10s bursts using a
Polytron tissue grinder (Brinkmann Instruments).

Homogenates were then

sonicated three times for 20s with a Vibra Cell sonicator (Sonics Materials Inc.).
The homogenates were adjusted to 40% sucrose and overlaid with 30% sucrose
and 5% sucrose solutions. The samples were centrifuged at 200,000 x gav for
16h at 4C, using a Beckman SW41 rotor. Twelve 1-mL fractions were collected,
and an aliquot of each fraction was eluted with Laemmli sample buffer, boiled,
and subjected to SDS-PAGE followed by Western blot analysis.

2.3.6

Immunoblotting
Proteins were separated by SDS-PAGE and transferred to nitrocellulose

membranes by electrophoretic transfer. Blots were then blocked in 5% skim
milk/TBS-5 for one hour. Following overnight incubation with primary antibody at
4˚C, blots were incubated with secondary antibody at room temperature for 45
minutes.

Bound

antibodies

were

then

detected

using

SuperSignal

chemiluminescence reagent (Pierce) and blots were imaged on a VersaDoc (11).

2.3.7

Immunoprecipitation
Transfected 293T cells were lysed (50 mM Tris-HCl, pH 7.4, 150 mM

NaCl, 1 mM EDTA, 0.5 % Triton X-100, 1 mM PMSF, and cocktail protease
inhibitors) and centrifuged at 15,000  gav at 4C for 5 min. 50 g aliquots of
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supernatants were collected for analysis of total protein concentration.

The

remaining cell lysates were incubated with anti-Flag mAb followed by protein G
sepharose incubation.

The precipitates were washed 3 times, eluted with

Laemmli sample buffer and subjected to SDS-PAGE and immunoblot analysis.

2.3.8

Tunicamycin treatment
A dose response curve of tunicamycin treatment on HEK293T cells was

completed and a concentration of 2g/mL was found to be optimal and did not
induce cell death. HEK 293T cells were treated with 2 µg/mL tunicamycin in
DMEM supplemented with 0.2% fetal bovine serum, 24h after transfection. After
20h of incubation with the antibiotic, cells were homogenized and fractionated by
sucrose density ultracentrifugation as described above.

2.4
2.4.1

Results
An extracellular truncation mutant of TRII interacts with TRI

To understand if the partitioning of TGF receptors between raft and nonraft membrane domains is dependent on a molecular address in the receptor, we
first explored the extracellular and intracellular domains of the TGF type II
receptor (TRII). A mutant containing only 13 amino acids of the extracellular
domain (TRII-EX-HA) was generated and examined along with a truncated
TRII which contains only 10 amino acids of the intracellular domain (HA-TRIICyt; (27); Figure 2.1A). The full length TRII-HA and HA-TRII-Cyt have been
previously described and are both present at the cell surface. They also bind
ligand and the TGF type I receptor (27). However, TRII-EX-HA had not been

Figure 2.1 Characterization of TRII lacking the extracellular domain.
(A) TRII mutants lacking the extracellular or the intracellular domain. Full length TRIIHA and intracellularly truncated TRII (HA-TRII-Cyt) have been previously
characterized (26,27). The extracellularly truncated receptor tagged at the carboxyl
terminus (TRII-EX-HA) was generated for this study. The different domains of the
receptors, the hemagglutinin tag (HA) as well as the plasma membrane (PM) and
cytoplasm are indicated.
(B) TRII-EX-HA interacts with wild type TRI.

HEK 293T cells were transiently

transfected with cDNA encoding the indicated receptors. Cell lysates were subjected to
immunoprecipitation (IP) with mouse anti-Flag antibody followed by immunoblotting with
rabbit anti-HA antibody (-HA) to detect TRI-associated type II receptor or rabbit antiFlag (-Flag) antibody to detect total TRI expression as indicated (top panel). The
relative expression of each construct was assessed by immunoblotting 50 g of total
cell lysates. The relative mobilities of the receptors are indicated (N=3).
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characterized. Therefore, I sought to assess whether TRII-EX-HA is able to
associate with the type I TGF receptor (TRI). This occurs independently of
ligand binding and is mediated by the cytoplasmic domains of the receptors (30).
Indeed, immunoprecipitation of TRI and immunoblotting for type II receptors
revealed that TRII-EX-HA associated with TRI (Figure 2.1B). It is noteworthy
that both forms of the membrane-bound TRII-EX receptor, the 50 and 52 kDa
forms, associate with the TRI, whereas the 47 kDa cytosolic fragment of TRIIEX does not associate with membrane-localized TRI. As positive controls, I
assessed the interaction of TRI with the wild type TRII-HA as well as HATRII-Cyt and I observed that they both associate with immunoprecipitated
TRI.

2.4.2

TRII-EX-HA is largely excluded from membrane raft fractions
Having found that the TRII-EX-HA associates with TRI, the membrane

raft partitioning of the three versions of TRII was next compared (Figure 2.2).
To assess membrane partitioning, cell homogenates were fractionated via
sucrose density centrifugation as previously described (11-13,19). Briefly, cell
homogenates were adjusted to 40% sucrose, overlaid with 30% and 5% sucrose
cushions and centrifuged (Figure 2.2A; left panel). One mL fractions were then
collected and immunoblotted with markers of either membrane rafts or early
endosomes. Confirmation of the partitioning of raft from non-raft membranes is
shown in Figure 2.2A (right panel) where fractions 4-6 on the sucrose gradient
contained the majority of caveolin-1, a membrane raft resident protein (31) and

Figure 2.2 The TRII extracellular domain is important for membrane raft
partitioning.
(A) Subcellular fractionation of HEK 293T cells. Schematic representation of membrane
raft isolation protocol (left panel). Cell homogenates were sonicated and adjusted to
40% sucrose, overlaid with 30% and then 5% sucrose cushions prior to
ultracentrifugation (C). Twelve 1 mL fractions were then collected with membrane rafts
(white region) usually present in fractions 4-6.

Aliquots were immunoblotted for

endogenous EEA1 (-EEA1), or endogenous cav-1 (-Cav-1), (right panel) (N=3).
(B) Membrane raft partitioning of full length TRII and the truncation mutants. HEK
293T cells transiently transfected with cDNA containing the indicated receptor
constructs were subjected to subcellular fractionation as described in panel A.

All

fractions were then immunoblotted with anti-HA antibody (-HA). HEK 293T cells
transiently transfected with wild-type TRII cDNA were treated with 500 pMol TGF for
1 hour and subjected to subcellular fractionation (bottom panel). The fractions were
then subjected to SDS-PAGE and immunoblotted with anti-TRII antibody (N=3).
(C) Quantitation of wild-type and mutant forms of TRII in membrane raft and non-raft
fractions.

Membrane raft (fractions 4-6) or non-raft (fractions 8-12) fractions from

experiments described in (B) were pooled, adjusted to the same volume and
immunoblotted with anti-HA (-HA) antibody. The relative amount of TRII receptors in
membrane-raft and non-raft fractions were quantitated using QuantityOne software and
graphed as a percentage of total receptors expressed. Each data point represents the
mean of three experiments ± standard deviation (N=3).
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fractions 8-12 contained the early endosomal auto-antigen 1 (EEA1), an early
endosomal resident protein (32,33) . To analyze receptor partitioning TRII-HA,
HA-TRII-Cyt or TRII-EX-HA was transiently expressed in HEK 293T cells
and fractionated cell homogenates on sucrose gradients (Figure 2.2B). TRII-HA
was found to be present in both the raft and non-raft fractions and HA-TRII-Cyt
was also observed in raft and non-raft fractions (Figure 2.2B). In contrast, the
TRII-EX-HA receptor was predominantly observed in the non-raft fractions. To
assess whether ligand treatment affects TRII membrane partitioning, I treated
HEK 293T cells with 500 pM TGFone hour prior to membrane raft isolation.
Following SDS-PAGE and immunoblotting, I observed that TGFtreatment does
not affect partitioning, as TRII was still found primarily in raft fractions.

To

measure the relative amounts of receptors in the raft and non-raft fractions, raft
fractions (fractions 4-6) or non-raft fractions (8-12) were pooled from experiments
carried out as shown in Figure 2.2B, adjusted to the same volume and were
subjected to quantitative immunoblotting (Figure 2.2C). It was observed that
approximately 65% of TRII was in rafts whereas 85% of TRII-Cyt fractionated
in rafts (Figure 2.2C; right panel). In marked contrast, only 20% of TRII-EXHA was in the membrane raft fractions.

These results indicate that the

extracellular domain of TRII mediates partitioning into membrane rafts, but the
extracellular domain is not affecting partitioning via its ligand-binding capabilities.
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2.4.3

Perturbation of glycosylation alters membrane raft partitioning of TRII
Cells lacking proper glycosylation have defects in cytokine, and in

particular TGF signaling (25). Therefore the pharmacological perturbation of
cellular glycosylation was assessed to determine if this would alter TGF
receptor partitioning in membrane raft domains (Figure 2.3). HEK293T cells
transiently expressing wild-type TRII were incubated with tunicamycin, an
antibiotic that blocks the reaction of UDP-GlcNAc and Dol-P in the first step of
glycoprotein synthesis and

thus inhibits the synthesis of all N-linked

glycoproteins (34). A reproducible decrease of receptors in the raft fractions and
a concomitant increase in non-raft fractions in tunicamycin-treated cells was
observed (Figure 2.3A). Importantly I illustrated that this shift was not due to
perturbation of lipid rafts with tunicamycin treatment as shown in Figure 2.3B.

2.4.4

The glycosylation status of TRII does not alter its membrane raft
partitioning
These results suggest that the glycosylation state of TGF receptors

and/or the proper glycosylation of other cell surface proteins regulate the
membrane raft partitioning of receptors.

To distinguish between these two

possibilities, a construct of TRII that contains mutations in all three putative Nlinked glycosylation sites was generated (TRII-3ND-HA; Figure 2.4A). Based on
the molecular weight of the mutant compared to the wild-type receptor, it appears
that the three putative sites are indeed glycosylation sites (Figure 2.4).The
partitioning of TRII-3ND-HA in membrane raft and non-raft fractions was next
assessed. It was shown that this receptor co-fractionated with both membrane

Figure 2.3 Perturbation of glycosylation alters membrane raft partitioning of TRII
(A) Quantitation of pharmacological inhibition of glycosylation on receptor partitioning.
Membrane raft (fractions 4-6) or non-raft (fractions 8-12) fractions from experiments
described in were pooled, adjusted to the same volume and immunoblotted with anti-HA
(-HA) antibody. The relative amount of TRII receptors in membrane-raft and non-raft
fractions were quantitated using QuantityOne software and graphed as a percentage of
total receptors expressed. Each data point represents the mean of three experiments ±
standard deviation.
(B) Evaluation of tunicamycin treatment on membrane raft formation. HEK 293T cells
were grown in the presence or absence of 2 ug/mL tunicamycin for 20 hours. Cells were
then subjected to sucrose-density ultracentrifugation and immunoblotted for early
endosome autoantigen 1 (-EEA1) or caveolin-1 (-Cav-1) (N=3).

68

Figure 2.3

Figure 2.4. The TRII glycosylation mutant partitions in membrane rafts.
(A) Schematic representation of wild type TRII and the mutant in which the three Nlinked glycosylation sites were mutated from asparagine (N) to aspartic acid (D) (TRII3ND-HA).
(B) Membrane raft partitioning of TRII-HA and TRII-3ND-HA.

HEK 293T cells

transiently transfected with control vector (pCMV5) or cDNA containing the indicated
receptors were subjected to subcellular fractionation in order to separate cellular
membrane raft and non-raft components. The fractions were immunoblotted with antiHA antibody (-HA; top panel). The membrane-raft and non-raft fractions were pooled,
immunoprecipitated (IP) with anti-TRII antibody and immunoblotted with anti-TRII
antibody (-TRII; bottom panel). The percentage of receptors in membrane rafts was
quantitated using QuantityOne software and is indicated as % in the raft compartment
(N=3).
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raft and non-raft fractions in a similar fashion to the wild type TRII (Figure 2.4B).
Quantitation of pooled raft and non-raft fractions revealed that in both cases
approximately 60% of the receptors were found in the raft fractions and 40% in
the non-raft fractions (Figure 2.4B, bottom panel).

Together, these results

demonstrate that the glycosylation state of TRII per se is not a determinant for
membrane-raft partitioning, and suggest that partitioning may rely on the proper
glycosylation of other cell surface proteins.

2.4.5

GMCSF-TRII does not partition with membrane rafts
Having observed that the glycosylation state of the TRII was not a factor

in raft vs. non-raft partitioning, I therefore assessed whether a substitution of the
extracellular domain of TRII with another receptor that also contained 3 N-linked
glycosylation sites would affect membrane raft partitioning. To do this I studied a
hybrid GMCSF-TRII receptor construct (28). This hybrid receptor contains the
extracellular domain of the granulocyte/macrophage colony stimulating factor
(GMCSF) 2B receptor, fused to the transmembrane and intracellular domains of
the TRII. Similar to the wild-type TRII, it has three N-linked glycosylation sites
but was reported to be excluded from caveolin-positive membrane domains
structures ((35); Figure 2.5A). In contrast to the wild type TRII, I found that the
wild type GMCSF2BR was predominantly found to partition in non-raft fractions
(Figure 2.5B and C). Interestingly, the GMCSF-TRII chimeric receptor was also
found to mostly partition with the non-raft fractions (Figure 2.5B and C). This
supports the previous findings that the glycosylation state of the receptor does

Figure 2.5 GMCSF-TRII hybrid receptors partition predominantly in non-raft
fractions.
(A) Schematic comparison of TRII, the GMCSF-TRII receptor hybrid, and GMCSF2RB.
(B) HEK 293T cells transiently expressing the receptor constructs as indicated were
subjected to subcellular fractionation to separate membrane raft and non-raft
components. Fractions were then immunoblotted with anti-HA or anti-CD131 antibody
as indicated. All fractions were also subjected to immunoblotting with caveolin-1
antibodies (-Cav1) in order to indicate membrane rafts (N=3).
(C) Fractions from the experiments carried out as described in (B) were pooled into raft
and non-raft fractions and adjusted to the same volume. Pooled membrane raft and
non-raft fractions were then immunoblotted with anti-TRII (-TRII) antibody or antiCD131 (-CD131) antibody (top panel), quantitated and graphed as a percentage of
total receptor expressed (bottom panel). Each data point represents three experiments
± standard deviation.
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not play a direct role in membrane raft partitioning and that the native
extracellular domain of TRII is essential for raft partitioning.

2.5

Discussion

Different transmembrane proteins have been shown to partition into
membrane raft domains via their extracellular, intracellular or transmembrane
regions (14-16). For TRII it was unclear which domain is responsible because
this receptor associates with proteins on both the extracellular and intracellular
facet of the plasma membrane. On the outer aspect of the plasma membrane,
Galectin 3 interacts with TRII and maintains receptors at the cell surface (25) .
The intracellular domain of the receptor associates with clathrin and AP2 (21),
and the TRII/TRI complex associates with caveolin-1, a resident membrane
raft protein (13,23).
To address this problem, the partitioning of TRII lacking the majority of
the extracellular or intracellular domains was assessed.

It was found that a

mutant TRII that lacked the intracellular domain almost entirely partitioned with
membrane rafts similarly to wild type TRII, whereas the extracellularly truncated
receptor was mostly excluded from rafts. These results indicate that while the
extracellular domain of TRII directs receptors into rafts, the intracellular domain
directs them to non-raft domains. This was surprising because it was assumed
that the intracellular domain, which contains a caveolin-1 binding motif, would
play a larger role in membrane partitioning.

If receptor partitioning is not
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mediated by caveolin-1 binding, then the association may be important for other
functions within the membrane raft compartment after receptor partitioning.
Indeed, it was previously found in HEK 293T cells that the association of
receptors with Smad7 and Smurf2 occurred in membrane rafts and the
degradation of the receptor complex was enhanced when caveolin-1 protein was
expressed (11).

Furthermore, the chemical perturbation of membrane rafts

induced an increase in TGF signal transduction. Therefore, the partitioning of
receptor complexes may be important for receptor degradation and/or inhibition
of signal transduction and this may be dependent on caveolin-1 association with
receptors post membrane raft targeting.
The partitioning of receptors into membrane rafts also has important
implications in receptor trafficking. The intracellular domain that has the AP2 and
clathrin binding sites was shown to be important for clathrin-dependent
internalization (20). Internalization from membrane rafts/caveolae leads to the
formation of caveolin-1-positive vesicles.

The balance between the two

internalization pathways would therefore be an important mediator in receptor
signaling and degradation.
Previous work showed that TGF receptors bound the cell surface Nglycan binding protein Galectin 3 (25). In that study, Mgat5-/- cells were found to
contain more receptors in the EEA1-early endosomal compartment compared to
wild type cells and the receptor half-life was prolonged (25). In this study, it was
shown that mutation of all of the N-linked glycosylation sites of the full-length
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receptor did not affect entrance into membrane rafts.

Therefore, it was

concluded that glycosylation of TRII per se does not control trafficking but that
the interaction of TRII with other cell surface glycoproteins or glycoprotein
binding proteins, are critical. This mode of raft/caveolae association is similar to
that of the EGF receptor where the extracellular domain was found to be critical
in the targeting of receptors to membrane rafts (14). In fact, there are several
parallels between EGF receptor and TRII raft partitioning: 1) they both bind cell
surface Galectin-3, and

2) their partitioning is dependent on proper cellular

glycosylation but not their own glycosylation. Moreover, studies have shown that
the ubiquitination and trafficking of EGF receptors are membrane raft-dependent
processes (36,37). It would therefore be of interest to assess if both of these
receptors associate with common glycoproteins at the cell surface, which could
direct them into membrane rafts.
Since the glycosylation state of the receptor was not responsible for the
partitioning of receptors into membrane rafts and the scanning deletion mutants
did not provide insight into the extracellular domain that regulate partitioning of
receptors, I assessed if replacing the extracellular domain would influence raft
partitioning.

I therefore turned my attention to a chimeric receptor, GMCSF-

TRII, which has three N-linked glycosylation sites, as does wild-type TRII, and
upon endocytosis was shown to co-localize exclusively with clathrin-positive, but
not caveolin-positive, structures (35).

Based on previous data, I therefore

considered that absence of the native extracellular domain of TRII would
interfere with normal raft partitioning and entrance into the caveolin-1
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compartment. Indeed, I found that partitioning of the GMCSF-TRII hybrid into
rafts was substantially reduced compared to the wild type TRII. Since the
partitioning was not completely abolished, a question remains as to why there
are still a proportion of the hybrid receptors observed in the raft fractions?
Previously, it was shown that TRI directly interacts with caveolin-1 via a
consensus motif in the cytoplasmic tail of the receptor (23). Interestingly, TRII
contains putative caveolin-1 binding motifs, which may play a partial role in the
partitioning of receptors into membrane rafts.

It was estimated that this

partitioning is approximately 20% based on the observations using the TRIIEX-HA construct (Figure 2.2). The wild type GMCSF receptors also partially
partition into membrane rafts (Figure 2.5).

Therefore the combination of a

caveolin-1-binding motif and the small propensity of GMCSF receptors to
partition into membrane rafts may account for the 40% of GMCSF-TRII hybrid
receptor membrane raft partitioning.
Receptors that are endocytosed via clathrin-mediated endocytosis enter
the early endosome, access Smad 2/3, and propagate TGF signal transduction;
however, receptors that are localized in membrane rafts are targeted for
degradation by ubiquitination (1). While the downstream signal transduction of
the TGF signalling pathway has been well characterized, the signal(s) directing
receptors to either method of endocytosis is still unclear. Here, it is shown that
the extracellular domain of the type II receptor is necessary for entrance into
caveolin-1 positive vesicles. It is also shown that the glycosylation status of the
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cell, but not of TRII itself, affects the membrane partitioning of TRII. This
suggests that there may be interacting glycosylated protein(s) acting at the cell
surface that direct the partitioning of the type II receptor.
Several articles have attempted to identify signals affecting TRII
partitioning at the cell surface. A study by Chen and colleagues illustrated that
cells lacking heparin sulphate synthesis have significantly less TRII found in
membrane rafts (38). The authors postulated that since TRIII has many
proteoglycan attachments, it may be the signal that dictates TRII internalization.
TRIII is the least well characterized of the TGF receptors, and its role in TGF
signaling is only beginning to be understood. Several reports show that loss of
TRIII can potentiate TGF-dependent epithelial-to-mesenchymal transition.
Gordon and colleagues have shown that TGF-dependent EMT in pancreatic
cancer cells results in a loss of TRIII expression (39). TRIII loss also occurs in
prostate cancer cells and non-small cell lung adenocarcinoma cells, with
increased loss of TRIII correlating with a more aggressive cancer phenotype
(40, (40). However, a study by Criswell and colleagues showed that loss of
TRIII in breast cancer cells decreased TGF dependent invasion, migration,
and signal transduction (41). Recently, an article evaluated the endocytosis of
TRIII and its membrane localization. The authors showed that while the receptor
can internalize via both clathrin-dependent and independent mechanisms,
inhibiting membrane raft internalization decreased TGF signal transduction (42).
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All of these studies illustrate the fact that the role of TRIII in TRII endocytosis
and signaling will be a fascinating area of study.
Another interesting line of investigation will be to assess the contribution of
TGF type I receptors in the partitioning of receptor complexes. Huang and
colleagues have observed that membrane raft and non-raft fractions contain
altered ratios of the type I receptor to the type II receptor (38, 44, 45) . They
further found that this ratio plays a role in clathrin vs. caveolar endocytosis of
receptors and influences their signaling potential. Therefore, future studies
identifying how the different TGF receptors, as well as other cell surface
receptor-interacting proteins, regulate TGF signaling and trafficking will be of
great interest.
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CHAPTER 3

TGF RECEPTOR TYPE III DIRECTS CLATHRIN-MEDIATED ENDOCYTOSIS
OF TGF BETA RECEPTOR TYPES I AND II

A version of this chapter has been published in Biochem J. (2010) 429, 137-145
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3

Chapter 3
3.1

Chapter Summary

Chapter 2 of my thesis illustrated that the extracellular domain of TRII and
the glycosylation status of the cell as a whole was important in directing
membrane-raft partitioning of TRII. This suggested that a glycosylated protein
which could interact with TRII at the cell surface may direct TRII partitioning. In
this chapter, I assessed a candidate protein, TRIII, for its ability to direct
internalization and trafficking of TRII/TRI complexes. Overall, I found that
TRIII increased non-membrane raft partitioning of TRII/TRI complexes and
increased their trafficking to early endosomal compartments. Furthermore, the
interaction of TRIII with the receptor complex could occur both in the presence
and absence of ligand. Finally, the interaction of TRIII with TRII/TRI
complexes increased the complex half-life as well as basal TGFsignalling.
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3.2

Introduction

The Transforming Growth Factor Beta (TGF) signalling pathway is
necessary for the normal functioning of a variety of cells; its cell-type specific
responses often mediate growth inhibition, extracellular matrix synthesis and cell
migration. While this signalling pathway is crucial for normal development, it also
plays a much more sinister role in a number of pathologies, including cancer (1).
Somatic mutations of the TGFβ receptors, along with activation of potent growthpromoting oncogenes can override the tumour-suppressive effects of TGFβ
(reviewed in (2)).
There are three principle receptor subtypes in the classical TGFβ
pathway. TGFβ receptor I (TβRI) and TGFβ receptor II (TβRII) are structurally
related

glycoproteins

with

cytoplasmic

serine/threonine

kinase

domains

(reviewed in (3)). A third receptor, TGFβ receptor III (TβRIII) or betaglycan, is a
large proteoglycan that is able to regulate TGFβ signal transduction by binding
and presenting active TGFβ ligand to TRII (1).
In the canonical TGFβ signalling pathway, the binding of ligand to TβRII
causes TβRII to phosphorylate the TβRI receptor at serine-threonine residues in
its GS domain (1). Activated TβRI then phosphorylates and activates Smad
transcription factors. With the aid of specific nuclear localization signals, the
Smad

complex

translocates

to

induce

TGF-dependent

transcriptional

programmes (4). The signal transduction pathway of activated TGFβ receptors
has been well characterized. However, the role of receptor interactions at the
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plasma membrane and their effect on endocytosis and trafficking has yet to be
fully evaluated.
Endocytosis of nutrients, growth factors and receptors is necessary for the
normal functioning of a cell. When cell-surface receptors are activated, they are
able to interact with cytosolic adaptor proteins that can promote polymerization of
clathrin (reviewed in (5)). Clathrin from the cytosol is recruited to the plasma
membrane and aggregates to form pits (6). These pits can then form vesicles for
the transportation of nutrients and signals from the extracellular environment to
the cell interior (7).
Clathrin-independent endocytosis through membrane rafts is also a
common mechanism for the uptake of signals and nutrients from the extracellular
environment. Membrane rafts are microdomains in the plasma membrane that
are enriched in cholesterol and sphingolipids (8). Membrane rafts have been
implicated in the endocytosis of a variety of receptors, including the group I
metabotropic glutamate receptors (9), insulin-like growth factor receptor (10), and
epidermal growth factor (reviewed in (11)). Similarly, membrane raft mediated
endocytosis plays a crucial role in TGFβ signalling, specifically in regards to
receptor turnover and degradation. TGF receptors endocytosed by clathrindependent endocytosis increase TGFβ signal transduction, while membrane raft
endocytosis of receptors promotes receptor degradation (12). It has been shown
that the extracellular domain of TRII is necessary for entrance into membraneraft domains (13). Furthermore the glycosylation state of the cell, though not of
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TRII itself, mediates TRII endocytosis (13). This suggests that TRII may
interact with glycosylated protein(s) at the cell surface to direct receptor
partitioning.
While many studies have evaluated the contribution of the type II and type
I TGF receptors to Smad signalling, few have investigated the role of TRIII.
The type III TGF receptor is a highly glycosylated proteoglycan with a large
extracellular domain (14, 15). Previously, TRIII was thought to simply function
in presentation of ligand to the type II receptor (16); however, several recent
studies illustrate that TRIII may play a crucial role in TGF-dependent cancer
metastasis. Expression levels of TRIII have been correlated with a number of
cancers, including prostate cancer (17), ovarian cancer (18), granulosa tumours
(19), and non-small cell lung adenocarcinomas (20). In some instances, TRIII
overexpression appears to contribute to cancer cell motility and invasion (21),
while in other cases knockdown of TRIII increases tumour cell metastasis (22).
Furthermore, TRIII endocytosis has been implicated in the activation of
TGFsignalling (23). These studies highlight the fact that TRIII may play a
crucial role in TGF signalling, particularly in cancer.
The objective of the present study is to evaluate the role of the type III
TGF receptor in TGF receptor endocytosis and degradation.

Using

immunofluorescence microscopy and sucrose-density ultracentrifugation, I show
that TRIII directs TRII and TRI to undergo clathrin-mediated endocytosis.
TRIII also increases trafficking of TRII into early endosomal compartments.
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Furthermore, this re-directed trafficking increases TRII/TRI complex half-life
and basal TGF signalling.

3.3
3.3.1

Materials and Methods
Cell culture

HEK (human embryonic kidney)-293T cells were maintained in DMEM
(Dulbecco’s modified Eagle’s medium) (Gibco) supplemented with 10% fetal
bovine serum. Mink Lung cells stably transfected with HA-tagged TRII (Mink
Lung HAT cells) were cultured in MEM supplemented with non-essential amino
acids, 10% fetal bovine serum and 0.3% hygromycin. HepG2 cells were
maintained in MEM supplemented with non-essential amino acids and 10% fetal
bovine serum. All cells were maintained at 37°C in 5% CO2.

3.3.2

Constructs
Constructs encoding the carboxy terminus hemagluttinin (HA) epitope

tagged type II TGF receptor (TβRII-HA), the intracellularly truncated receptor
(TβRII-Δcyt) and an extracellularly truncated receptor (TβRII-ΔEX) were
previously described (13, 24).

The GFP-tagged Rab5 wild-type (WT),

constitutively active (Q79L) and dominant negative (S34N) constructs were used
as previously described (25).

3.3.3

Transfection
HEK293T cells were transiently transfected using the calcium phosphate

precipitation method as previously. Cells were plated at 50% confluency in
100mm dishes. The following day cells were transfected with 5 g TRII-HA, 5
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g of TRI-flag, and 5 g of myc-TRIII. Mink lung HAT cells were transiently
transfected using the polyethyleneimine (PEI) method.

3.3.4

Isolation of caveolae/membrane-raft-enriched membrane fractions
Membrane rafts were isolated as previously described (12, 13) . Briefly,

transfected HEK293T cells were grown to confluence in 100-mm-diameter
dishes. Cells were washed twice with cold 1X PBS and lysed in 0.5M Na2CO3,
pH 11.0 containing protease inhibitors. After the cells were scraped, the cell
lysate was homogenized in three 10 second bursts using a Polytron tissue
homogenizer (Brinkmann Instruments). Cells were then sonicated three times for
20 seconds each with a Vibra Cell sonicator (Sonics and Materials). The
homogenates were then adjusted to 40% sucrose, and overlaid with 30%
sucrose and 5% sucrose solutions. The samples were centrifuged for 16h at
200,000 gav at 4°C using a Beckman SW41 rotor. Following centrifugation,
12x1mL samples were collected and an aliquot of each sample was denatured
with Laemmli sample prep buffer, boiled and subjected to SDS-PAGE followed
by immunoblotting.

3.3.5

Immunoblotting
Proteins were separated by SDS-PAGE (10% gels) and transferred to

nitrocellulose by electrophoretic transfer. Blots were incubated for 1 hr in 5%
skim milk/TBST. After incubation with primary and secondary antibodies, bound
antibodies were detected using SuperSignal chemiluminescence reagent
(Pierce) and a VersaDoc imager (Biorad).
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3.3.6

Immunoprecipitation
HEK293T cells transiently transfected with cDNA were lysed in TNTE

(50mM Tris/HCl, pH 7.4, 150 mM NaCl, 1mM EDTA, 0.5% Triton X-100, 1mM
PMSF and protease inhibitors) and centrifuged at 14000 gav for 10 min. at 4°C. A
protein assay was conducted on total cell lysates for analysis of protein
concentration. The remaining cell lysates were then incubated with 1g -HA
primary antibody for 16 hrs at 4°C followed by incubation with Protein G
sepharose beads for 2 hrs at 4°C. The precipitates were washed three times,
eluted with Laemmli sample prep buffer and subjected to SDS-PAGE (10% gels)
and immunoblotting.

3.3.7

Immunofluorescence/Receptor Internalization
HAT Mv1Lu cells were plated on coverslips in 12 well dishes. Twenty-four

hours post-transfection of myc-TRIII (0.3 g/well), Rab5-GFP (0.5 g/well),
Rab5-S34N-GFP (0.5 g/well), Rab5-Q79L-GFP (0.5 g/well) or Cav-1 GFP (0.5
g/well) cDNA with polyethylenimine, cells were serum-starved and treated with
50 μM ZnCl2 to induce HA-TRII expression.

The following day, cells were

cooled to 4°C, and treated with -HA antibody for 2 hours at 4°C to label
receptors at the cell surface. Coverslips were then incubated with donkey antirabbit Cy3 antibodies. After labelling, cells were either permitted to internalize, by
incubating at 37°C for 30 minutes or 1 hour, or were immediately fixed and
permeabilized. Cells were incubated with -EEA1 antibody, followed with donkey
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-mouse Cy5. All coverslips were then immunomounted and visualized using an
IX81 inverted immunofluorescence microscope (Olympus, Canada).

3.3.8

Affinity Labelling
Transiently transfected HEK293T cells were labelled for 2 hrs with 250 pM

[125I] TGF1 ligand in 0.5% bovine serum albumin (BSA) in Krebs Ringers Hepes
(KRH) at 4°C. Cells were cross-linked to ligand using disuccinimidyl suberate
(DSS) as described previously (12). Cells were then either immediately lysed in
1XTNTE or incubated in media/10% FBS at 37°C for 2, 4 or 8 hrs prior to lysis.
Samples were eluted with Laemmli sample prep buffer, and separated using
SDS-PAGE (7.5% gels). Receptors were visualized using phosphorimaging
(Molecular Dynamics).

3.3.9

Luciferase Reporter Assay
HepG2 cells were transiently transfected using the calcium phosphate

precipitation method with an Activin Response element upstream of a luciferase
construct (ARE-Lux), -galactosidase, and FoxH1 alone (control) or with TRI,
TRII and/or increasing concentrations of TRIII. FoxH1 is a transcriptional coactivator necessary to induce maximal Smad-dependent transcription.

Cells

were serum-starved in 0.2% FBS/MEM for 4 hrs prior to treatment. Cells were
incubated in the presence or absence of 100 pMol TGF1 for 16 hrs. Luciferase
activity was normalized to -galactosidase activity prior to analysis.
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3.4
3.4.1

Results
TRIII is concentrated in non- raft membrane fractions

Previous work has shown that the extracellular domain of the type II
TGFreceptor is necessary for membrane raft partitioning (13). Deletion of the
extracellular domain decreases the endocytosis of TRII receptors via membrane
raft-dependent mechanisms (13). As both the type I and type III TGF receptors
interact with the type II receptor, I first sought to identify the membrane
localization of the three TGF receptor subtypes.

To evaluate the membrane localization of the TGF receptor subtypes,
membrane raft fractions were isolated using sucrose-density ultracentrifugation
as previously described

(12,13). Briefly, HEK293T cells were transiently

transfected with myc-TRIII, TβRII-HA or TRI-flag cDNA. Cells were lysed in 1
M Na2CO3 with protease inhibitors, homogenized and sonicated, then overlaid
with a sucrose gradient.

Following overnight high-speed ultracentrifugation,

fractions were collected and subjected to SDS-PAGE. Immunoblotting for
endogenous caveolin-1, a marker of membrane rafts, was performed to ensure
membrane raft isolation. As shown in Figure 3.1A, membrane rafts were
concentrated in fractions 4-6. Membrane raft and non-raft fractions were pooled,
adjusted for the same volume, and subjected to SDS-PAGE as shown in Figure
3.1B. Interestingly, I observed that TRII and TRI largely partition in membrane
raft fractions, with approximately 70% of type II receptors and 75% of type

Figure 3.1 Membrane partitioning of TGF receptors.
(A)

HEK293T cells transiently expressing myc-TRIII, HA-TβRII or TRI-flag were

subjected

to

sucrose-density ultracentrifugation

as described

in

experimental

procedures. Fractions 1-12 were then collected and immunoblotted using -myc, -HA,
and -flag antibodies as indicated. Fractions were also immunoblotted for endogenous
caveolin-1, a marker for membrane rafts (N=3).
(B) Quantification of TGF receptor membrane partitioning. Fractions 4-6 (membrane
raft) and 8-12 (non-raft) from each condition were pooled, adjusted to the same volume,
and subjected to SDS-PAGE. Following immunoblotting with -myc, -HA or -flag
antibodies (left panel), receptors levels were quantified using QuantityOne software and
graphed (right panel; N=3 ± SD).
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receptors found in membrane raft fractions (Figure 3.1B). However, TRIII is
found more heavily concentrated in non-raft fractions with only 30% of receptors
found in membrane raft fractions, and approximately 70% of receptors found in
non-raft fractions (Figure 3.1B).
I also evaluated the partitioning of endogenous TRII and TRI in HepG2
cells by sucrose-density ultracentrifugation (Figure 3.2). I first assessed the
membrane raft content of HepG2 cells by immunoblotting collected fractions for
caveolin-1 (Figure 3.2A). To visualize endogenous receptors, I used [125I] TGF1
ligand to label cell-surface receptors, subjected lysates to sucrose-density
ultracentrifugation and performed autoradiography. Importantly, the radioactive
ligand is cross-linked to the receptors, and and it has been shown that
TGFligand does not dissociate from the receptor complex at low pH (pH 2)
(12). Similar to what has been previously shown for Mv1Lu cells (12),
endogenous TRII is found primarily concentrated in membrane raft fractions in
HepG2 cells (Figure 3.2B), similar to my over-expression studies. TRI is found
in both raft and non-raft fractions, with slightly more receptors found in non-raft
fractions (Figure 3.2B). While I show more TRI in membrane raft fractions in
our over-expression studies, (Figure 3.2B), this difference may be due to the
relative levels of TRI and TRII in HepG2 cells.

Figure 3.2 Partitioning of endogenous TRI and TRII.
(A) HepG2 cells were subjected to sucrose density subcellular fractionation as
previously described. Fractions were immunoblotted with a marker for the early
endosome (-EEA1) or a marker for membrane rafts (-cav1) to ensure isolation of
membrane raft fractions. A non-specific band is seen underneath the caveolin-1 protein
band and is indicated (*) (N=3).
(B) HepG2 cells were affinity-labelled with

[125]

I-TGF prior to sucrose density

subcellular fractionation, as previously described. Following subcellular fractionation,
lysates were subjected to SDS-PAGE. Receptor partitioning was visualized and
quantified by phosphorimaging (Molecular dynamics). TRI and TRII partitioning into
raft and non-raft fractions was quantified using QuantityOne software (N=3 ± SD).
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3.4.2

TRIII forms a stable interaction with TRII in the presence and
absence of ligand and affects its membrane partitioning
Having found that TRIII was more concentrated in non-raft fractions, I

sought to evaluate whether TRIII could alter the partitioning of TRII. I initially
wanted to assess the ability of TRIII to form a stable interaction with TRII, as
previous studies had simply suggested that the role of TRIII was to present
TGF ligand to the receptor. To address this question, I used a coimmunoprecipitation approach in HEK 293T cells transiently transfected with
TβRII-HA, myc-TRIII and TRI-flag cDNA (Figure 3.3A). Following transfection,
cells were serum-starved and then either treated with 500 pMol TGF for 1 hr or
left untreated.

Immunoprecipitation of cell lysates with -HA pAb and

subsequent immunoblotting with -myc mAb revealed that TRIII is able to form
a stable interaction with TRII in both the presence and absence of TGF (Figure
3.3A). The interaction of TRIII with TRII in the absence of ligand suggests that
TRIII may play a greater role in TGF signal transduction than simply ligand
presentation.
Since TRIII is found robustly in non-membrane raft fractions and can
stably associate with TRII, I speculated that the interaction of TRIII with TRII
might increase the partitioning of TRII in non-membrane raft fractions.

To evaluate the ability of TRIII to differentially partition TRII, HEK 293T
cells transiently transfected with TβRII-HA and myc-TRIII cDNA were subjected
to sucrose-density ultracentrifugation as previously described. Figures 3.3B and

Figure 3.3. TRIII stably interacts with TRII and affects its membrane partitioning.
(A) HEK293T cells were transiently transfected with myc-TRIII, TβRII-HA and/or TRIflag as indicated in the panel. Cells were then serum-starved and incubated in lowserum media in the presence or absence of 500 pMol TGF1 for 1 hr. Cell lysates were
immunoprecipitated

with

-HA

antibody

and

subjected

to

SDS-PAGE

and

immunoblotting as indicated. The non-specific heavy chain of the immunoprecipitating
antibody is indicated as IgG. (N=3)
(B) Fractions 4-6 (membrane raft; R) and 8-12 (non-raft; NR) were pooled, adjusted to
the same volume, and subjected to SDS-PAGE and immunoblotting. (N=3)
(C) Membrane partitioning of TRII in the presence and absence of TRIII. HEK293T
cells were transiently transfected with TβRII-HA or TβRII-HA + myc-TRIII. Cells were
then subjected to sucrose-density ultracentrifugation. Twelve 1mL fractions were
collected and subjected to SDS-PAGE and immunoblotted as indicated. (N=3)
(D) Quantitation of membrane raft partitioning was then performed on the pooled
fractions using QuantityOne software and graphed (N=3 ± SD).
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3.3C illustrate that the interaction of TRII with TRIII increases the proportion of
TRII found in non-membrane raft fractions. Quantitation of membrane raft
partitioning was performed by pooling raft (R) and non-raft (NR) fractions and
performing SDS-PAGE (Figure 3.3B). Quantitative analysis of this differential
partitioning was performed using Quantity One software. As shown in the graph
in Figure 3.3D, upon co-expression with TRIII, 72% of TGF type II receptors
are found in non-membrane raft fractions, as opposed to the amount of TRII
found in non-membrane raft fractions in the absence of TRIII (33%). This
suggests that the association of TRIII with TRII increases the endocytosis of
TRII by clathrin-mediated mechanisms. As clathrin-dependent endocytosis
promotes TGF signalling, TRIII expression may increase downstream
signalling events.

3.4.3

TRIII alters the endocytosis of the cytosolic truncation mutant of TRII
It has been previously shown that the cytosolic truncation mutant of

TRII, TRIIΔcyt, is found nearly exclusively in membrane raft fractions (13). To
assess whether TRIII can also re-direct the partitioning of TRIIΔcyt, I first
performed a co-immunoprecipitation experiment to assess the interaction of
TRIII with TRIIΔcyt and TRIIΔEX, which lacks the extracellular domain
(Figure 3.4). As TRIII has a large, heavily glycosylated extracellular domain, I
predicted that it primarily interacts with the extracellular domain of TRII. I used
-HA primary antibodies to immunoprecipitate full-length TRII and the truncation

Figure 3.4 TRIII interacts with the extracellular domain of TRII
HEK293T cells were transiently transfected with myc-TRIII and full length TβRII-HA
(WT), HA-TβRII lacking the intracellular domain (TRII-cyt) or TβRII-HA lacking the
extracellular domain (TRII-EX-HA). Cell lysates were immunoprecipitated with -HA
antibody and immunoblotted with -myc or -HA antibodies (top panel).

Total cell

lysates were also immunoblotted with -myc or -HA antibodies to indicate relative
protein expression (bottom panel) (N=3).
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mutants and to evaluate their association with the myc-TRIII. I observed that
while TRIII can interact with both truncation mutants, it forms a more robust
interaction with TRIIΔcyt (Figure 3.4).
To address whether TRIII can re-direct the partitioning of TRIIΔcyt, I
used sucrose-density ultracentrifugation to concentrate membrane rafts from
HEK293T cells over-expressing TRIIΔcyt, and TβRIIΔcyt in the presence of
TβRIII (Figure 3.5). Interestingly, I found that similar to full-length TRII, TRIII
also shifts TRIIΔcyt from membrane rafts into non-membrane raft fractions
(Figure 3.5). As an internal control, I also confirmed that TRIII was able to alter
the membrane partitioning of full-length TRII (Figure 3.5). As TRIII can redirect the partitioning of TRIIΔcyt, this illustrates that the ability of TRIII to redirect the partitioning of TRII is not dependent on the intracellular domain of
TRII, which has binding sites for clathrin (26).

3.4.4

TRIII associates with TRI in the absence of ligand and affects its
partitioning
As TRI plays a crucial role in the propagation of TGF signalling by

phosphorylating downstream R-Smads, I also wanted to assess whether TRIII
may affect the partitioning of TRI.

I first assessed whether TRIII could interact with TRI using a coimmunoprecipitation approach (Figure 3.6). I used -flag antibodies to
immunoprecipitate TRIII, and similar to my results with TRII, I found that TRI

Figure 3.5 TRIII moderately re-directs the membrane partitioning of a cytosolic
truncation mutant of TRII
HEK293T cells were transiently transfected with full length TβRII-HA, TβRII-HA lacking
the intracellular domain (HA-TβRII-cyt) and/or myc-TβRIII and subjected to sucrose
density subcellular fractionation and immunoblotted with -HA or  -myc antibodies
(N=3).
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Figure 3.5

Figure 3.6. TRIII interacts with TRI in the absence of ligand and directs its
membrane partitioning.
(A) HEK293T cells were transiently transfected with TRI-flag, myc-TRIII or p3xflag
(control) as indicated. Cell lysates were immunoprecipitated with -flag antibodies,
processed for SDS-PAGE and immunoblotted with -myc or -flag antibodies (left
panel). 50 g of total cell lysates were also immunoblotted with -myc or -flag
antibodies to indicate relative protein levels (right panel) (N=3).
(B) HEK293T cells were transiently transfected with TRI-flag, and/or myc-TRIII and
subjected to sucrose density subcellular fractionation as previously described. Fractions
were then processed for SDS-PAGE and were immunoblotted with -myc or -flag
antibodies (N=3).
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can form a robust interaction with TRIII in the absence of ligand (Figure 3.6A).
Importantly, this interaction occurs in the absence of TRII, as HEK293T cells
express very little endogenous TGF receptors.

To assess the membrane

partitioning of TRI, I again used sucrose-density ultracentrifugation to isolate
membrane rafts. Similar to Figure 3.1A, TRI is found predominantly in
membrane raft fractions. To assess whether TRIII can re-direct concentrated in
membrane raft fractions (Figure 3.6B). Interestingly, and complementary to my
findings with TRII, TRIII also shifts TRI into non-raft fractions (Figure 3.6B).
My results evaluating the partitioning of both TRI and TRII in the presence of
TRIII suggest that TRIII is able to direct the partitioning of the TRII/TRI
complex, but importantly, can interact with either receptor independently.

3.4.5

TRIII decreases entry of TRII into caveolin-1-positive vesicles
The intracellular trafficking of TGF receptors is also directly influenced by

their endocytosis.

When TGF receptors are endocytosed via membrane

rafts/caveolae, the receptors enter into caveolin-1-positive vesicles, and the
receptors are targeted for ubiquitination and degradation (12). Furthermore, no
signal transduction occurs in caveolin-1-positive vesicles, as TRI is blocked
from interacting with Smad 2/3 by the inhibitory Smad, Smad7 (12). Thus, I
predicted that since TRIII shifted TRII out of membrane raft fractions, less
TRII would also be found in caveolin-1 positive vesicles.

To address this

question, I used an immunofluorescence microscopy approach to visualize colocalization of TRII and TRIII with GFP-tagged caveolin-1. Mv1Lu HAT cells
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stably over-express HA-TRII under the control of a zinc-inducible promoter.
Cells were transiently transfected with myc-TRIII and GFP-tagged caveolin-1.
The following day cells were cooled to 4˚C to prevent receptor internalization,
and then were labeled with -HA antibodies and Cy3 donkey anti-rabbit
secondary antibodies. Receptors were then permitted to internalize by warming
the cells to 37ºC. I then performed immunofluorescence microscopy to visualize
TRIII and caveolin-1. at 4˚C to label HA-tagged TRII at the cell surface.

The top panel of Figure 3.7 shows that in the absence of TRIII, a large
fraction of TRII co-localizes with caveolin-1. However, upon addition of TRIII,
less TRII is found co-localized with caveolin-1 (Figure 3.7). Furthermore, very
little co-localization between TRIII and caveolin-1 was found. Not only do these
results confirm my ultracentrifugation data, they also illustrate that TRIII can
direct TRII out of the caveolin-1-positive vesicles, and therefore may also have
a direct effect on TRII half-life.

3.4.6

TRIII increases early-endosomal trafficking of TRII
Having shown that TRIII directs TRII out of caveolar vesicles, I sought

to evaluate whether TRIII also increases TRII entrance into the early
endosome. It has been previously shown that receptors internalized via clathrincoated pit mediated endocytosis traffic into early endosomes, where they can
interact with Smad transcription factors to propagate TGF signalling (12).

Figure 3.7. TRIII decreases TRII localization into caveolin-1 positive vesicles

Top panel- Mv1Lu HAT cells stably expressing extracellularly HA-tagged TRII were
transiently transfected with caveolin-1 GFP. Tagged TRII receptors were incubated
with -HA antibodies at 4ºC. Following incubation with Cy3-labelled secondary
antibodies (red), the cells were incubated at 37ºC to allow receptor endocytosis. TRII
co-localizing with caveolin-1-GFP results in yellow staining (N=3).
Bottom panel- Mv1Lu HAT cells stably expressing extracellularly HA-tagged TRII were
transiently transfected with myc-TRIII cDNA and caveolin-1 GFP.

Tagged TRII

receptors were incubated with -HA antibodies as described above. After receptor
internalization, TRIII was labelled with Cy5 secondary antibodies (blue) to assess
receptor co-localization. TRII co-localizing with caveolin-1 results in yellow staining,
TRII co-localizing with TRIII results in magenta staining, and all three co-localizing
results in white staining (N=3).
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Therefore, if TRIII can re-direct the intracellular trafficking of TRII, then it may
also have a direct effect on TGF signal transduction. To evaluate the ability of
TRIII to affect TRII receptor trafficking I used an immunofluorescence
microscopy approach to evaluate the co-localization of the receptors. As before,
Mv1Lu HAT cells were transiently transfected with myc-TRIII cDNA.
Approximately 36 hrs post-transfection, receptors were labelled at the cell
surface by cooling cells to 4°C and incubating with -HA pAb. After labelling with
 -rabbit Cy3, receptors were permitted to internalize by warming to 37°C. Cells
were also labelled with -myc primary antibody, followed by donkey -mouse
secondary antibody to visualize TRIII. To evaluate early endosomal trafficking of
receptors two markers for the early endosome, early endosomal antigen 1
(EEA1-FITC) (Figure 3.8A) and Rab5-GFP a GTPase involved in early
endosomal sorting, (Figure 3.8B) were evaluated in terms of co-localization with
receptors.
Using immunofluorescence microscopy, I found that in the absence of
TRIII, TRII co-localized with EEA1; however, a substantial proportion of
receptors did not localize with EEA1 (Figure 3.8A). One possibility is that
receptors are

internalized

by both

clathrin

and

non-clathrin

mediated

mechanisms. However, upon co-expression with TRIII, more TRII was found
co-localized with EEA1, suggesting an increase in clathrin-mediated endocytosis
or endosomal retention (Figure 3.8A). Co-localization experiments with Rab5
also showed that in the presence of TRIII, it appears that more TRII are found

Figure 3.8 TRIII increases early-endosomal trafficking of TRII
(A) Top panel- Mv1Lu HAT cells stably expressing extracellularly HA-tagged TRII were
incubated with -HA antibodies at 4ºC. Following incubation with Cy3-labelled
secondary antibodies (red), the cells were incubated at 37ºC for 1 hr to allow receptor
endocytosis. After receptor internalization, the cells were immunostained with FITClabelled -EEA1 antibodies (green). TRII co-localizing with early endosomes results in
yellow staining and non-EEA1 localized TRII is also found in the cytoplasm (red)
(N=3).
Bottom panel- Mv1Lu HAT cells stably expressing extracellularly HA-tagged TRII and
transiently expressing myc-TRIII were incubated with -HA and -Myc antibodies at
4ºC and processed for immunofluorescence microscopy as described in Figure 3.7
(N=3).
(B) Top panel- Mv1Lu HAT cells stably expressing extracellularly HA-tagged TRII were
transiently transfected with Rab5-GFP. Following incubation with Cy3-labelled
secondary antibodies (red), the cells were incubated at 37ºC to allow endocytosis. TRII
co-localizing with Rab5-GFP results in yellow staining (N=3).
Bottom panel- Mv1Lu HAT cells expressing HA-tagged TRII and myc-TRIII were also
assessed for their co-localization with Rab5-GFP. Cells were processed as before.
TRII co-localizing with Rab5-GFP results in yellow staining, TRIII co-localizing with
TRII results in magenta staining, and all three co-localizing results in white staining
(N=3). Bar= 10m.
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in early endosomes (Figure 3.8B). As Rab5 has been shown to cause endosomal
enlargement, I also performed co-localization studies with GFP-labelled S34N
(dominant-negative) or Q79L (constitutively-active) Rab5 mutants to assess
whether the co-localization of the receptors with the Rab5-positive vesicle was
simply due to endosomal enlargement (Figure 3.9). My results indicate that while
Rab5 Q79L can cause endosomal enlargement, this does not appear to increase
the localization of TRII with the early-endosomal compartment (Figure 3.9).
Overall, my study strongly suggests that the type III TGF receptor is able to
direct the trafficking of TRII.

3.4.7

TRIII extends the half-life of TRII

Efficient turnover of TGF receptors is essential for optimal TGF signal
transduction, as TGF receptors and ligand are ubiquitously expressed. It has
been previously shown that the intracellular compartmentalization of TGF
receptors directs receptor degradation and recycling. Receptors in early
endosomal compartments are recycled to the cell surface, whereas receptors
localized in caveolin-1 positive compartments are targeted for ubiquitination and
degradation (12). Therefore, having found that TRIII re-directs trafficking of
TRII into early endosomal compartments, I predicted that TRIII expression
would also increase the half-life of TRII. To assess this further, I used [125I]labelled TGF1 ligand to track cell-surface TGF receptor half-life in both the
presence and absence of TRIII. Briefly, HEK293T cells were transfected with
TRI, TRII, TRIII, Smurf2 and Smad7, as shown in Figure 3.10.

Figure 3.9 TRII trafficking in the presence of S34N or Q79L Rab5.
(A) Top panel- Mv1Lu HAT cells stably expressing extracellularly HA-tagged TRII and
transiently expressing Rab5 S34N-GFP (Rab5-GDP) were incubated with -HA
antibodies at 4ºC. Following incubation with Cy3-labelled secondary antibodies (red),
the cells were incubated at 37ºC for 1 hour to allow receptor endocytosis. TRII colocalizing with Rab5-GDP results in yellow staining and non-Rab5-GDP localized TRII
is also found in the cytoplasm (red) (N=3).
Bottom panel- Mv1Lu HAT cells stably expressing extracellularly HA-tagged TRII and
transiently expressing myc-TRIII and Rab5 S34N-GFP (Rab5-GDP) were incubated
with -HA and -myc antibodies at 4ºC and processed for immunofluorescence
microscopy as described above (N=3).
(B) Top panel- Mv1Lu HAT cells expressing HA-tagged TRII were also assessed for
their co-localization with transiently expressed Rab5 Q79L-GFP (Rab5-GTP), shown in
yellow (N=3).
Bottom panel- Mv1Lu HAT cells expressing HA-tagged TRII and myc-TRIII were also
assessed for their co-localization with Rab5 Q79L-GFP (Rab5-GTP). As before,
receptors were labelled at the cell surface, internalized, then assessed for their colocalization. TRII co-localizing with Rab5-GTP results in yellow staining, TRIII colocalizing with TRII results in magenta staining, and all three co-localizing results in
white staining (N=3). Bar= 10m.
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Figure 3.9

Figure 3.10 TRIII expression reduces TRII and TRI complex degradation.
HEK293T cells were transiently transfected with TβRII-HA (II), TβRI-flag (I) and mycTβRIII (III) in the presence or absence of Smurf2/Smad7 (Smf2/S7). Cells were then
incubated with

[125]

I-TGFβ , cross-linked and incubated at 37˚C for 2, 4 or 8 hrs.

Following cell lysis and SDS-PAGE, receptors levels were visualized and quantified by
phosphorimaging (Molecular dynamics). Relative receptor levels of TRII (left) and TRI
(right) were compared to the amount of receptor measured at time zero and graphed
(bottom panel; N=3). Shown is a representative graph of receptor levels.
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Figure 3.10
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Smurf2 and Smad7 were transiently transfected to promote receptor degradation,
as in the absence of Smurf2 and Smad7 TGF receptors over-expressed in
HEK293T cells have a prolonged half-life (Figure 3.10, top panel). Posttransfection, cells were labelled with [125I] TGF1 at 37˚C. The ligand was then
cross-linked to receptors and the cells were warmed to 37ºC to promote receptor
internalization. Cells were lysed at 0, 2, 4 and 8 hrs of internalization, subjected
to SDS-PAGE and visualized using autoradiography.
The top panels of Figure 3.10 illustrate that in the absence of Smurf2 and
Smad7, TRII has a prolonged half-life both in the presence and absence of
TRIII. However, upon addition of Smurf2 and Smad7, which promote receptor
ubiquitination and degradation, TRIII greatly extends the half-life of both TRI
and TRII. These results confirm my receptor trafficking studies and imply that
TRIII can have direct effects on TGF signal transduction by altering the
TRII/TRI complex half-life.

3.4.8

TRIII enhances basal TGFsignalling
As it has been previously shown that clathrin-mediated endocytosis

enhances TGF signal transduction (12), I sought to identify whether TRIII
expression could affect TGF signalling (Figure 3.11). To address this question, I
used a TGF-responsive promoter upstream of a luciferase construct to
quantitatively assess the role of TRIII expression on signalling. HepG2 cells
have previously been shown to be TGF-responsive and are amenable to
calcium chloride transfection and were therefore used as my model system to

Figure 3.11 TRIII expression increases basal TGF signalling
HepG2 cells were transfected with ARE-lux, -gal and FoxH1 alone (control) or together
with TRII/I (RII+RI) and/or increasing concentrations of TRIII (RIII). Transfected cells
were incubated in the absence (gray bars) or presence (black bars) of 100 pM TGF.
Luciferase activity was normalized to -galactosidase activity and is plotted as the mean
± SD of triplicates from a representative experiment (N=3).
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Figure 3.11

111

assess TGF-depdendent transcription (12). HepG2 cells were transiently
transfected with ARE-Lux, -galactosidase,FoxH1 (a transcriptional co-activator)
and/or TRII and TRI, or increasing concentrations of TRIII (Figure 3.11).
Interestingly, it seems that TRIII expression may increase Smad-dependent
signalling in the absence of TGF (Figure 3.11). This result was surprising, as
TRIII is best known for its role in ligand presentation. I hypothesize that the
ability of TRIII to enhance basal TGF signalling is due to its enhanced clathrinmediated endocytosis of the TRII/TRI complex. Indeed, it has been shown that
TGF receptors can signal at a basal level in the absence of ligand (27). In
contrast to this result, it appears that increasing levels of TRIII cDNA
transfection decreases TGF signalling in the presence of ligand (Figure 3.11). I
hypothesize that this may be accounted for the ability of over-expressed TRIII to
pre-load the early endosomes with receptors. This would result in a loss of
TRII/TRI from the cell surface, and therefore may explain why luciferase
activity is decreased in the presence of increasing concentrations of TRIII.
Future studies to evaluate the role of TRIII to mediate expression of validated
TGF-responsive genes, such as PAI-1 and Smad7 should be performed to
confirm these results.
In conclusion, analysis of both membrane fractionation and receptor
trafficking illustrate that TRIII promotes clathrin-mediated endocytosis of both
TRII and TRI and directs TRII into the early endosome. TRIII expression
therefore has functional consequences on TGF signal transduction, as it
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extends receptor half-life by re-directing the TRII/TRI complex out of the
degradative membrane raft pathway and enhances basal TGFsignalling.

3.5

Discussion

The mechanism of endocytosis at the cell membrane can have immediate
downstream effects in signal transduction. In the canonical TGF signalling
pathway, clathrin-mediated endocytosis increases TGF signalling through
enabling the association of the receptors with SARA (Smad anchor for receptor
activation) in the early endosome. SARA is able to mediate the interaction of the
TGF receptors with Smad proteins, which are the downstream effectors of
TGF signal transduction (12). Membrane raft/caveolar endocytosis however,
decreases TGF signalling through promoting the degradation of the receptors
(12). In membrane rafts, Smurf2 (Smad ubiquitination regulatory factor 2)
associates with the receptors, promotes the ubiquitination and degradation of the
TGF receptors, and prevents the association of Smad proteins (reviewed in (7)).

Therefore, since the endocytic mechanism of TGF receptors can have
such profound effects on TGF signalling, and a number of pathologies including
metastatic cancers and fibrotic diseases show aberrant TGF signalling, an indepth study evaluating the mechanism through which TGF receptors are
directed to endocytose is warranted.
To address the issue of endocytic partitioning in TGF signalling, I first
attempted to evaluate the contribution of TGF receptor subtypes to the raft and

113

non-raft partitioning of TRII. Interestingly, using co-immunoprecipitation studies,
I showed that TRIII, the least characterized TGF receptor, is able to associate
with both TRII and TRI even in the absence of ligand.

I confirmed these

results with sucrose-density ultracentrifugation, which quantitatively illustrated
that the association of TRIII with TRII and TRI can greatly shift the partitioning
of TRII and TRI into non-membrane raft/clathrin fractions. In support of my
subcellular fractionation studies, I also show that TRIII directs TRII into the
early endosome and out of the degradative pathway using immunofluorescence
microscopy. Using [125I] labelled TGF1 to track TRII and TRI half-life, I show
that TRIII can have a direct effect on the signalling capacity of the TRII/TRI
complex, as its association can extend the half-life of TRII/TRI. Finally, I
illustrate that TRIII increases basal TGF signalling, but decreases signalling in
the presence of ligand.
While my study evaluates the contribution of TRIII to TGF receptor
trafficking, other studies have also attempted to evaluate factors that affect TGF
receptor half-life. Koli and Arteaga illustrated that binding of TGFto TRII can
shorten its half-life (28). Interestingly, it has also been recently shown that
inhibiting clathrin-mediated endocytosis of TRII extends receptor half-life and
promotes TGF signalling (29). In this study, the authors illustrated that inhibitors
of clathrin-mediated endocytosis prevent internalization of TGF receptors, but
allow the association of SARA and TRI at the cell surface; this then promotes
and extends TGF signalling (29).
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Another study has attempted to evaluate the contribution of TRIII to
TRII membrane partitioning. The authors concluded that

TRIII was

endocytosed via membrane rafts in Cos7 and HepG2 cell lines (23).
Furthermore, they reported that membrane-raft associated TRIII regulates
phosphorylation of Smad2 and p38 (23). While I show differing results in this
report, in that TRIII is primarily found in non-membrane raft fractions, and is
able to differentially partition the TRII/TRI complex, this result may be due to
the cell types used in both studies. Differences in membrane raft content
between HepG2 and HEK 293T cells may account for some of the discrepancies
observed. This study nonetheless illustrates that while TRIII endocytosis can
affect TGF signalling, there may be other interacting protein partners that
influence the effect of TRIII. Indeed, a recent review highlights several
RhoGTPases which can have a modulating effect on TGF endocytosis and
signal transduction (30).
The importance of the effect of TRIII on TGF signal transduction is only
beginning to be explored. This TGF receptor has recently drawn attention due
to its aberrant expression in several cancers. Indeed, TRIII overexpression is
found in seminomas (31) and knockdown of TRIII decreases invasiveness and
motility of breast cancer cells (21). However, it has also been shown that loss of
TRIII can promote metastasis and invasiveness in a number of cancers,
including non-small cell lung cancer (20), pancreatic cancer (22) and prostate
cancer (17,32). Our finding that TRIII promotes basal TGF signalling but
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decreases ligand-dependent signalling may help explain some of the duality of its
function in cancer. Perhaps the levels of TRIII may play a role- a total loss of
TRIII may increase TGF signalling by preventing ligand sequestration from the
TRII/TRI complex and thus may promote the metastatic effects of TGF
signalling. While the opposing effects of TRIII warrant further investigation of
this pathway, my studies suggest that TRIII expression may play a critical role in
control of TGFsignal transduction.

Overall, in this study I have shown that TRIII directs TRII and TRI to
undergo clathrin-mediated endocytosis. This altered endocytosis directs TRII
into early endosomal pathways, extends TRII and TRI half-life and enhances
basal TGF signalling. As TRIII is aberrantly expressed in a number of
pathologies, my study suggests that TRIII may mediate TGF signal
transduction by altering TGF receptor endocytosis.
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CHAPTER 4

ARRESTIN2 INTERACTS WITH TRII TO REGULATE SMAD-DEPENDENT
AND SMAD-INDEPENDENT SIGNAL TRANSDUCTION

A version of this chapter has been submitted to Cellular Signalling, manuscript #
CLS-D-12-00204.
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4

Chapter 4
4.1

Chapter Summary

In chapter 3 I assessed the ability of TRIII, a heavily-glycosylated cellsurface protein, to mediate receptor partitioning of TRII/TRI complexes.
Reports have shown that TRIII interacts with arrestin2 to mediate its
internalization with TRII. Therefore, in this chapter I assessed the ability of
arrestin2 to influence TGF receptor trafficking and signal transduction.
Interestingly, I found that arrestin2 can interact with TRII in the absence of
TRIII. Furthermore, arrestin2 traffics to the early endosome with TRII where it
increases the association of TRII with SARA. Depletion of endogenous
arrestin2 increased levels of TRII at the cell-surface and also induced hyperphosphorylation of p38. Increased phosphorylation of p38 correlated with an
increased sensitivity of cells to cell death both in the presence and absence of
TGF.
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4.2

Introduction

The Transforming Growth Factor Beta (TGF) signalling pathway is a cell
and context-dependent pathway that is under intense study due to its complex
roles in cancer and fibrotic diseases. In the classical TGF pathway, TGF
ligands stimulate the formation of a heteromeric serine/threonine kinase complex
of TGF receptor I (TRI) and TGF receptor II (TRII). Ligand-binding to TRII
activates its kinase domain, promoting phosphorylation of TRI on its GS domain
(reviewed in (1)). Activated TRI then induces a Smad signalling cascade by
phosphorylating Smad2/3, which allow them to interact with the Co-Smad,
Smad4, and

translocate

to

the

nucleus to

activate

cell-type

specific

transcriptional programmes (1).
While endocytosis of plasma membrane receptors is classically thought to
function to downregulate signalling, it has been shown in the TGF pathway that
the endocytic route of the receptors can play a direct role in signalling outcome.
TRII/TRI complexes internalized via clathrin-coated pits enter the early
endosome, where SARA (Smad Anchor for Receptor Activation) enhances
Smad-dependent signal transduction by recruiting Smad 2/3 and facilitating their
phosphorylation by TRI (2,3). Receptor complexes internalized by clathrinindependent, caveolin-positive vesicles however, are sterically prevented from
signalling by the inhibitory Smad7 and targeted for degradation by Smurf2, an E3
ubiquitin ligase (2). Indeed, several studies have shown that trafficking of the
TGF receptors inside the cell has important signalling consequences. For
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example, it has been shown that Dab2 is necessary for sorting of TBRII from the
early endosome into the late endosome (5). Furthermore, the regulation of
trafficking to late endosomes plays a role in Smad signal transduction, as a
dominant-negative

Rab5

causes

constitutive,

ligand-independent

Smad

signalling and nuclear translocation (5).
While the importance of trafficking in regards to signal transduction is wellappreciated in the TGF pathway, the specific signal(s) directing receptors to be
internalized and trafficked via either pathway is not well-understood. Previously I
have shown that the type III TGF receptor (TRIII, or betaglycan) which was
thought to simply present ligand to TRII, can direct TRII/TRI complexes into
the early endosome (3). As others have shown that TRIII can interact with
arrestin2 (7), and arrestin2 is known to have an important role in GPCR
internalization (4), I sought to evaluate the contribution of arrestin2 to TRII
internalization, trafficking and signal transduction.
The relatively simplified view of arrestin2 solely acting to internalize
GPCRs has been challenged by a myriad of experiments that implicate it as a
pleiotropic scaffolding protein. While it is true that arrestin2 can interact with
components of the endocytic machinery, including clathrin (5) and AP-2 (6), it
can also act as a scaffolding protein and binds to a variety of proteins in the
cytoplasm including Src, cofilin, Akt and MAP kinases (reviewed in (7)). Indeed,
arrestin2 has been implicated in diverse processes such as Ras-independent
cytoskeletal re-arrangement (12), ERK signal transduction (8), activation of beta-
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catenin via endothelin receptors (14) and activation of epidermal growth factor
receptors (9). Based on this plurality of arrestin2 function, and the fact that
TRIII can bind to arrestin2 (7), I sought to further evaluate the role of arrestin2
in TGF signal transduction. In this chapter I show that arrestin2 interacts with
TRII and that decreased arrestin2 levels cause an increase in TRII cellsurface levels, and the phosphorylation of Smad2. Interestingly, decreased
arrestin2 levels do not increase Smad-dependent transcription, as decreased
arrestin2 decreases the production of luciferase under the control of a Smadresponsive promoter. I also assessed a Smad-independent pathway, the p38
pathway, and found that the increased phosphorylation of p38 through decreased
arrestin2 levels functionally results in an increase in TGF-dependent and independent apoptosis.

4.3
4.3.1

Materials and Methods
Antibodies and reagents

Commercially available antibodies were used as per manufacturers’
instructions from the following sources: -HA (Santa Cruz-Y11-SC-805),  -myc
(Santa Cruz sc-40), -flag (Sigma F3165), -EEA1 (BD Trans Labs-610457), GFP (Clontech- 632381), -PSmad2 (Millipore- AB3849), -arrestin2 (AbcamAB54790), -actin (Sigma-A2668), -Smad2/3 (BD- 610843), -PSmad3 (Cell
Signaling- 3101), -pp38 (Cell Signaling-92115), -p38 (Cell Signaling-92125),
-PARPc (Cell Signaling- 9541). HRP-conjugated goat -mouse (Thermo
Scientific- 31430), and goat -rabbit (Thermo Scientific-31460) were used for
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western blotting. Fluorescently labelled donkey -rabbit Cy3 (Jackson- 711-165152) and donkey -mouse AlexaFluor 647 (Invitrogen- A21236) were used for
visualization of immunofluorescence experiments. The constructs encoding
TRII-HA, myc-TRIII, arr2-flag, arr2-GFP and SARA-flag were used as
previously described (3,10,11). Stealth siRNA (negative control, 634978;
arrestin2 siRNA1, ARRB2VHS40600; or arrestin2 siRNA2, ARRB2VHS40604)
and Lipofectamine RNAiMax were purchased from Invitrogen. TGF1 was
purchased from Peprotech. Hoechst 33342 was a generous gift from Dr. S.
Cregan (Robarts Research Institute, Western University).

4.3.2

Cell Culture
HEK 293T human embryonic kidney cells (American Type Culture

Collection) were maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS). Mink lung cells stably
expressing a carboxy terminus HA tagged TRII construct (HAT Mv1Lu) were
maintained in Modified Eagle’s medium (MEM) supplemented with 10% FBS,
non-essential amino acids and 0.3% hygromycin. A549 non-small cell lung
adenocarcinoma cells (American Type Culture Collection) were maintained in
F12K media supplemented with 10% FBS. H1299 non-small cell lung
adenocarcinoma cells (ATCC) were maintained in RPMI media supplemented
with 10% FBS. HepG2 hepatocellular carcinoma cells were maintained in
Modified Eagle’s medium (MEM) supplemented with 10% FBS and non-essential
amino acids. All cells were kept in a humidified atmosphere at 37°C and 5% CO 2.
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4.3.3

Transfection
HEK 293T and HepG2 cells were transiently transfected using the calcium

phosphate method. HAT Mv1Lu cells were transfected using polyethylenimine.

4.3.4

Immunoprecipitation
Transfected HEK 293T cells were lysed (50 mM Tris-HCl, pH 7.4, 150 mM

NaCl, 1 mM EDTA, 0.5% Triton X-100, 1 mM PMSF, and cocktail protease
inhibitors) and centrifuged at 14,000 × gav at 4°C for 10 min. Aliquots of
supernatants were collected for analysis of total protein concentration. The
remaining cell lysates were incubated with antibody followed with protein G
sepharose incubation. The precipitates were washed 3 times, eluted with
Laemmli sample buffer and subjected to SDS-PAGE and immunoblot analysis.

4.3.5

Immunoblotting
Proteins were separated by SDS-PAGE and transferred to nitrocellulose

membranes by electrophoretic transfer. Following blotting with primary and
secondary antibodies, bound antibodies were detected using SuperSignal
chemiluminescence reagent (Pierce).

4.3.6

Isolation of Caveolae/membrane-raft enriched membrane fractions
The caveolin/raft-rich membrane fractions were isolated as previously

described (12). Briefly, transfected HEK 293T cells grown to confluence in 100mm dishes were used to prepare the membrane fractions. All steps were carried
out on ice. After two washes with cold phosphate-buffer saline (PBS), cells were
lysed with 0.5 M Na2CO3, pH 11.0, containing protease inhibitors. After scraping,

125

the cell lysate was collected and homogenized three times for 10 s by using a
Polytron tissue grinder (Brinkmann Instruments). Homogenates were then
sonicated three times for 20 s with a Vibra Cell sonicator (Sonics Materials Inc.).
The homogenates were adjusted to 40% sucrose and overlaid with 30% sucrose
and 5% sucrose solutions. The samples were centrifuged at 200,000 x g av for 16
h at 4°C, using a Beckman SW41 rotor. Twelve 1-mL fractions were collected,
and an aliquot of each fraction was eluted with Laemmli sample buffer, boiled,
and subjected to SDS-PAGE followed by Western blot analysis.

4.3.7

Immunofluorescence/Receptor Internalization
HAT Mv1Lu cells were plated on coverslips in 12 well dishes. Twenty-four

hours post-transfection of arrestin2-GFP cDNA with polyethylenimine, cells
were serum-starved and treated with 50 μM ZnCl2 to induce HA-TRII expression
as previously described (3,10). The following day, cells were cooled to 4°C, and
treated with -HA antibody for 2 hours at 4°C to label receptors at the cell
surface. Coverslips were then incubated with donkey anti-rabbit Cy3 antibodies.
After labelling, cells were either permitted to internalize, by incubating at 37°C for
30 minutes or 1 hour, or were immediately fixed and permeabilized. Cells were
incubated with -EEA1 antibody, followed with donkey -mouse Cy5.

All

coverslips were then immunomounted and visualized using an IX81 inverted
immunofluorescence microscope (Olympus, Canada).
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siRNA-mediated Knockdown of arrestin2 in A549 and H1299 cells

4.3.8

Endogenous levels of arrestin2 protein were decreased by Stealth siRNA
(Invitrogen). At approximately 50% confluency, cells were transfected with siRNA
(negative control, arrestin2 siRNA1, or arrestin2 siRNA2) using Lipofectamine
siRNA Max as per manufacturers’ instructions. Forty-eight hours following
transfection, cells were assayed for silencing by SDS-PAGE and immunoblotting
with -arrestin2 antibodies and - actin antibodies.
TGF Receptor Binding Assay

4.3.9

A549 cells were transiently transfected with arrestin2 siRNA as
previously described. Approximately 48 hours following transfection, cells were
placed on ice and then labelled with 250 pM [125-I] labelled TGF ligand. Cells
were incubated with ligand for 2 hours at 4C and then receptors were crosslinked using 10 mg/mL DSS in DMSO for 15 minutes. Cells were then either
lysed in 1X TNTE (time 0) or were placed in 10% FBS in DMEM and incubated at
37C for 2, 4, or 8 hours prior to lysis. Lysates were then subjected to SDSPAGE and visualized using phosphorimaging.

4.3.10

Phospho-Smad and phospho-p38 Time Course

A549 and H1299 cells were transiently transfected with control or
arrestin2 siRNA as described above.

Prior to TGF treatment, cells were

serum-starved overnight in 0.2% FBS in F12K or 0.2% FBS in RPMI media. The
following day cells were treated with 250 pM TGF ligand for 30 minutes. Cells
were then washed with PBS, and were either lysed or incubated at 37C for an
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additional 1 or 4 hours. Lysates were subjected to SDS-PAGE and were
immunoblotted with -phospho-Smad2, -phospho-Smad3, -phospho-p38, p38 or -Smad2/3 antibodies.

4.3.11

siRNA-mediated Knockdown of arrestin2 in HepG2 cells

Endogenous levels of arrestin2 were decreased by Stealth siRNA
(Invitrogen) using a reverse-transfection method as per manufacturers’
instructions. Approximately 72 hours following transfection, cells were assayed
for knockdown by SDS-PAGE and immunoblotting.

4.3.12

Luciferase reporter assay

HepG2 cells were transiently transfected using the calcium phosphate
precipitation method with ARE (activin-response element)-Lux (luciferase), βgalactosidase, arrestin2 cDNA and FoxH1 reporter plasmids. Cells were serumstarved in 0.2% FBS/MEM/NEAA for 4 hours prior to treatment. Cells were then
incubated in the presence or absence of 250 pM of TGFβ for 16 hours.
Luciferase activity was normalized to β-galactosidase activity.

4.3.13

cleaved-PARP assay

A549 cells were transiently transfected with control or arrestin2 siRNA as
previously described. Sixteen hours following transfection, cells were serumstarved in 0.2% FBS/F12K media for 4 hours. Cells were then incubated in the
presence or absence of 250 pM TGF for 48 hours. Cells were then lysed, and
subjected to SDS-PAGE and immunobloted with -cleaved-PARP antibodies.
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4.3.14

Hoechst Cell Death assay

A549 cells were transiently transfected with control or arrestin2 siRNA as
previously described. Sixteen hours following transfection, cells were serumstarved in 0.2% FBS/F12K media for 4 hours. Cells were then incubated in the
presence or absence of 250 pM TGF for 48 hours. Following the 48 hour
incubation, cells were treated with cell-permeant Hoechst (Hoechst 33342) for 30
minutes at 37˚C. Apoptotic and non-apoptotic cells were then visualized using an
IX71 inverted immunofluorescence microscope (Olympus, Canada). The number
of apoptotic vs. non-apoptotic cells were then counted and plotted as percentage
of apoptotic cells per condition. Statistical analysis was performed using
GraphPad Prism® 5.0 software.

4.3.15

Statistical analysis

One-way ANOVA analyses followed by post-hoc Bonferroni test were
used to evaluate the significance of the results. Statistical analyses were
performed using GraphPad Prism ® 5.0 software and p values of <0.05 were
considered statistically significant.

4.4
4.4.1

Results
TRII binds arrestin2 in the absence of TRIII

TRII functions primarily as a serine/threonine kinase capable of both
autophosphorylation

and

TGF

signal

propagation

through

the

trans-

phosphorylation of TRI (reviewed in (13)). As arrestin2 has been shown to bind
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TRIII following its phosphorylation by TRII (14), I sought to assess whether
TRII may also be able to bind arrestin2.
To address this question I used an immunoprecipitation approach using
HEK293T cells, as they express very few endogenous TGF receptors (10).
HEK293T cells were transiently transfected with combinations of arr2-Flag,
TRII-HA, and myc-TRIII cDNA. Cells were then lysed and immunoprecipitated
with -Flag antibodies and subjected to SDS-PAGE and immunoblotting (Figure
4.1). I observed that TRII interacts with arrestin2 both in the presence and
absence of TRIII (Figure 4.1, lanes 4 and 8). As a positive control, I evaluated
the ability of arrestin2 to interact with TRIII. Indeed, I was able to
immunoprecipitate TRIII with arrestin2 (Figure 4.1, lane 6). Since TRII is
essential for TGF signal transduction, my finding that TRII can interact with
arrestin2 when they are over-expressed in HEK 293T cells suggests that
arrestin2 may have an important role in TRII signal transduction and receptor
internalization.

4.4.2

arrestin2 localizes to early endosomal compartments with TRII
The intracellular trafficking of the TGF receptor complex can have

significant implications in TGF signal transduction, as TGF receptors that traffic
to the early endosome have enhanced TGF signalling capacity (2). Having
shown that arrestin2 can interact with TRII, I next assessed the intracellular

Figure 4.1 TRII interacts with arrestin2 in the absence of TRIII
HEK 293T cells were transiently transfected using the calcium phosphate precipitation
method to express Flag-tagged arrestin2, HA-tagged TRII and/or myc-tagged TRIII,
as indicated. Cells were lysed, immunoprecipitated with 1 g -Flag antibodies and
subjected to SDS-PAGE and immunoblotting as indicated. Fifty g of lysates was used
to assess total expression. The top panel shows immunoprecipitated proteins, while the
bottom panel illustrates total protein expression in cell lysates. (N=3).

130

Figure 4.1

131

trafficking of TRII/arrestin2 complexes. In order to address this question, I
used a receptor-chase approach. Briefly, Mv1Lu cells stably expressing TRII
were cooled to 4˚C to halt receptor internalization, and receptors were labelled at
the cell surface. Cells were then warmed to 37˚C to permit receptor
internalization for 30 minutes or 1 hour, and then the cells were fixed,
permeabilized, and processed for immunofluorescence microscopy. Early
endosomal compartments were visualized by using antibody against early
endosomal autoantigen 1 (EEA1). As I have previously shown, at time 0 all TRII
is found at the cell surface and does not co-localize with EEA1 (3) (Figure 4.2,
top panel). Following 30 minutes of internalization, TRII began to cluster and
partially co-localize with EEA1, and it appears that further co-localization with
EEA1 occurring at 60 minutes (Figure 4.2, middle panel). Interestingly, it appears
that arrestin2 co-localizes with TRII at the early endosome at 30 minutes
(Figure 4.2, middle panel). Strikingly, following 60 minutes of internalization,
TRII was observed to co-localize with EEA1 and arrestin2 in large vesicles
(Figure 4.2, bottom panel).

4.4.3

arrestin2 does not alter the membrane raft partitioning of TRII
The intracellular trafficking of TGF receptors is dependent upon their

internalization route; TGF receptors gain access to the early endosome
following clathrin-mediated internalization. Having found that TRII can directly
interact with arrestin2, and since arrestin2 has been shown to directly interact

Figure 4.2. arrestin2 localizes to the early endosome with TRII
Mv1Lu cells stably transfected with HA-tagged TRII were transiently transfected with
arr2-GFP cDNA. To assess receptor internalization and trafficking, cells were
incubated at 4˚C to prevent receptor internalization, and cell-surface receptors were
labeled with -HA antibody. Following incubation with fluorescently labeled secondary
antibodies, cells were either immediately fixed and permeabilized (time 0, top panel), or
were warmed to 37˚C and permitted to internalize for 30 minutes (middle panel) or 60
minutes (bottom panel). Cells were incubated with -EEA1 antibodies followed by Cy5
secondary antibody to visualize early endosomes (N=5). To analyze receptor colocalization, 5-10 cells per condition per experiment were evaluated. Shown are
representative cells from each condition. Bar= 10 m

132

Figure 4.2

133

with components of the clathrin-coated pit machinery (6,15) I sought to establish
whether arrestin2 could enhance clathrin-mediated internalization of TRII. To
evaluate this question, I performed sucrose-density ultracentrifugation of HEK
293T cells as previously described (3,12). I found TRII to be primarily in
membrane raft fractions, TRIII in both membrane raft and non-raft fractions, and
arrestin2 solely enriched in non-membrane raft fractions (Figure 4.3). The coexpression of arrestin2 with TRII did not shift its partitioning into nonmembrane raft fractions (Figure 4.3). Since I have previously shown that TRIII is
able to increase clathrin-mediated endocytosis of TRII (3), I next sought to
establish whether the interaction of TRIII and arrestin2 with TRII could further
drive its non-membrane raft partitioning. Co-expression of TRII and TRIII shifts
the partitioning of TRII into non-membrane raft fractions, as I have previously
shown (3). However, the addition of arrestin2 did not further increase the
partitioning of TRII into non-membrane raft fractions (Figure 4.3).

4.4.4

Loss of arrestin2 increases steady-state levels of cell-surface TRII
The path of TRII trafficking directly influences TRII recycling and/or

turnover. Receptors trafficked to the early endosome promote signal propagation;
while receptors trafficked to the caveolin-1 positive vesicles are targeted for
degradation. As I have shown that arrestin2 traffics to the early endosome with

Figure 4.3. arrestin2 does not alter the membrane raft partitioning of TRII
(A) Lipid raft partitioning of TRII upon co-expression with TRIII, arrestin2 both
individually and together. HEK 293T cells transiently expressing the indicated constructs
were subjected to sucrose-density ultracentrifugation as described in methods. Samples
were then pooled into raft (R) and non-raft (NR) fractions and subjected to SDS-PAGE
and immunoblotting with the antibodies indicated. (N=3)
(B) Using Quantity One software, partitioning of TRII into either raft or non-raft
fractions was measured and calculated as a % of total TRII levels for all conditions.
The graph shown is the mean ± SD. (N=3)
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TRII, I wanted to assess the role of arrestin2 in a second way, and evaluate its
role in the internalization of cell-surface TGFreceptor complexes. To assess the
role of arrestin2 in internalization, I again used siRNA to decrease arrestin2
protein levels.
Following siRNA transfection, cells were treated at 4˚C with 250 pM [125ITGF to label cell-surface receptors. Following cross-linking, cells were either
immediately lysed, or warmed to 37˚C and incubated for 2, 4, or 8 hours. Lysates
were subjected to SDS-PAGE and then developed by phosphorimaging. I
observed that decreasing arrestin2 levels had little effect on TGFreceptor halflife (Figure 4.4A). Surprisingly, decreasing protein levels of arrestin2 induced
increased TRII cell-surface levels at time zero, which were sustained at 2 hours.
To quantify my results, phosphorimaging analysis was performed. Figure 4B
illustrates TRII levels as a percentage of TRII levels in the negative control
condition at time 0. Quantification revealed that the levels of TRII were
approximately 1.5 fold higher at time 0 in the arrestin2 siRNA conditions
compared to the siRNA control (Figure 4.4A and 4.4B).

4.4.5

Effects of arrestin2 siRNA on Smad2 phosphorylation levels
Having discovered that decreased arrestin2 expression increased TRII

cell-surface levels, I was interested to assess the effect of decreased arrestin2
levels on Smad signal transduction. TRII initially propagates the Smad
signalling cascade by phosphorylating TRI, which can then propagate signal

Figure 4.4. Decreased arrestin2 protein expression increases TRII levels at the
cell surface.
(A) A549 cells transiently transfected with control siRNA (Ctrl siRNA) or two different
siRNA to arrestin2 (arr2 siRNA1 or arr2 siRNA2) were assessed for TRII half-life.
Following labelling with

125

I-TGF1 at 4˚C for 2 hours, cells were cross-linked and

immediately lysed, or were warmed to 37˚C and were permitted to internalize for 2, 4 or
8 hours. Lysates were subjected to SDS-PAGE and visualized using phosphorimaging
(left panel) (N=4). Total lysates not labelled with

125

I-TGF1 were also subjected to

SDS-PAGE and immunoblotted to ensure efficient arrestin2 silencing (right panel).
(B) Receptor levels were quantitated from experiments carried out as described in
Panel A and graphed as receptor levels (% of control siRNA at time zero) vs. time for
each condition (mean ± SD, N=4)
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transduction by phosphorylating Smad2 (reviewed in (1)). As it is necessary for
TRII to bind TGF ligand in order to activate TRI, I predicted that increased
cell-surface levels of TRII should increase Smad 2 phosphorylation, as a
greater number of receptors would be exposed to ligand.
To assess the role of arrestin2 in Smad signalling, I performed a
phospho-Smad signalling assay. Non-small cell lung adenocarcinoma A549 cells
were chosen for the signal transduction studies, as these cells have negligible
TRIII levels (16), and any results I observed would therefore be TRIIIindependent. In A549 cells transfected with control siRNA I observed that 250 pM
TGFinduced robust Smad2 phosphorylation within 30 min of ligand treatment
which then gradually decreased after 1.5 hours and 4.5 hours. In cells
transfected with siRNA constructs towards arrestin2, the phospho-Smad2 levels
appeared similar to those transfected with negative siRNA control (Figure 4.5A). I
confirmed these results in another non-small cell lung cancer cell line, H1299
cells, which also showed little difference

in phospho-Smad2 levels between

arrestin2 siRNA treated cells and control (Figure 4.6). To ensure that I was
accurately assessing the levels of phospho-Smad2 in each instance, I quantified
the levels of phospho-Smad2 using Quantity One software and densitometric
analysis (Figure 4.5B). Indeed, quantitative analysis supported my observation
that

the

silencing

phosphorylation.

of

arrestin2

increased

TGF-dependent

Smad2

Figure 4.5 Effects of decreased arrestin2 protein expression on Smad2
phosphorylation
(A) A549 cells transiently transfected with control siRNA (Ctrl siRNA) or two different
siRNA to arrestin2 (arr2 siRNA1 or arr2 siRNA2) were assessed for TGFdependent Smad2 phosphorylation. Serum-deprived cells were either immediately lysed
or treated with 250 pM TGF1 for 30 minutes. Cells were then washed in PBS and
further incubated for 1 or 4 hours or were lysed. All lysates were subjected to SDSPAGE and immunoblotted for phospho-Smad 2, Smad 2, arrestin2 and actin levels
(N=3).
(B) Using Quantity One software analysis, phospho-Smad2 levels as a ratio of total
Smad2 levels were plotted for all conditions. The graph shown represents the mean
±SD vs. time (N=3).
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Figure 4.5

Figure 4.6 Effects of decreased arrestin2 protein expression on PSmad2 levels
in H1299 cells
H1299 cells transiently transfected with non-specific control siRNA (Ctrl siRNA) or two
different siRNA to arrestin2 (arr2 siRNA1 or arr2 siRNA2) were assessed for TGFdependent Smad2 phosphorylation. Serum-deprived cells were either immediately lysed
or treated with 250 pM TGF1 for 30 minutes. Cells were then washed in PBS and
further incubated for 1 or 4 hours or were lysed. All lysates were subjected to SDSPAGE and immunoblotted for phospho-Smad 2, Smad 2, arrestin2 and actin levels
(N=3).
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4.4.6

Transcription of a Smad-dependent luciferase construct in response to
decreased arrestin2 protein expression
In the canonical TGF signalling pathway, following phosphorylation of

Smad2 by TRI, phospho-Smad2 translocates to the nucleus with Smad4 to
activate TGF-dependent signal transduction. My results thus far illustrated that
decreasing arrestin2 protein levels increased Smad2 phosphorylation. I was
therefore interested to assess the effects of arrestin2 expression on TGFdependent transcription. To address this question I performed ARE-Lux
luciferase analysis (Figure 4.7). I was surprised to find that loss of arrestin2
decreased TGF-dependent transcription (Figure 4.7A). While siRNA1 had a
modest dampening effect on luciferase production, siRNA2 showed greater than
two-fold decreases in luciferase production relative to negative control (Figure
4.7A).
As a complementary approach, I sought to evaluate the effect of
increasing levels of arrestin2 on TGF-dependent transcription. As in Figure
4.7A, HepG2 cells were transiently transfected with ARE-lux construct, as well as
FoxH1 and -galactosidase. Furthermore, cells were transfected with increasing
amounts of arrestin2 as indicated (Figure 4.7C). The specificity of my
experiment was assessed using the inhibitory Smad, Smad7, which decreases
transcriptional responses and causes decreased luciferase production in this
assay. I observed that increasing concentrations of arrestin2 enhanced TGFdependent luciferase transcription (Figure 4.7C). As a control, we also
transfected increasing amounts of arrestin1 cDNA and found that arrestin1

Figure 4.7 Decreased arrestin2 protein levels decreases TGF-dependent
transcription
(A) HepG2 cells were transiently transfected with control siRNA (Ctrl) or two different
siRNA to arrestin2 (siRNA1 or siRNA2). The following day, cells were transfected with
cDNA encoding ARE-lux, FoxH1, and -galactosidase. To induce ARE-lux activation,
transfected cells were incubated in the absence or presence of 250 pM TGF overnight.
The graph is representative of the mean of triplicates (± SD) from one representative
experiment. (N=4)
(B) HepG2 cells were transiently transfected with control siRNA (Ctrl) or two different
siRNA to arrestin2 (siRNA1 or siRNA2) as described in Panel A. Forty eight hours
post-transfection, cells were lysed, subjected to SDS-PAGE and immunoblotted to
assess arrestin2 protein expression.
(C) HepG2 cells were transiently transfected with cDNA encoding ARE-lux, FoxH1, and
-galactosidase and increasing amounts of arrestin2 cDNA or arrestin1 cDNA (as
indicated). Smad7 was also transfected in condition 2 to assess the robustness of the
system. Transfected cells were incubated in the absence or presence of 250 pM TGF.
Luciferase activity was normalized to -galactosidase activity and is represented as the
mean ± SD of triplicates from one representative experiment (N=3).
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did not greatly increase TGF-dependent transcription (Figure 4.7C). This result
supported my finding in Figure 4.7A that arrestin2 mediates TGF
transcriptional responses.

4.4.7

arrestin2 expression increases SARA-TRII association
My results from figures 4.5 and 4.7 showed paradoxical effects. Although

loss of arrestin2 had minimal effects on Smad2-phosphorylation, loss of
arrestin2 decreased Smad-dependent transcription. To confirm this result, we
showed that increasing the amount of arrestin2 increased TGF-dependent
luciferase production. Runyan et al. illustrated that Smad2 phosphorylation can
occur independently of receptor internalization, but receptor internalization is
necessary for TGF-dependent transcription. Since SARA is enriched in the early
endosome, and it has been shown that TGF receptor localization to the early
endosome propagates TGF signal transduction (10), I decided to assess
whether arrestin2 modulated the interaction of TRII with SARA. Using a coimmunoprecipitation approach in HEK293T cells, I observed that over-expression
of arrestin2 increased the association of TRII with SARA (Figure 4.8). Since
access to the early endosome facilitates TGFsignalling, the ability of TRII to
associate with components of the early endosome may therefore be a regulatory
mechanism in TGF signal transduction. Thus, my finding that arrestin2
increases SARA-TRII association and Smad-dependent transcription suggests

Figure 4.8 arrestin2 increases the interaction of SARA with TRII
HEK293T cells were transiently transfected with Flag-tagged SARA, GFP-tagged
arrestin2 and/or HA-tagged TRII, as indicated. Approximately 36 hours posttransfection, cells were lysed and immunoprecipitated with -Flag antibodies.
Immunoprecipitates were subjected to SDS-PAGE and immunoblotting. The top panel
shows immunoprecipitated proteins, while the bottom panel shows total protein
expression levels (N=3).
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that arrestin2 may enhance Smad-dependent TGF signal transduction.

4.4.8

siRNA directed to arrestin2 enhances p38 phosphorylation
TGF can also activate signal cascades that are independent of the

canonical Smad pathway. As I had discovered that loss of arrestin2 protein
expression caused increased phosphorylation of Smad2 but decreased Smaddependent transcription, I wanted to assess the effect of decreasing arrestin2
levels

on

TGF-dependent,

Smad-independent

signalling

pathways.

Several groups have shown that TGF can activate the MAPK pathway
through MKK3/6

(22,23). Importantly, the induction of p38

and JNK

phosphorylation by TGF is independent of the Smad pathway and is mediated
by TRAF6 and TAK1 (17,18).
To evaluate the role of arrestin2 on Smad-independent pathways, I
silenced endogenous arrestin2 levels in A549 cells using siRNA, then treated
the cells with 250 pM TGF1 for 30 minutes (Figure 4.9). I observed that
phosphorylated p38 increased robustly at 1.5 hours, and is sustained at 4.5
hours (Figure 4.9A). Similar to my observations with phosphorylated Smad2, I
found that loss of arrestin2 increases levels of phosphorylated p38, with a
statistically significant difference between negative control and arrestin2
knockdown occurring at 4.5 hours (Figure 4.9B). I also assessed levels of
phosphorylated p38 in H1299 cells (Figure 4.10), and found that loss of
arrestin2 levels also increased phosphorylated p38 levels, similar to my results
with A549 cells.

Figure 4.9 Decreased arrestin2 expression increases p38 phosphorylation
(A) A549 cells transiently transfected with non-specific control siRNA (Ctrl siRNA) or
two different siRNA to arrestin2 (arr2 siRNA1 or arr2 siRNA2) were assessed for
TGF-dependent p38 phosphorylation. Serum-deprived cells were either immediately
lysed or treated with 250 pM TGF1 for 30 minutes. Cells were then washed in PBS
and further incubated for 1 or 4 hours or were lysed. All lysates were subjected to SDSPAGE and immunoblotted for phospho-p38, total p38, arrestin2 and actin levels (N=3).
(B) Using Quantity One software, phospho-p38 levels as a ratio of total p38 levels were
plotted for all conditions. The graph shown represents the mean ±SD vs. time (N=3).
*p<0.05
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Figure 4.9

Figure 4.10 Decreased arrestin2 expression increases p38 phosphorylation in
H1299 cells
H1299 cells transiently transfected with non-specific control siRNA (Ctrl siRNA) or two
different siRNA to arrestin2 (arr2 siRNA1 or arr2 siRNA2) were assessed for TGFdependent p38 phosphorylation. Serum-deprived cells were either immediately lysed or
treated with 250 pM TGF1 for 30 minutes. Cells were then washed in PBS and further
incubated for 1 or 4 hours or were lysed. All lysates were subjected to SDS-PAGE and
immunoblotted for phospho-p38, total p38, arrestin2 and actin levels (N=3).

146

Figure 4.10

147

4.4.9

siRNA directed to arrestin2 predisposes cells to apoptosis and
increases TGF-dependent apoptosis
Having found that decreasing arrestin2 expression increased levels of

phosphorylated p38, I wanted to assess whether this increase in phosphorylation
would have functional outcomes for the cell; or, similar to my results with
phosphorylated Smad2, would not result in increased signal transduction. The
p38 MAPK pathway is well-known as a stress-activated pathway, and its
activation has been shown to induce apoptosis (19). Furthermore, Yu and
colleagues have shown that p38 is necessary for TGF-induced apoptosis (20).
Therefore, I decided to assess TGF-induced apoptosis in A549 cells as a
functional read-out for phosphorylated p38. A549 cells were plated in 12-well
dishes and transfected with siRNA against arrestin2, as previously described.
The day following transfection, cells were serum-starved in 0.2% FBS/F12K for 4
hours, then were either left in low-serum media or were treated with 250 pM
TGFfor 48 hours. Following treatment, cells were incubated with Hoechst
33342 prior to imaging on an inverted IX-71 immunofluorescence microscope.
Figure 4.11 illustrates the outcome of the apoptosis assays. In the negative
control siRNA treated cells, cells that were not stimulated with TGF
demonstrated little apoptosis (approximately 7% of cells) (Figure 4.11A, 4.11B),
while those treated with TGF had a moderate increase in apoptosis
(approximately 12% of cells) which did not reach statistical significance (Figure
4.11).

Figure 4.11 Decreased arrestin2 protein levels increase cell death
(A) A549 cells were transiently transfected with ctrl siRNA or two different siRNA to
arrestin2 (arr2 siRNA1 or arr2 siRNA2). Following transfection cells were serumstarved and either treated with 250 pM of TGF1 for 48 hours or left untreated. Cells
were then incubated with Hoechst 33342 and imaged on an inverted IX-71
immunofluorescence microscope. Panel A illustrates representative fields of view for the
different conditions. (N=4). Bar= 10 µm.
(B) Quantification of apoptosis assay. Nine fields of view over four separate
experiments (>100 cells/condition/experiment) were quantified by dividing apoptotic
cells by total number of cells per field of view. The graph illustrates the percentage of
apoptotic cells. One-way ANOVA followed by Bonferroni correction statistical analysis
was performed. (*) indicate a statistically significant difference between the indicated
conditions (p<0.05).
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Interestingly, in the absence of TGF stimulation, both arrestin2 siRNA
conditions had a statistically significant increase in apoptotic cells compared to
control (Figure 4.11B). Furthermore, both arrestin2 siRNA conditions showed a
statistically significant increase of apoptosis with TGF treatment, with
approximately a 10% increase in total apoptosis (Figure 4.11B). This figure
illustrates that decreasing arrestin2 expression sensitizes cells to cell death.
As the Hoechst apoptosis assay only allowed me to qualitatively assess
dead cells, I wanted to ensure the cell death that I had found was indeed
apoptosis and not necrosis. In order to answer this question, I performed a
western blot to evaluate levels of the protein cleaved PARP. Poly(ADPribosylation) is a post-translational modification that is commonly implicated in
DNA repair (21). The process of poly(ADP-ribosylation) is regulated in part by
PARP, poly(ADP-ribosylation) polymerase (21). During the intermediate phase of
apoptosis, PARP is activated but is later cleaved by a number of proteases, with
the best-known being caspase-3 (22). The cleavage of PARP inactivates its
activity, and apoptosis continues to progress.
To assess levels of cleaved-PARP in my cells, I performed western blot
analysis and immunoblotting (Figure 4.12). Cells were transfected with arrestin2
siRNA, then 16 hours post-transfection, cells were serum-starved for 4 hours and
then either treated with 500 pM TGF for 48 hours or left untreated. Similar to my
results using the Hoechst assay, I found that decreasing arrestin2 levels
increased the amount of cleaved-PARP, in the absence of TGFparticularly in
the case of siRNA2 (see Figure 4.12, arr2 siRNA2). However, similar to the

Figure 4.12 Decreased arrestin2 levels increase cleaved-PARP
A549 cells were transiently transfected with ctrl siRNA or two different siRNA to
arrestin2 (arr2 siRNA1 or arr2 siRNA2). Following transfection, cells were serumstarved and either treated with 500 pM of TGF1 for 48 hours or left untreated. Cells
were then lysed and subjected to SDS-PAGE and immunoblotting for cleaved-PARP as
well as arrestin2 and actin (N=3).
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Hoechst experiments I saw an inductive effect of TGF in enhancing levels of
cleaved-PARP (Figure 4.12).
Taken together, my results indicate a role for arrestin2 in modulating
TGF signalling pathways.

4.5

Discussion

While receptor complexes were previously thought to signal solely at the
cell surface, a number of studies have shown that the localization of receptor
complexes in different subcellular compartments can directly affect signal
transduction. For example, it has recently been shown that the trafficking of the
VEGF receptor, VEGFR-2, is dependent on its interaction with NRP-1, which
enhances VEGFR-2 signalling and entrance into a recycling pathway (23).
Similarly, Purvanov and colleagues found that the early endosomal GTPase
Rab5 can directly interact with G to activate the planar-cell-polarity pathway of
Frizzled signalling (24).

In the TGFsignalling pathway, SARA, an early

endosomal protein, enhances the ability of TRI to phosphorylate Smads by
bringing them into close proximity with one another (3, 27).
In this chapter, I have attempted to elucidate the role of arrestin2 in
TGF signal transduction. arrestin2 has greater than twenty known binding
partners (7), and is an important scaffolding protein in GPCR signalling. Chen et
al., originally reported that arrestin2 functions to promote the internalization of
TRIII/TRII complexes following the phosphorylation of TRIII by TRII (7).
However, I have shown that the role of arrestin2 in TGF signal transduction is
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not merely limited to its interactions with TRIII. Rather, I have shown that
arrestin2 can interact with TRII in the absence of TRIII. This interaction has
significant implications in TGFsignal transduction, as A549 cells, which have
been shown to have very little endogenous TRIII (16), show significant
differences in TGF signal transduction through both canonical and noncanonical pathways. My results indicate that the loss of arrestin2 promotes
increased

phosphorylation

of

both

Smad2

and

p38.

However,

the

phosphorylation of Smad2 does not translate into functional signalling, as loss of
arrestin2 decreases TGF-dependent luciferase production. In their manuscript,
Chen et al suggested that arrestin2 increased TGF receptor endocytosis and
loss of arrestin2 increased TGF signalling (14). In this chapter, I have shown
that loss of arrestin2 increases the phosphorylation and activity of the p38
pathway.
While it may seem contradictory that loss of arrestin2 increases
phosphorylated Smad2 levels but decreases TGF-dependent transcription, an
elegant study by Runyan et al. supports my findings. In their report, Runyan and
colleagues evaluated the role of internalization in TGF-dependent Smad signal
transduction. Using human kidney mesangial cells, the authors illustrated that
inhibition of internalization only slightly affected levels of phosphorylated Smad2,
and Smad2-SARA complexes (25). However, the authors also showed that
inhibition of endocytosis greatly decreased Smad2 nuclear localization as well as
Smad2-dependent transcriptional activation (25). Indeed in my study, I found
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increased cell-surface levels of TRII in the absence of arrestin2. Since the
inhibition of internalization does not affect the ability of Smad2 to be
phosphorylated (25), it follows then that loss of arrestin2 should not decrease
Smad2 phosphorylation. However, given our finding that arrestin2 increases the
association of TRII with SARA, it is plausible that while loss of arrestin2 does
not affect Smad2 phosphorylation, it may traffic with the receptor complex to the
early endosome and enhance SARA-TRII association.
In my study I also assessed a Smad-independent pathway, the p38
pathway, and my results showed that loss of arrestin2 greatly increases p38
phosphorylation in the presence of TGF. Since one possibility is that greater
numbers of TGF receptors are found at the cell surface in the absence of
arrestin2, this would mean that more receptors would be exposed to ligand and
therefore activated for signalling. Since the activation of the p38 pathway by
TGF is Smad-independent (17, 18); the internalization of the receptor complex
does not appear to be necessary for p38 signal transduction. Indeed, I showed
that increased levels of phosphorylated p38 had a functional outcome in the cell,
as loss of arrestin2 increased apoptosis, a well-established signalling event
downstream of p38 signal transduction.
The trafficking of TGF receptors plays a crucial role in signal
transduction, not only biochemically but in disease states as well. Recently, Park
and colleagues showed that a TRII mutant found in oral squamous cell
carcinoma exhibits delayed internalization and promotes cancer cell migration
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and invasion (26). Similarly, in scleroderma, a fibrotic disease which exhibits
elevated TGF signalling, patients exhibit decreased levels of caveolin-1, a key
component of membrane raft dependent internalization (32). These studies
suggest that internalization and trafficking of TGF receptors can have significant
implications in disease states. Therefore proteins like arrestin2, which alter
TGF trafficking can have significant affects on signal transduction and should be
studied in detail to evaluate their effects in disease states such as cancer and
fibrosis.
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CHAPTER 5

TGF3 IS A LESS POTENT INDUCER OF TGF SIGNALING THAN TGF1 IN
NON-SMALL CELL LUNG CANCER CELLS
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5

Chapter 5
5.1

Chapter summary

In Chapters 3 and 4 of my thesis, I assessed the ability of proteins which
interact with TRII, namely TRIII and arrestin2, to influence trafficking and
signaling of the receptor complex. In this chapter I have evaluated the role of
TGFligand types 1 and 3, which can bind all three TGF receptors, in their
ability to affect TGFtrafficking and signaling. I show that overall TGF3 is much
less potent than TGF1 at propagating TGFsignalling. While I initially
hypothesized that this would be due to alterations in endocytosis and trafficking
similar to my other chapters, I found that both TGFligands induced similar
membrane raft partitioning and trafficking of the TGFreceptor complex.
However, I found that TGF3 induced a different binding ratio of TRII/TRI cellsurface complexes than TGF1. Therefore the level of receptor engagement at
the cell surface may differ between the two ligands and may be able to account
for the observed differences in signal transduction.
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5.2

Introduction

The TGFsuperfamily consists of structurally and functionally related
cytokines that are released into the extracellular matrix as inactive precursors (1).
The TGFβ superfamily has two distinct subfamilies: the TGFβ/Activin/Nodal
subfamily and the bone morphogenetic protein (BMP)/growth and differentiation
factor (GDF)/ Muellerian inhibiting substance (MIS) subfamily (2). The
TGF/Activin/Nodal subfamily binds to serine-threonine kinase receptors at the
cell surface which results in signal propagation utilizing Smads 2 and 3 (3).
Similarly, signal transduction by the

BMP/GDF/MIS subfamily

is also

propagated by serine-threonine kinase receptors, but their activation results in
signal transduction utilizing Smads 1, 3, 5 and 8 (2).

While signal transduction

by the TGFsuperfamily has been implicated in normal development, such as
dorsal/ventral patterning and angiogenesis, the TGFsuperfamily, in particular
the canonical TGFpathway has been implicated in pathologies such as cancer
and fibrosis (3).
There are three TGFβ ligands which share significant sequence
homology and have relatively specific, non-overlapping functions in vivo: TGF1,
TGF2 and TGF3 (4). For example, while Tgfb1-/- mice and Tgfb2-/- mice both
generally die during development, Tgfb1-/- mice have significant vasculogenic
defects (5), whereas Tgfb2-/- mice have cardiovascular, skeletal and pulmonary
issues (6). Interestingly, Tgfb3-/- mice survive gestation but die shortly after birth
due to an inability to suckle caused by cleft palate (7). Although TGFβ ligands
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have different functional roles, they are all secreted as inactive, homodimeric
proproteins that must be cleaved by TGFβ activating molecules, such as matrix
metalloproteinase 2, thrombospondin-1 and plasmin (8-10) . Active TGFβ is a
homodimer stabilized by disulfide bridges and hydrophobic interactions (11).
Once TGFβ has been activated, it is able to elicit downstream transcriptional
events through binding and activating TGFβ receptors.
To propagate TGFβ signaling, ligand is presented to the TβRII with the aid
of ΤβRIII. The binding of ligand to ΤβRII causes ΤβRII to transphosphorylate the
ΤβRI at serine-threonine residues in its GS domain (12). Phosphorylated ΤβRI
recruits the receptor-regulated Smads, or R-Smads, and phosphorylates, and
thereby activates them. Once the R-Smads have been phosphorylated, they are
able to recruit the Co-Smad, Smad4, to form a heteromeric complex. With the aid
of specific nuclear localization signals, the heteromeric Smad complex is able to
translocate to the nucleus and interact with transcriptional co-activators and corepressors in order to induce cell-specific transcriptional programs (11).
Despite

activating

the

same

signal

transduction

pathway,

the

TGFligands have vastly different effects in the wound microenvironment. For
example,

TGF1 signalling in fibroblasts promotes ECM production and

myofibroblast differentiation, resulting in a scar following wound-resolution (13).
Similarly, inhibition of either TGF1 or TGF2 with neutralizing antibodies
improves wound resolution and scar appearance in adult rodent wounds (14,15).
However, application of exogenous TGF3 results in scar-free wound-resolution
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in the same model system (16). This suggests that the different TGFligandsdo
not have the same signalling effect in the wound microenvironment.
The vast majority of studies on TGFin cancer have focussed on
TGF1 (4). TGF1 has a dual role in cancer: in early stages of tumourigenesis,
TGF1 is growth-inhibitory and induces cell cycle arrest (17). However, in
advanced cancers, TGF1 promotes epithelial-to-mesenchymal transition of
tumour cells and promotes migration and invasion (17). While all three
TGFligands are elevated in various tumours, the role of TGF3 has simply
been assumed to be the same as TGF1 without subsequent in-depth
biochemical studies to support this notion (4). Given the opposite roles of TGF1
and TGF3 in the wound microenvironment and in development, it is unlikely that
these two ligands have the same signalling outcome in the tumour
microenvironment and cancer cells. Therefore in this chapter I have attempted to
evaluate the mechanism of how structurally related TGF ligands activate
receptor signaling cascades and downstream cellular events.

5.3
5.3.1

Materials and Methods
Cell culture

HEK293T cells were maintained in DMEM (Dulbecco’s modified Eagle’s
medium) (Gibco) supplemented with 10% fetal bovine serum. A549 cells were
maintained in F12K media (ATCC) supplemented with 10% fetal bovine serum.
Mink Lung cells stably transfected with HA-tagged TRII (Mink Lung HAT cells)
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were cultured in MEM supplemented with non-essential amino acids, 10% fetal
bovine serum and 0.3% hygromycin. All cells were maintained at 37°C in 5%
CO2.

5.3.2

Constructs
The pCMV5 cDNA construct encoding the carboxy terminus hemagluttinin

(HA) epitope tagged type II TGF receptor (TβRII-HA) was used as previously
described (18).

5.3.3

Transfection
HEK293T cells were transiently transfected using the calcium phosphate

precipitation method; 5g of TRII-HA was transfected per 100mm dish (19,20).

5.3.4

Isolation of caveolae/membrane-raft-enriched membrane fractionsMembrane rafts were isolated as previously described (18-20). Briefly,

transfected HEK293T cells were grown to confluence in 100-mm-diameter
dishes. Cells were washed twice with cold 1X PBS and lysed in 0.5 M Na2CO3,
pH 11.0 containing protease inhibitors. After the cells were scraped, the cell
lysate was homogenized in three 10 second bursts using a Polytron tissue
homogenizer (Brinkmann Instruments). Cells were then sonicated three times for
20 seconds each with a Vibra Cell sonicator (Sonics and Materials). The
homogenates were then adjusted to 40% sucrose, and overlaid with 30%
sucrose and 5% sucrose solutions. The samples were centrifuged for 16h at
200,000 gav at 4°C using a Beckman SW41 rotor. Following centrifugation,
12x1mL samples were collected and an aliquot of each sample was denatured
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with Laemmli sample prep buffer, boiled and subjected to SDS-PAGE followed
by immunoblotting.

5.3.5

Immunofluorescence Microscopy
Mv1Lu HAT cells were plated on coverslips in a 12 well plate and

transfected with the indicated constructs. Cells were then incubated with
biotinylated-TGF1 or biotinylated-TGF3 (Peprotech) in 0.5% BSA in KRH for
2hrs at 4°C. Cells were washed three times with buffer, and then incubated with
Cy3-labelled streptavidin for 1 hr at 4°C. Cells were fixed, permeabilized and
incubated with anti-EEA1 primary and secondary antibodies as described
previously (18,19). Images were obtained using an Olympus Ix81 inverted
microscope using InVivo® software.

5.3.6

Immunoblotting
Proteins were separated by SDS-PAGE (10% gels) and transferred to

nitrocellulose by electrophoretic transfer. Blots were incubated for 1 hr in 5%
skim milk/TBST. After incubation with primary and secondary antibodies, bound
antibodies were detected using SuperSignal chemiluminescence reagent
(Pierce) and a VersaDoc imager (Biorad).

5.3.7

Epithelial to mesenchymal cell marker analysis
A549 cells were incubated with low-serum containing control medium or

low-serum media containing increasing concentrations of TGF1 or TGF3 for 48
hours. Cells were then lysed and immunoblotted with -E-cadherin (epithelial cell
marker) or -N-cadherin (mesenchymal cell marker) as described above.
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5.3.8

Affinity labelling
A549 cells were labelled for 2 hrs with 250 pM [125I] TGF1 or 250 pM

[125I] TGF3 ligand (Peprotech) in 0.5% BSA in KRH at 4°C. Cells were crosslinked to ligand using DSS as described previously (19). Cells were then either
immediately lysed in 1XTNTE or incubated in media with 10% FBS at 37°C for 2,
4 or 8 hrs prior to lysis. Samples were eluted with Laemmli sample prep buffer,
and separated using SDS-PAGE (7.5% gels). Receptors were visualized using
phosphorimaging (Molecular Dynamics).

5.4
5.4.1

Results
TGF3 is less potent at inducing Smad2 phosphorylation than TGF1

As it has previously been shown that TGFβ1 and TGFβ3 exert vastly
different outcomes in the wound microenvironment (21), I wanted to assess the
ability of these ligands to transmit signals in cancer cells, as many of the same
growth factors elevated in the wound microenvironment are also elevated in the
tumor microenvironment. A549 non-small cell lung adenocarcinoma cells were
used as a model to begin to characterize the role of these ligands in cancer cell
signaling. A549 cells were serum-starved overnight prior to a one hour treatment
with TGFβ1 or TGF3 ligand, ranging in concentration from 50 pM to 1 nM prior
to lysis and immunoblotting with anti-phosphoSmad2 antibodies (Figure 5.1A). I
observed that TGF1 induced the phosphorylation of Smad2 maximally at 50 pM.
This is consistent with our previous results using Mv1Lu cells (20). TGFβ3 was
also observed to stimulate a similar amount of Smad2 phosphorylation, however

Figure 5.1. TGF3 is less potent than TGF1 in inducing Smad2 phosphorylation.
(A) A549 cells were serum-starved and treated with increasing concentrations of TGF1
or TGF3 for 1 hour. Following lysis, cells were subjected to SDS-PAGE and
immunoblotting for phosphorylated Smad2 (PSmad2) or Smad 2 (N=3).
(B) Three separate experiments as described in Panel A were carried out and the
amounts of PSmad2 and Smad2 were quantified using QuantityOne software and
plotted as the ratio of PSmad2/Smad2. The mean (Arbitrary Units) ± SD is shown. Oneway ANOVA followed by a Tukey’s Multiple Comparison test was conducted to evaluate
statistical significance. * indicates a statistical significance of p<0.05.
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at a concentration of 250 pM (Figure 5.1B).

This five-fold difference in the

stimulation of Smad2 phosphorylation was next functionally tested in the ability of
TGF1 and TGF3 to induce differences in protein expression of the EMT
markers E-cadherin and N-cadherin.
TGFβ1 is more potent at altering steady-state cellular EMT markers
than TGFβ3

5.4.2

In order for epithelial-based cancers to metastasize, they first must
release their cell-cell contacts, change their cytoskeletal arrangement, and
acquire a motile phenotype (22). Loss of E-cadherin, an adhesion molecule, is
one of the first indications of epithelial-to-mesenchymal transition. As TGFβ1 has
been shown to induce loss of E-cadherin (reviewed in (22)), I wanted to assess
whether TGFβ3 also shared this capability. A549 cells were serum-starved
overnight and then treated with increasing concentrations of TGFβ1 or TGFβ3 for
48 hours (Figure 5.2). I observed that TGF1 stimulated a loss of steady state Ecadherin levels in A549 cells that was maximal at 250 pM (Figure 5.2B).
Interestingly, TGFβ3 did not induce a pronounced decrease in the steady-state
levels of E-cadherin, compared to TGFβ1 (Figure 5.2A). Indeed, I observed a 10fold difference in the abilities of TGFβ3 or TGFβ1 to decrease the steady-state
levels of E-cadherin by 50% (Figure 5.2B; 100 pM for TGFβ1 vs. 1 nM for
TGFβ3).
While loss of E-cadherin occurs frequently with the progression of cancer,
upregulation of N-cadherin, a neuronal cadherin, has also been shown to occur
during EMT (23). Increased levels of N-cadherin are correlated with tumor

Figure 5.2. TGF1 is more potent than TGF3 at reducing E-cadherin levels
(A) A549 cells were serum-starved and treated with increasing concentrations of TGF1
or TGF3 for 48 hours. Following lysis, cells were subjected to SDS-PAGE and
immunoblotting for E-cadherin (Ecad) or Actin (N=3).
(B) Three separate experiments as described in Panel A were carried out and the level
of E-cadherin was quantitated using QuantityOne software. The means (Arbitrary Units)
± SD are shown. Statistical significance was evaluated using a One-Way ANOVA test
followed by a Bonferroni correction (* p<0.05).
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metastasis (23). Therefore I wanted to assess the effect of TGFβ3 on steadystate levels of N-cadherin. Again, A549 cells were serum-starved then treated
with increasing concentrations of either TGF1 or TGF3 for 48 hours (Figure
5.3). I observed that TGFβ3 is less potent than TGFβ1 in increasing N-cadherin
steady-state levels (Figure 5.3A). While TGFβ1 induces more N-cadherin protein
at concentrations as low as 100 pM, TGFβ3 required higher concentrations to
induce only very minor increases in N-cadherin levels (Figure 5.3B).

These

differences in steady state EMT markers may be a global effect that these two
TGF sub-types have on cells.

5.4.3

TGFβ1 and TGFβ3 ligand treatment do not alter TGFβ receptor
membrane partitioning

As I have shown that TGFβ1 and TGFβ3 have strikingly different signal
transduction capabilities I hypothesized that these differences in signaling could
be accounted for by receptor membrane partitioning, similar to my other data
chapters. To address this question, HEK293T cells were transiently transfected
with HA-TβRII cDNA. Cells were serum-starved 16 hours prior to membrane raft
preparation, and were then treated with either 250 pM TGFβ1, 250 pM TGFβ3,
0.2% FBS or 10% FBS (as indicated) for 30 minutes. Cells were subjected to
sucrose-density ultracentrifugation and immunoblotting with anti-HA antibodies to
identify tagged TGF receptors. Figure 5.4 illustrates that in the presence and
absence of ligand, the ΤGFβ receptors were observed primarily in membrane raft
fractions. Therefore, it appeared that ligand treatment of specific TGF isoforms
did not directly affect membrane partitioning of receptors.

Figure 5.3. TGFβ1 induces greater N-cadherin steady-state levels than TGFβ3
(A) A549 cells were serum-starved and treated with increasing concentrations of TGF1
or TGF3 for 48 hours. Following lysis, cells were subjected to SDS-PAGE and
immunoblotting for N-cadherin (Ncad) or Actin (N=3).
(B) Three separate experiments as described in Panel A were carried out and the level
of N-cadherin was quantitated using QuantityOne software.

The means (Arbitrary

Units) ± SD are shown. One-way ANOVA followed by a Tukey’s Multiple Comparison
test was conducted to evaluate statistical significance. * indicates a statistical
significance of p<0.05, whereas ** indicates a statistical significance of p<0.001.
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Figure 5.4. Ligand treatment does not influence TGFβ receptor partitioning
HEK 293T cells were transiently transfected with TβRII-HA cDNA. Cells were serumstarved for 16 hours prior to a 30 minute treatment with 250 pM ligand or FBS (as
indicated). The cells were then lysed and processed for ultracentrifugation as previously
described (18). The collected fractions containing membrane rafts (R) and non-raft (NR)
were immunoblotted with anti-HA antibodies to visualize the partitioning of expressed
TRII (N=3).
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5.4.4

TGF1 or TGF3 treatment do not differ in their trafficking of TRII to
the early endosome

Although TGFβ1 and TGFβ3 do not alter TGFβ receptor complex
membrane partitioning, I wanted to assess the trafficking of receptors following
ligand treatment. It has been shown that the greater the amount of time spent in
the early endosome, the greater the Smad signalling potential (20,24,25).
Therefore, I hypothesized that perhaps the differences in signaling could be
accounted for by receptor trafficking to the early endosome. Using biotinylatedTGFβ1 or TGFβ3, HAT Mv1Lu cells stably expressing TβRII were labelled at the
cell surface at 4˚C. Receptors were then incubated with streptavidin-Cy3, and
permitted to internalize for 10, 20, or 60 minutes (Figure 5.5). Using EEA1 (early
endosomal autoantigen-1) as a marker for the early endosome, I found that both
ligands co-localized in EEA1-positive compartments at 20 minutes, and
significant co-localization occurred at 60 minutes.

5.4.5

TGFβ3 promotes a different binding ratio of TβRII/TβRI complexes
than TGFβ1

While it has been previously found that TGFβ3 binds to TβRII dimers with a
greater affinity than TGFβ1 (26), I wanted to ensure that our ligands bound
similarly in our experiments. To address this question, TGFβ1 and TGFβ3 were
labelled with

125

I and performed receptor binding studies. Briefly, Mv1Lu cells

were labelled with saturating doses of

125

I-TGFβ isoforms, for 2 hours at 4˚C. The

ligands were cross-linked, and lysates were subjected to SDS-PAGE.

Figure 5.5 Cells treated with TGFβ1 or TGFβ3 exhibit similar trafficking of TRII
Mv1Lu cells stably over-expressing HA-TβRII were labelled at 4˚C for 2 hours with
biotinylated TGFβ1 (A) or TGFβ3 (B). Following incubation of Cy3-labelled streptavidin
at 4˚C, cells were incubated for 10, 20 or 60 minutes (as indicated) at 37˚C to permit
receptor internalization. Standard immunofluorescence staining was used to visualize
EEA1, a marker for the early endosome, and nuclei (DAPI staining). Cells were
assessed for receptor complex co-localization with the early endosome, which results in
a yellow overlay (N=4). Bar= 10 m
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I observed that both TGFβ1 and TGFβ3 associated with TβRII (Figure 5.6A).
However, it appears that the amount of TβRI recruited to the TGFβ/TβRII
complex was lower for TGFβ3 than TGFβ1 (Figure 5.6B). As the kinase activity
of TβRI is responsible for initiating the Smad signaling cascade, and TβRI must
be activated by TβRII following ligand binding to initiate the cascade, TβRII/TβRI
ratios may play a crucial role in determining signaling potential. Therefore, if
TGFβ3 induces less TβRI to be bound to TβRII, this may result in fewer activated
TβRI to propagate Smad signal transduction.

5.5

Discussion

In the canonical TGF signaling pathway, the association of TGF to the
type II receptor (TRII) is the first step in activation of the signaling cascade
(27,28). This is followed by the recruitment of the type I receptor (TRI) to the
TRII/TGF complex and the transphosphorylation of TRI in its GS domain by
TRII.

The now active TRI initiates downstream R-Smad (Smad2/3)

phosphorylation leading to the formation of a complex between R-Smads with the
common Smad, Smad4, and their nuclear import to affect transcription (2).
In this chapter, I have demonstrated that the degree of recruitment of TRI
to the TRII/TGF complex is dependent on isoform-specific TGF ligands. I
observed that TGF1 is more effective in recruiting TRI to the complex than
TGF3. This has greater implications to signal transduction and I observed a
muted response to ligand-dependent activation of the Smad signaling pathway

Figure 5.6. TGF isoform specific receptor complex formation
(A) Mv1Lu cells were labelled at 4˚C for 2 hours with

125

I-TGFβ1 or 125I-TGFβ3, cross-

linked, subjected to SDS-PAGE and visualized by phosphorimaging (N=3).
(B) Ratios of TβRI and TβRII were determined using QuantityOne software. The graph
illustrates the amount of TβRI associated with TβRII. (mean ± SD). (N=3)
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and muted changes of EMT markers when cells were incubated with TGF3
compared to TGF1. As previously mentioned, during adult wound healing,
TGFβ1 is found at very high levels, and promotes myofibroblast differentiation,
extracellular matrix production, and fibroblast chemotaxis (29). In contrast,
TGFβ3 promotes scar-free healing (29). Therefore, my results may account for
some of the differences seen in wound healing because even though TGFβ
ligands can activate the same receptors to propagate signal transduction, the
level of isoform specific receptor engagement will influence transcriptional
outcome in TGFβ signaling. To confirm these results, it may be of interest to
assess the ability of TGF3 to induce differentiation of fibroblasts to
myofibroblasts.
Though studies have shown that TGF3 promotes scar-free healing (29),
few studies have assessed the ability of TGF3 to induce myofibroblast
differentiation. Interestingly, a study by Waddington and colleagues showed that
increasing the bioavailability of TGF3 may increase its efficacy in promoting
scar-free wound-healing. In this study, the authors created a mutant TGF3
which did not bind latent TGFbinding protein (LTBP), thereby increasing its
bioavailability, as LTBP has been shown to sequester TGFligand in the ECM
(30). The authors used a lentiviral-based delivery system to deliver this construct
in vivo and illustrated that it decreased scar tissue markers in a mouse wounding
model (30). Therefore, modulating the bioavailability of TGF3 in the ECM may
provide an interesting therapeutic target for scar tissue formation. Since my
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results also show differences between TGF1 and TGF3 signalling ability in
cancer cells, it may be interesting to assess whether modulating the
bioavailability of TGF3 in the tumour microenvironment through a similar system
could mediate tumourigenicity in an in vivo model.
An intriguing avenue of study to complement my work on isoform-specific
TGFsignal transduction would be to assess the binding capacity of TGF1 and
TGF3 to the TGFreceptor complex. It has been reported that TGF3 has the
greatest ability to bind TRII (4). Therefore it would be interesting to assess
whether TGF1 and TGF3 could compete for binding of TRII. If TGF3 is able
to displace TGF1 from TRII, and since my results show that TGF3 induces
less signal transduction in cancer cells, increasing the amount of TGF3 may be
able to competitively displace TGF1 and therefore decrease the detrimental
effects of TGF1 signalling in cancer cells.
TGFβ ligands normally dimerize to associate and cluster receptors
effectively. A recent study substituted one of the dimerized TGFβ3 with TGFβ3
WD (31). The TGF3 WD that was designed by the authors is a heteromeric
TGFligand composed of one wild-type TGF3 and one TGF3 in which Arg25
and Arg94 were substituted with glutamate, and Tyr90 was substituted with
alanine (31), residues shown to be important for ligand binding. These residues
are also missing in TGF2. This TGFβ3 wild-type/ TGFβ3 WD dimer was found
to associate with TβRII and recruited the TβRI with affinities similar to wild-type
TGFβ3, but with one-half the stoichiometry (31). TGFβ3 WD was further shown
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to retain approximately half the signaling activity of TGFβ3 in three TGFassays
such as Smad3 phosphorylation and growth inhibition.

The authors also

provided evidence that the two TβRI/TβRII heterodimers bind and signal in an
independently of one another.

Taken together, these results and my

observations suggest that TGF1 and TGF3 have different receptor clustering
potential. Future work comparing the amino acid sequences of the TGFβ1 vs.
TGFβ3 ligands, which are >76% identical, may show specific regions of the
ligands that are responsible for receptor binding and engagement.
Another interesting consequence of my study was the observation that
TRII membrane partitioning and trafficking is not influenced by isoform-specific
ligand binding. This is consistent with previous results which illustrated that the
trafficking of TRII is not dependent on ligand association (20).

Indeed, the

recruitment of TRI to the constitutively trafficking TRII may be the limiting factor
in receptor signaling potential, where TRI must access the early endosome to
phosphorylate Smad2 and initiate the signal transduction cascade.

Further

studies on the effect of ligand specific trafficking of TRI may further elucidate
this theory.
Since the mechanism of TGFβ receptor endocytosis has a profound effect
on TGFβ signaling, and a number of pathologies show aberrant TGFβ signaling,
an in-depth study evaluating the mechanism through which TGFβ receptors are
directed to internalize is warranted.
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Chapter 6
6.1

Summary and General Discussion

The TGFsignalling pathway is a cell-type and context-dependent
pathway which has pleiotropic effects. While it was initially thought that
TGFsignal transduction simply occurred from the cell surface and was
mediated by the Smad family of transcription factors, it is now understood that
TGFreceptor internalization and trafficking play key roles in regulating signalling
outcome. It has been shown that receptors internalized by clathrin-mediated
endocytosis traffic to the early endosome where they can interact with SARA to
propagate Smad-mediated transcription (1-3). However, receptors internalized by
membrane raft-dependent, clathrin-independent mechanisms traffic to the
caveolin-1 positive vesicle, are prevented from signal propagation and are
targeted for degradation. While the role of endocytosis and trafficking in this
pathway has now been established, the signal(s) directing the TGFreceptors to
internalize

via

clathrin-dependent

endocytosis

or

clathrin-independent

endocytosis were not well understood. The overall purpose of my study was to
evaluate factors directing TGFreceptor internalization. I evaluated the role of
domains of TRII, the interaction of TRII with TRIII, the interaction of TRII
with arrestin2, and the role of TGFligand isoforms on TGFreceptor trafficking
and subsequent signal transduction. Therefore, in this body of work I have
assessed both intracellular and extracellular factors which direct TGFreceptor
trafficking and have direct effects on signalling outcome.
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6.1.1

The extracellular domain of TRII directs entry into membrane-raft
fractions
My work, presented in chapter 2, complemented a study I carried out with

Valbona Luga to identify domains of TRII which may direct receptor
internalization. We used truncation mutants of TRII and evaluated their ability to
partition into membrane raft fractions. Previously very little work had been done
on identifying motifs involved in TRII internalization. A study performed by
Ehrlich and colleagues had identified a di-leucine motif in the cytoplasmic domain
of TRII which regulated clathrin-mediated endocytosis (4); but no studies had
attempted to evaluate the role of the extracellular domain in regulating TRII
internalization. In chapter 2, I showed that both the extracellular and intracellular
truncation mutants of TRII were able to interact with TRI. This was an
important parameter to assess as it has been shown that TRII and TRI form
heterocomplexes at the cell surface (5) and it has been suggested that the
binding ratio of TRII:TRI may also affect endocytic trafficking of the receptors
(6). Upon analysis of TRII receptor partitioning, we found that the extracellular
truncation mutant of TRII had a marked decrease in membrane-raft
internalization. As TRII has several extracellular glycosylation sites (7) we
assessed whether the glycosylation status of TRII affected its ability to partition
into membrane rafts. We found that the glycosylation status of TRII itself did not
affect its membrane raft partitioning, but the glycosylation status of the cell as a
whole did affect the partitioning of TRII. Importantly, this was not due to a
disruption in the ability of the cell to produce membrane rafts, as I illustrated that
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treatment with nystatin did not disrupt membrane raft formation. Finally, I
illustrated using a chimeric receptor composed of the GMCSF receptor
extracellular domain and the intracellular domain of TRII that it is specifically the
extracellular domain of TRII, and not a similarly glycosylated receptor, which
directs entry of TRII into membrane rafts.

6.1.2

TRIII increases clathrin-mediated endocytosis of TRII/TRI
complexes and basal TGFsignalling
As shown in Chapter 2 that the extracellular domain of TRII and the

glycosylation status of the cell as a whole affected membrane raft partitioning of
TRII, I decided to assess the role of TRIII in directing TRII/TRI internalization
and trafficking. Previously the role of TRIII in TGFsignal transduction had
been thought to be simply involved in ligand-presentation to TRII. Since TRIII
has a large, heavily glycosylated extracellular domain (7) and it has been shown
to interact with TRII, I thought it could potentially be the signal regulating TRII
trafficking based on my work from Chapter 2.
In Chapter 3, I demonstrated that TRIII was able to interact with both
TRII and TRI in the absence of ligand. Furthermore, unlike TRII and TRI
which were found primarily localized in membrane-raft fractions, TRIII was
found enriched in non-membrane raft fractions. Interestingly, its association with
TRII and TRI re-directed both receptor complexes into non-membrane raft
fractions and subsequently into the early endosome (Figure 6.1). This altered

Figure

6.1

TRIII

increases

clathrin-mediated

endocytosis

of

TRII/TRI

complexes
In Chapter 3 of my thesis, I evaluated the ability of TRIII to direct internalization of
TRII/TRI complexes. My work illustrated that TRIII could direct the TRII/TRI
complex to increase its non-membrane raft partitioning, traffic to the early endosome,
and increase its half-life and basal signalling potential.
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Figure 6.1
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internalization had effects on signal transduction as well, as the association of
TRIII with the TRII/TRI receptor complex increased their half-life and basal
TGFsignal transduction. As mentioned, while the role of TRIII had previously
been thought to be in ligand-presentation, I showed in Chapter 3, that TRIII
could alter the trafficking of the receptor complex thus supporting my model, that
this altered receptor trafficking has direct implications in TGFsignalling
potential.

6.1.3

arrestin2 interacts with TRII to mediate Smad-dependent and
Smad-independent signal transduction
I was interested in studying the role of arrestin2 in TGFsignal

transduction, as Chen and colleagues had found a novel role for arrestin2 in
mediating TRII/TRIII endocytosis through binding TRIII (8). Since they
showed that arrestin2 promoted endocytosis of TRII/TRIII, I was interested in
assessing whether this interaction directed membrane trafficking of the receptors.
As arrestin2 bound to a phosphorylated threonine residue on TRIII, and TRII
has multiple phosphorylated residues on its intracellular domain (7), I wanted to
test the possibility that arrestin2 could bind TRII in the absence of TRIII. In
Chapter 4, I illustrated that TRII and arrestin2 could interact in the absence of
TRIII (Figure 6.2). Furthermore, this interaction had direct consequences on
signalling. I used a cell line which has been shown to have very little endogenous
TRIII (A549 cells) (9), and illustrated that loss of arrestin2 protein expression
increased phosphorylation of both Smad2 and p38. Interestingly, the increased

Figure 6.2 arrestin2 interacts with TRII to increase early endosomal trafficking
of TRII and enhance Smad-dependent signal transduction
In Chapter 4 of my thesis I evaluated the ability of arrestin2 to affect TGF signalling.
My work illustrated that arrestin engages TRII and traffics with TRII to the early
endosome. Here, its presence increases TRII-SARA interaction and Smad-dependent
transcription.
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Figure 6.2
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phosphorylation of Smad2 did not translate into increased Smad signal
transduction as arrestin2 increased TRII trafficking to the early endosome and
mediated

the

interaction

of

TRII

with

SARA.

However,

increased

phosphorylation of p38 in the absence of arrestin2 predisposed cells to
apoptosis both in the presence and absence of TGF.
Therefore, in Chapter 4 I illustrated that arrestin2 associates with TRII
and may direct Smad-dependent and Smad-independent responses to
TGFstimulation.

6.1.4

TGF3 is a less potent inducer of TGFsignalling than TGF1 in nonsmall cell lung cancer cells
During my preparation for my comprehensive exam, I noticed that the

majority of work done on TGFin cancer had been done with TGF1 ligand and
very few research articles had evaluated the role of TGF2 or TGF3 in cancer.
Furthermore, it was generally assumed that the role of TGF2 and TGF3 would
be the same as TGF1 in TGFsignalling in cancer. Interestingly, in the wound
microenvironment, TGF3 has opposite effects to TGF1 and TGF2 and
promotes scar-free wound resolution, whereas TGF1 and TGF2 both cause
scar formation (10). Since many of the same cellular players are present in the
wound microenvironment and the tumour microenvironment, I predicted that
TGF3 would have different effects than TGF1 in TGFsignal transduction in
cancer cells.
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In Chapter 5 I evaluated the signalling ability of TGF1 and TGF3 in
A549 cells. In this chapter, I illustrated that TGF1 was a much more potent
inducer of TGFsignal transduction than TGF3 and increased both Smad2
phosphorylation and EMT to a greater extent than TGF3. Initially, I predicted
that this difference in signal transduction would be due to an alteration of
TGFreceptor partitioning and membrane trafficking, as was the case for my
other studies. However, I found that both ligand treatments induced similar
membrane-raft partitioning and trafficking of the receptor complex. Interestingly I
did observe differences in cell-surface receptor complex formation with TGF3
treatment compared to TGF1 treatment (Figure 6.3). I found that TGF3
induced fewer TRI bound to TRII than TGF1 treatment. The generally
accepted model of TGFcomplex formation is that at the cell surface TRII and
TRI form a hetero-oligomeric complex composed of two TRII and two TRI
(11). As TRI phosphorylates the downstream Smad transcription factors, having
less TRI associated with TRII may cause less activated TRI available for
activating the Smad pathway.

6.2

Limitations and Future Studies

It is important to note that all of the studies performed in this thesis used
immortalized cultured cell lines and purified ligands. The majority of my work is
heavily mechanism-based and assesses TGFsignal transduction pathways.
Using cell culture models that have been established for TGFsignalling assays
allowed me to carry out my work in a simplified and well-characterized system.

Figure 6.3 TGFligands cause altered TGFreceptor complex formation
In Chapter 5 of my thesis I evaluated the role of TGF1 and TGF3 to induce Smad
signal transduction in a non-small cell lung cancer cell line. I found that TGF3 induces
less Smad-signal transduction than TGF1 and alters cell-surface TGFreceptor
complex formation.
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Figure 6.3
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Furthermore, using these established cell lines where receptor levels and
TGFsignalling capacity had been established allowed me to manipulate
different protein-interactions to assess the effects on trafficking and signal
transduction.
In all of my data chapters I used HEK293T cells to assess TGFreceptor
interactions and membrane raft partitioning. These cells are an ideal model
system for this type of work, as HEK293T cells do not express high levels of
endogenous TGF receptors and also have a high level of membrane raft
content (1). This allowed me to assess receptor interactions in over-expression
assays using tagged receptors for ease of detection. However, there are some
issues regarding relying solely on over-expression studies to assess membrane
raft partitioning. It is possible that the over-expression of a construct, such as
TRIII may alter its distribution in the plasma membrane relative to endogenous
levels of receptors. Ultimately, it would have been ideal to assess levels of
endogenous TRIII in mediating the membrane partitioning of TRII/TRI
complexes. Unfortunately, there are few established antibodies available for the
detection of endogenous TGFreceptors. Therefore, when possible, I attempted
to evaluate endogenous TGFreceptors using
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I-TGFligand to bind

receptors, as this method is highly sensitive and can allow for detection of
receptors even in cell lines with low receptor levels. I used this method to detect
endogenous levels of receptors in HepG2 cells in membrane raft partitioning
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experiments in Chapter 3, and this method should be used to confirm membrane
raft partitioning results in future studies.
To confirm my membrane raft isolation experiments, I also used a wellestablished cell line, Mv1Lu HAT cells, to evaluate receptor trafficking using
immunofluorescence microscopy. This cell line is ideal for evaluating TRII
trafficking, as it is stably transfected with a zinc-inducible HA-tagged TRII
construct. These cells are also amenable to PEI transfection, which allowed me
to evaluate the effects of TRIII and arrestin2 on TRII trafficking in Chapters 3
and 4, respectively. While it would be ideal to assess the ability of endogenous
receptors to traffic into different endosomal compartments, we do not currently
have a sufficiently sensitive immunofluorescence approach to answer this
question.
Finally, to evaluate Smad-dependent transcription, I employed the use of
luciferase assays under the control of a Smad-responsive promoter in HepG2
cells in Chapters 3 and 4. HepG2 cells have been established for luciferase
assays and are easily transfected using the calcium-phosphate precipitation
method. Therefore, this approach allowed me to evaluate the role of different
combinations of receptors and their interacting protein(s) on TGF-dependent
transcription. When possible, I confirmed these results with signalling assays in
non-small cell lung cancer cells, such as A549 and H1299 cells, which allowed
me to assess the role of endogenous proteins on Smad-dependent and
independent signal transduction.
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Chapter 2 of this thesis provided evidence that the extracellular domain of
TRII regulated the entrance of TRII into membrane raft fractions. Furthermore,
it was shown that the glycosylation state of the cell as a whole, but not TRII
itself, was involved in regulating its membrane partitioning. This suggests that
there are cell-surface glycosylated TRII-interacting protein(s) which may direct
the entrance of TRII into membrane rafts. I evaluated one of these candidate
proteins, TRIII, in Chapter 3 of this thesis, but actually found that TRIII
increased

clathrin-dependent

internalization

of

TRII,

and

not

clathrin-

independent internalization, as was suggested in Chapter 2. This leads to the
notion that there are likely other proteins directing TRII into membrane raft
fractions. One such protein is CD109, which is a glycoprotein with 17 potential
N-linked glycosylation sites (12) and has been shown to enhance internalization
of TGFreceptors into the caveolin-1 positive vesicle (13). Future studies to
identify

other

glycosylated

cell-surface

proteins

directing

TGFreceptor

endocytosis may have important implications in TGFsignal capacity, and could
potentially be performed by isolating membrane raft fractions, performing coimmunoprecipitations to purify TRII and subjecting the immunoprecipitated
proteins to mass spectroscopy to identify novel proteins.
Though I initially thought that TRIII would promote clathin-independent
internalization of TRII/TRI complexes, the finding that TRIII promotes clathrindependent

internalization

of

receptors

has

important

implications

in

TGFreceptor biology. TRIII has been shown to be dysregulated in a number of
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cancers (14-19), and the effect of its altered expression is similar to that of
TGFsignalling as a whole: at times, loss of TRIII inhibits cancer progression
and metastasis, while at other times it appears to increase tumorigenicity. While
initially it could be thought that these discrepancies in the role of TRIII may be
due to its role in ligand-presentation, my work suggests that the level of available
TRIII may affect TGFsignal transduction through increasing the trafficking of
the receptors to the early endosome and extending their half-life. Therefore, it
would be interesting to evaluate the effect of knockdown of TRIII in cancer cell
lines at different stages of tumorigenicity and evaluate the trafficking and receptor
half-life of TRII.
Chapter 4 of my thesis evaluated the role of arrestin2 in modulating
TGFsignal transduction. While it had previously been shown that arrestin2
could interact with TRIII, my work illustrating that arrestin2 can interact with
TRII and affect Smad-dependent and Smad-independent signalling pathways
suggests that it has a greater role than simply receptor internalization, as initially
thought (8). I found it particularly interesting that arrestin2 caused such a
marked increased in p38 phosphorylation resulting in apoptosis. It has been
shown that Smad-independent pathways can have important effects in cancer
progression such as through mediating EMT, cell survival and apoptosis
(reviewed in (20)).Therefore, it would be interesting to see if loss of arrestin2
could drive apoptosis in numerous cancer cell lines resistant to the growthinhibitory effects of TGF. Furthermore, it would be fascinating to evaluate the
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role of arrestin2 in mediating metastasis of tumors in vivo. If loss of arrestin2
was also able to induce apoptosis in vivo, this may represent a novel mechanism
to disrupt TGF-dependent metastasis and tumor outgrowth.
Finally, in Chapter 5 of my thesis I attempted to assess the differences
between TGF1 and TGF3 in TGFsignalling in a non-small cell lung cancer
cell line, A549 cells. Overall, I showed that TGF3 was much less potent than
TGF1 in inducing TGF-dependent signalling, especially in terms of EMT. Since
EMT is a necessary step for epithelial-based tumors to escape the primary tumor
site and metastasize, future studies should evaluate the role of TGF3 in cancer
cell migration and invasion. Furthermore, it would be interesting to assess
mechanistically how TGF3 induce less potent signalling even though both
TGF1 and TGF3 bind to the same cell-surface receptors. Initial work in
Chapter 5 of this thesis suggests that these ligands may induce different
signalling capacities through TGFreceptor complex formation at the cell
surface. However, as these ligands share 76% amino acid identity in their active
forms (21), it may be important to identify differences in the amino acid sequence
which could explain their differential ability to induce receptor complex formation.
One important way in which these ligands differ is in terms of their posttranslational modifications. Upon comparison of the sequences of TGF1 and
TGF3, it appears that TGF3 has a putative glycosylation site that is not found
in TGF1. Therefore, manipulating the glycosylation state of TGF3 may affect
its ability to bind to TRII and may change receptor complex formation. Overall,
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the differences in the ability of TGF1 and TGF3 to induce signal transduction
represent an exciting field of study applicable to numerous processes in addition
to cancer, such as development and fibrotic conditions.

6.3

Context of Findings in the Field of
TGFSignalling Regulation
In this thesis I focus on the mechanisms whereby protein interactions with

the TGF receptor complex can alter both membrane trafficking and signal
transduction. However, there are many other mechanisms which regulate
TGFsignal transduction.
For example, as suggested in the introduction, the bioavailability of
TGFligand in the extracellular matrix may greatly regulate TGFsignalling. The
latent TGFcomplex is composed of homodimeric TGF, latency associated
peptides, and the latent TGFbinding protein (LTBP). Importantly, the LTBP is
important for sequestering the TGFligand complex in the extracellular matrix
and TGFin its latent form is unable to bind TGFreceptors (22). Therefore, the
ECM acts as a reservoir for latent TGF; however, TGFactivation can occur in
several ways. For example, TGFcan be activated in vivo in low pH
environments, such as in lacunae surrounding osteoclasts (23, 24). Furthermore,
a number of proteases such as plasmin and thrombospondin can cleave latent
TGFat the cell surface and at wound-healing sites, respectively (22).
Interestingly, TRIII may regulate the bioavailability of active TGFthrough its
ectodomain shedding. Soluble TRIII can be found naturally in serum and the
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ECM and occurs as a protease cleavage of its extracellular, TGF-binding
domain (25). It has been shown that soluble TRIII can bind and inhibit all three
TGF ligands with relatively high affinity, but is best at binding and inhibiting the
actions of TGF2 (25). The protease responsible for producing the soluble form
of TRIII is still currently unknown (25). In chapter 3 of this thesis I examined the
role of TRIII in regulating the trafficking and signalling of the TRII/TRI
complex. In figure 3.11 I show that TRIII may increase the basal signalling of
the TGFreceptor complex, but decreases Smad signalling in the presence of
TGF1 ligand. One possible explanation for this finding is that the overexpressed form of TRIII may be shed from the cell surface and therefore acting
to sequester TGFligand from the TGFreceptor complex. Once the protease
which is responsible for inducing the ectodomain shedding of TRIII is
discovered, it will be possible to evaluate the potential for TRIII in negatively
regulating TGFsignalling.
In many different receptor families, regulating the level of cell-surface
receptors is an important mechanism for regulating signal transduction. Indeed,
in the TGFreceptor family, this is also the case. For example, it has been
shown that regulating the levels of endoglin can affect the ability of breast cancer
cells to perform angiogenesis (26). Li and colleagues illustrated that decreasing
the levels of endoglin in human vascular endothelial cells (HUVECs) inhibited in
vitro angiogenesis and mAb to endoglin in a mouse model of breast cancer
induced regression of breast cancer (26). Furthermore, the cell surface levels of
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TGFreceptors can also be affected by glycosylation. It is thought that
glycosylated receptors act as a network at the cell surface and delay
internalization (27). It was shown that Mgat5, a Golgi enzyme involved in Nglycan

processing,

sensitized

cytokine

receptors

such

as EGFR

and

TGFreceptors by keeping them at the cell surface (27). Indeed, loss of Mgat5
decreased cytokine signalling and this effect could be rescued by treating with
inhibitors of endocytosis (27). In chapter 4 of this thesis, I found that loss of
arrestin2 expression appeared to increase steady-state levels of TRII at the
cell-surface but did not appear to affect the half-life of the receptor. This increase
in levels of receptor at the cell-surface may allow for the formation of more
signalling complexes; however since receptor internalization is necessary for
Smad signal transduction, this may preferentially activate Smad-independent
pathways, such as the p38 pathway.
The main focus of this thesis was the role of receptor endocytosis on
signal transduction. While the model that I propose in this thesis suggests that
clathrin-mediated endocytosis enhances TGFsignalling and membraneraft/caveolae-dependent endocytosis decreases TGFsignalling, it is possible
that membrane-rafts could function to compartmentalize other non-Smad
signalling pathways. Zuo and Chen published an interesting article in which they
illustrated that the membrane-raft localization of the TGF receptor complex was
important for the activation of ERK and p38, but not Smad2/3 by TGF (28).
Indeed, they illustrated that depleting cholesterol, which is an integral component
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of membrane rafts, decreased TGF activation of ERK and p38 and also
decreased the migration of HaCaT cells in response to TGF (28). Further
supporting a role for caveolae in non-Smad signal transduction is a paper by
Meyer et al. that showed that caveolae formation in hepatocytes was necessary
for non-Smad mediated activation of the Akt pathway (29). In chapter 4 of this
thesis, I found that decreasing levels of arrestin2 enhanced TGF-induced
phosphorylation of p38. The mechanism of this enhanced phosphorylation could
occur by several means. First of all, as I suggested in chapter 4, loss of
arrestin2 also enhanced the levels of TRII at the cell surface which may
increase the ability of the receptor complex to activate non-Smad signalling
pathways. However, another possibility is that loss of arrestin2 may shift
endogenous TRII into membrane raft fractions, which can then activate p38
signalling as suggested by Zuo and Chen (28). While I found that overexpressing arrestin2 did not further shift TRII into non-membrane raft fractions,
it is essential to evaluate endogenous receptors and arrestin2 to completely
discount the role of arrestin2 in membrane raft partitioning.

6.4

Significance of Findings and Conclusion

In this thesis I provide evidence that TGFreceptor internalization and
trafficking can have direct effects on TGF-dependent signalling. I have identified
regions of TRII that are important in mediating its trafficking, as well as both
cytoplasmic and extracellular interacting-proteins which direct TGFreceptor
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trafficking. Furthermore, I have illustrated that the roles of TGFtrafficking in
mediating signalling output are not limited to Smad-dependent pathways, as the
Smad-independent p38 pathway is also affected by changes in TGFreceptor
trafficking.
The TGFsignalling pathway is important in normal physiological
conditions, such as development and cell differentiation, and pathological
conditions such as cancer and fibrosis. As I have demonstrated that the
trafficking of the receptors, and proteins which direct this trafficking, have
implications in TGFsignal transduction, my work has implications in a number
of fields. There is also support in the literature that perturbations in
TGFreceptor trafficking can influence disease states such as cancer and
fibrosis. For example, it has recently been shown that a mutation in TRII which
disrupts its endocytosis promotes cancer cell migration and invasion in an oral
squamous cell carcinoma (30). Similarly, in fibrotic conditions, such as systemic
sclerosis

which

also

show

enhanced

TGFsignalling,

perturbations

in

TGFendocytosis have also been demonstrated. Patients with systemic
sclerosis have decreased caveolin-1 expression in their lungs and studies have
shown that decreased caveolin-1 expression increases collagen production (31).
Therefore, identifying factors which promote and control TGFendocytosis will
have significant effects in disease states in which TGFsignal transduction is
deregulated.

201

6.5

References

1.

Di Guglielmo, G. M., Le Roy, C., Goodfellow, A. F., and Wrana, J. L.
(2003) Nature cell biology 5(5), 410-421

2.

Runyan, C. E., Schnaper, H. W., and Poncelet, A. C. (2005) The Journal
of biological chemistry 280(9), 8300-8308

3.

Mitchell, H., Choudhury, A., Pagano, R. E., and Leof, E. B. (2004)
Molecular biology of the cell 15(9), 4166-4178

4.

Ehrlich, M., Shmuely, A., and Henis, Y. I. (2001) Journal of cell science
114(Pt 9), 1777-1786

5.

Moustakas, A., Lin, H. Y., Henis, Y. I., Plamondon, J., O'Connor-McCourt,
M. D., and Lodish, H. F. (1993) The Journal of biological chemistry
268(30), 22215-22218

6.

Huang, S. S., and Huang, J. S. (2005) Journal of cellular biochemistry
96(3), 447-462

7.

Derynck, R., and Feng, X. H. (1997) Biochimica et biophysica acta
1333(2), F105-150

8.

Chen, W., Kirkbride, K. C., How, T., Nelson, C. D., Mo, J., Frederick, J. P.,
Wang, X. F., Lefkowitz, R. J., and Blobe, G. C. (2003) Science (New York,
N.Y 301(5638), 1394-1397

9.

Finger, E. C., Turley, R. S., Dong, M., How, T., Fields, T. A., and Blobe, G.
C. (2008) Carcinogenesis 29(3), 528-535

10.

Occleston, N. L., Laverty, H. G., O'Kane, S., and Ferguson, M. W. (2008)
Journal of biomaterials science 19(8), 1047-1063

11.

Siegel, P. M., and Massague, J. (2003) Nature reviews 3(11), 807-821

12.

Hagiwara, S., Murakumo, Y., Mii, S., Shigetomi, T., Yamamoto, N., Furue,
H., Ueda, M., and Takahashi, M. Oncogene 29(15), 2181-2191

13.

Bizet, A. A., Liu, K., Tran-Khanh, N., Saksena, A., Vorstenbosch, J.,
Finnson, K. W., Buschmann, M. D., and Philip, A. Biochimica et
biophysica acta 1813(5), 742-753

14.

Gatza, C. E., Holtzhausen, A., Kirkbride, K. C., Morton, A., Gatza, M. L.,
Datto, M. B., and Blobe, G. C. Neoplasia (New York, N.Y 13(8), 758-770

202

15.

Kim, J. H., Yu, S. J., Park, B. L., Cheong, H. S., Pasaje, C. F., Bae, J. S.,
Lee, H. S., Shin, H. D., and Kim, Y. J. Digestive diseases (Basel,
Switzerland) 29(3), 278-283

16.

Lambert, K. E., Huang, H., Mythreye, K., and Blobe, G. C. Molecular
biology of the cell 22(9), 1463-1472

17.

Zakrzewski, P. K., Mokrosinski, J., Cygankiewicz, A. I., Semczuk, A.,
Rechberger, T., Skomra, D., and Krajewska, W. M. Cancer investigation
29(2), 137-144

18.

Bilandzic, M., Chu, S., Farnworth, P. G., Harrison, C., Nicholls, P., Wang,
Y., Escalona, R. M., Fuller, P. J., Findlay, J. K., and Stenvers, K. L. (2009)
Molecular endocrinology (Baltimore, Md 23(4), 539-548

19.

Criswell, T. L., Dumont, N., Barnett, J. V., and Arteaga, C. L. (2008)
Cancer research 68(18), 7304-7312

20.

Zhang, Y. E. (2009) Cell research 19(1), 128-139

21.

Laverty, H. G., Wakefield, L. M., Occleston, N. L., O'Kane, S., and
Ferguson, M. W. (2009) Cytokine & growth factor reviews 20(4), 305-317

22.

Hyytiainen, M., Penttinen, C., and Keski-Oja, J. (2004) Critical reviews in
clinical laboratory sciences 41(3), 233-264

23.

Salo, J., Lehenkari, P., Mulari, M., Metsikko, K., and Vaananen, H. K.
(1997) Science (New York, N.Y 276(5310), 270-273

24.

Oursler, M. J. (1994) J Bone Miner Res 9(4), 443-452

25.

Vilchis-Landeros, M. M., Montiel, J. L., Mendoza, V., MendozaHernandez, G., and Lopez-Casillas, F. (2001) The Biochemical journal
355(Pt 1), 215-222

26.

Li, C., Guo, B., Bernabeu, C., and Kumar, S. (2001) Microscopy research
and technique 52(4), 437-449

27.

Partridge, E. A., Le Roy, C., Di Guglielmo, G. M., Pawling, J., Cheung, P.,
Granovsky, M., Nabi, I. R., Wrana, J. L., and Dennis, J. W. (2004) Science
(New York, N.Y 306(5693), 120-124

28.

Zuo, W., and Chen, Y. G. (2009) Molecular biology of the cell 20(3), 10201029

29.

Meyer, C., Godoy, P., Bachmann, A., Liu, Y., Barzan, D., Ilkavets, I.,
Maier, P., Herskind, C., Hengstler, J. G., and Dooley, S. Journal of
hepatology 55(2), 369-378

203

30.

Park, I., Son, H. K., Che, Z. M., and Kim, J. Cancer letters 315(2), 161-169

31.

Del Galdo, F., Lisanti, M. P., and Jimenez, S. A. (2008) Current opinion in
rheumatology 20(6), 713-719

204

Curriculum Vitae
Name:

Sarah Elizabeth Anne McLean

Post-secondary
Education and
Degrees:

University of Waterloo
Waterloo, Ontario, Canada
2003-2007, B.Sc.
Western University
London, Ontario, Canada
2007-2012 Ph.D.

Honours and
Awards:

University of Waterloo
Dean’s Honours List
2003-2007
University of Waterloo
NSERC Undergraduate Student Research Award
May 2006-August 2006
Western University
Schulich Graduate Scholarship
May 2007-May 2012
Ontario Graduate Scholarship (OGS)
May 2008-April 2011
Western University
Stevenson Lecture Poster Award
November 2008
Western University
Graduate Thesis Research Award
January 2009, January 2011
Western University
Margaret Moffatt Research Day Poster Award
March 2009, March 2010
Western University
Gowdey Research Day Poster Award
November 2009, November 2011

205

Western University
George W. Stavraky Teaching Scholarship in
Physiology/Pharmacology
November 2011
Western University
Gordon J. Mogenson Scholarship
November 2011

Related Work
Experience

Teaching Assistant
University of Waterloo
May 2005-December 2006
Teaching Assistant
Western University
September 2007-April 2011
Lecturer
Western University
September 2011
Course Manager/Instructor
Western University
May 2012-August 2012

Publications:
Sarah McLean, Gianni M. Di Guglielmo. TGF(transforming growth factor )
receptor type III directs clathrin-mediated endocytosis of TGFreceptor types I
and II. Biochem. J. (2010). 429: 137-145.
Valbona Luga, Sarah McLean, Christine Le Roy, Maureen O’Connor-McCourt,
Jeff L Wrana, Gianni M Di Guglielmo. The extracellular domain of the TGFβ type
II receptor regulates membrane raft partitioning. Biochem. J. (2009) 421: 119131.
Anita Woods*, Daphne Pala*, Laura Kennedy, Sarah McLean, Jason Rockel,
Guoyan Wang, Andrew Leask, Frank Beier. Osteoarthritis Cartilage (2009) 3:
406-413.
Shaoqiong Chen, Sarah McLean, David E. Carter, Andrew Leask. The gene
expression profile induced by Wnt 3a in NIH 3T3 fibroblasts. J. Cell Commun.
Signal. (2007) 1: 175-183.

206

Abstracts:
Sarah McLean, John Di Guglielmo. TGF3 is a less potent inducer of TGF
signalling than TGF1 in non-small cell lung cancer cells. Poster Presentation.
American Association for Cancer Research 103rd Annual Meeting. April 2nd,
2012, Chicago, Illinois, USA.
Sarah McLean, John Di Guglielmo. Research in Scleroderma: From
Understanding to Developing Therapies. Invited speaker. Scleroderma Society of
Ontario London Support Group Meeting, October 2011.
Sarah McLean, John Di Guglielmo. Ligand-dependent TGF Signalling
Potential. Poster Presentation. American Association for Cancer Research 102nd
Annual Meeting, April 4th 2011, Orlando, Florida, USA.
Sarah McLean, John Di Guglielmo. Perspectives on Cellular Research in
Scleroderma. Invited speaker. Scleroderma Society of Ontario London Support
Group Meeting, May 2010.
Sarah McLean, John Di Guglielmo. TRIII directs clathrin-mediated endocytosis
of TGF type I and II receptors. Poster Presentation. Margaret Moffatt Research
Day, University of Western Ontario, March 2010.
Sarah McLean, John Di Guglielmo. TRIII directs clathrin-mediated endocytosis
of TGF type I and II receptors. Poster Presentation. American Society for Cell
Biology Meeting, San Diego, California. December 2009.
Sarah McLean, John Di Guglielmo. TRIII directs clathrin-mediated endocytosis
of TGF type I and II receptors. Poster Presentation. Gowdey Research Day,
University of Western Ontario, November 2009.
Sarah McLean, Adrian Gunaratne, Moshmi Bhattacharya, John Di Guglielmo. arrestin2 directs clathrin-mediated endocytosis of TGF receptors. Poster
Presentation. Margaret Moffatt Research Day, University of Western Ontario,
March 2009.
Sarah McLean, Adrian Gunaratne, Moshmi Bhattacharya, John Di Guglielmo. arrestin2 directs clathrin-mediated endocytosis of TGF receptors. Poster
Presentation. American Society for Cell Biology Meeting, San Francisco,
California, December 15th, 2008.
Sarah McLean, Adrian Gunaratne, Moshmi Bhattacharya, John Di Guglielmo. arrestin2 directs clathrin-mediated endocytosis of TGF receptors. Poster
Presentation. Stevenson Research Day, University of Western Ontario,
November 2008.

207

Sarah McLean, Valbona Luga, Christine Le Roy, Jeffrey L. Wrana, Moshmi
Bhattacharya, John Di Guglielmo. 2008. The Extracellular Domain of the TGFβ
type II receptor is necessary for lipid raft partitioning. Poster Presentation.
Margaret Moffatt Research Day, University of Western Ontario, March 2008.
Sarah McLean, Jeff Cowger, David E. Carter, Shaoqiong Chen, Andrew Leask.
2007. Wnt Signalling in fibroblasts: a new target for anti-fibrotic therapy in
scleroderma? Poster Presentation. Canadian Scleroderma Researcher’s Group

